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Introduction 
1.1 Scope of the thesis 
Since the late nineteenth century, population's health has improved 
tremendously, at least in wealthy nations. Life expectancy at birth in the 
Netherlands has increased at an unprecedented pace from less than 40 years in 
1860 to currently 76 years for males and 81 years for females. It is widely 
accepted that better hygiene, housing and nutrition have contributed to this 
increase through a reduction in communicable diseases, rather than medical 
care. The small overlap between the period with the major declines in mortality 
and the period of major advances in medicine suggests that the contribution of 
medical care to population health is at least limited, and has even been doubted 
[170]. However, it is now commonly believed that many preventive and 
curative interventions have contributed to improved health [153]. Diseases that 
were killers in the past can now be cured or prevented. 
The improvement of population health comes at a price. Particularly 
from the 1970s onwards, health care spending has increased fast, and currently 
accounts for about 10% of the gross national product. The increase in health care 
spending is, apart from wage and price increases, generally attributed to two 
phenomena: the development of medical technology and, more recently, the 
ageing of society. It is too commonplace to claim that medical innovation is cost 
increasing in generaL Some innovations will increase costs, whereas others will 
be cost saving. In fact, the economic consequences of technologies can only be 
assessed for specific technologies related to specific indications [91]. For 
example, preventive interventions such as cervical and breast cancer screening 
are effectively reducing cancer incidence but costs have shown to outweigh 
savings [270 280]. In contrast, treatment of stroke patients in specialized stroke 
units results in more favourable health outcomes and cuts costs compared to 
treatment in general wards [122]. However, there are strong indications that on 
an aggregate level medical technology leads to increased health care spending 
[219]. 
An objective of health care policy is to provide health care in such 
manner that population's health is maximized with an efficient use of resources. 
The current situation has put pressure upon policy makers to contain health 
care costs, and to restrict access to health care interventions that are evidence-
8 
based, with proven effectiveness, and with acceptable cost-effectiveness. 
However, health (care) policies that maximize the overall health benefit at 
contained costs can only be successful when data are available on a 
population's health and its determinants, on health care needs, and on the 
effectiveness and efficiency of existing and newly developed medical 
technology. 
In this thesis we present these data for two quite different health 
problems: injury and cervical cancer. For injury, population based estimates are 
presented of health care costs and post-injury functional outcome, subdivided 
by injury diagnoses. We also investigated determinants of injury related health 
care costs and functional outcome. For cervical cancer, we evaluated several 
options to improve the efficiency of population based screening and follow-up. 
The thesis starts with a chapter on the distribution of total health care costs by 
diseases and injuries, and by basic demographic indicators. 
1.2 Injuries 
Acute physical injuries account for 12% of the burden of disease in established 
market economies, and for even higher shares in other global regions [194]. It is 
known as a heterogeneous health problem, ranging from high frequency, minor 
injuries (e.g. superficial injury) to low frequency, major injuries (e.g. 
polytrauma patients). A general distinction is between unintentional injury-
home and leisure, occupational and traffic accidents- and intentional injury-
violence, self-inflicted injury. 
The consequences of injuries can be estimated by the resulting health 
care utilization, with costs as a single index. Previous estimates of the cost of 
injury in the Netherlands were made for broadly defined accident categories, 
and include medical costs and production loss due to work absence, permanent 
disability and death, also known as 'indirect costs' [275]. About 60% of medical 
costs were attributed to home injuries, with high costs among elderly females. 
Traffic injury accounted for another one-fifth. So far, international studies have 
been occasional and fragmented, and have mainly focussed on per patient 
medical costs and its determinants. For instance, high medical costs per patient 
have been reported for lower extremity injury including hip fracture [10 159 
305] and for head injury [167]. 
However, considerable knowledge gaps remain. First, more detailed 
estimates are needed on the health care costs of specific injuries, because injury 
control measures and trauma care are often specific for narrowly defined injury 
groups. Examples are poisonings in children, or severe traumatic brain injury in 
motor cyclists. Second, cost estimates should preferrably be comprehensive and 
encompass all injuries to make comparisons among injury groups, identify 
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previously unrecognized injury groups, and put other injuries into perspective. 
Third, injuries are a dynamic public health area. History has shown that 
exposure to newly emerging risks leads to an increasing incidence in specific 
injury categories. As a result, there is a need for detailed monitoring of injury 
related health care demands together with incidence and mortality. The first 
research question will therefore be: 
1. How are medical costs of injury at national level distributed by type of injury and 
health care sector, and what are their major determinants? 
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Apart from data on health care consumption and costs, epidemiological 
indicators are very important. Since the beginning of the 1970s the overall 
injury mortality rate has shown a considerable decline (crude and age-
adjusted), following an increase in previous decades. The decline in mortality is 
partly due to a decreasing incidence in specific areas, e.g. traffic injury, and 
partly due to improved survival rates (all injury categories), reflecting the 
success of several preventive interventions, such as mandatory helmet use, and 
improved trauma care, respectively [274]. 
The decline in mortality has contributed to a growing attention for the 
disability component in the burden of injury. In the Netherlands little 
quantitative information on injury related disability is available. Estimates of 
the burden of injury by broadly defined types of injury were made for the 
Population Health Forecasts in 1997, with traffic injury and suicide ranking 
highest in terms of disability adjusted life years lost (DALY) [232]. However, 
these estimates were based on expert guesses of the prevalence and severity of 
permanent disability. 
Since then, empirical data have been collected on the functional 
outcome of major trauma [283 291], hip fractures [13] and tibial fractures [112]. 
So far, international studies have concentrated on functional limitations in 
patients with high energy injuries that require hospitalization, including 
polytrauma patients [5 109 123 154 159 289]. Others considered specific major 
injuries, such as vertebral fractures [11148], pelvic ring fractures [208 278], tibial 
shaft fractures [97] and ankle fractures [224]. Nevertheless, there are indications 
that a considerable share of total disability is attributable to patients that have 
never been hospitalized [169 217 292]. Because studies in these patient groups 
hardly exist, research on functional outcome is urgently needed in 
comprehensive populations of minor and major trauma patients. 
Typical for injuries are their heterogeneous functional sequelae and 
recovery patterns. Injuries can struck any body region, and multiple 
mechanisms (fall, fire, chemical substance, etcetera) lead to evenly multiple 
10 
types of injury (fracture, strains, bums, etcetera). A uniform and systematic 
measurement of functional outcome can therefore make an important 
contribution to the comparison of functional outcome among different injury 
diagnoses. The second research question is therefore: 
2. How is injury related disability at national level distributed by type of injury, and 
what are its major determinants? 
Although the description of the functional and economic consequences of injury 
are two separate scientific fields, it is likely that they are related. Total medical 
costs are by definition incidence multiplied with cost per patient, whereas cost 
per patient will in many cases be related to the level and duration of disability, 
apart from several socio-demographic characteristics that are known as 
determinants of health service use (e.g. age, sex, living alone, socio-economic 
status) [205 281]. 
1.3 Cervical cancer 
Cervical cancer is the second most common cancer among women around the 
world, but the incidence and mortality varies among global regions. In 
developed countries the incidence is lower. In the Netherlands the chance that a 
woman gets cervical cancer during her life is about 1-2% [290]. Yearly about 700 
women develop cervical cancer, of whom about 235 die of the disease. The low 
incidence of invasive cancers is partly due to population based screening. In the 
Netherlands Pap smear screening was introduced in the 1960s. For many years 
women were screened on their own demand. This so called "spontaneous" 
screening practice led to irregular screening intervals whereas many women 
were not screened at all. Organized screening, by which women in the target 
age range are invited according to a fixed schedule, has taken place from 1988 
onwards in some regions, and nationwide from 1995 onwards. 
The impact of cervical cancer screening on mortality reduction has 
never been determined in a controlled experiment. By the time the effectiveness 
was doubted, screening had already been widely disseminated. This made an 
assessment in a controlled experiment impossible. But in the past decades 
convincing indirect observational evidence has been collected primarily 
through the analysis of screening data, supported by advanced modelling 
techniques [140 267]. By now the evidence that cervical cancer screening is 
effective is so strong, that a controlled experiment is deemed unethical. 
There are several reasons for the remaining cervical cancer incidence 
and mortality despite widespread screening. Invasive cancers can still be found 
in age groups uncovered by screening. In the age group that is invited for 
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screening (30 to 60 years in the Netherlands) invasive cancers may be due to 
non-participation (about 60%) or insufficient screening (about 10%) [30]. About 
30% are 'interval cancers' detected inbetween two subsequent screening 
rounds, which might partly be missed in the previous screening round due to a 
false negative smear. 
For decades the Pap smear has been the screening test. The technique 
works as follows: cell material is scraped from the cervix uteri, and 
subsequently stained on a glass slide, which can be assessed microscopically. 
Depending on the degree of abnormality of the screening smear, women will 
follow the screening schedule, will have a repeat smear, or will be referred to 
the gynecologist for further diagnosis and treatment. 
Ever since its introduction, there have been worries about the accuracy 
of the Pap smear [6 135 197]. In systematic reviews its sensitivity has been 
estimated at about 50-80% [82 197]. These estimates depend on the cut-off value 
for smear abnormality, the study population, the reference test used, and other 
characteristics of study design. Also, it is essential to distinguish the sensitivity 
of a single Pap smear from the 'programme sensitivity' in organized screening. 
Due to the long duration of the pre-invasive stages, estimated at 16 years on 
average [287], missed cases will have a considerable chance to be detected at 
subsequent screening rounds. Nevertheless, a low sensitivity of the Pap smear 
compromises its ability to detect cervical lesions at an early stage. Particularly 
in the US, the debate on Pap smear accuracy is enforced by lawsuits of women 
with invasive cancer, whose diagnoses have probably been missed in the 
pathologic laboratory [236]. In this respect the high workloads in commercial 
laboratories have been mentioned as a possible cause. 
In recent years several cytologic technologies have been developed that 
claim to faciltate the screening process and reduce the number of missed cases. 
Some of these are based on thinlayer technology that makes the smear easier to 
interpret (ThinPreplM, SurePathlM). Others are based on automation of the 
screening, by which slides can be triaged into low and high risk slides. This 
accelerates the throughput of screening smears, most of which can be assessed 
as normat whereas the high risk slides can be assessed with increased alertness. 
In some countries these technologies are already applied in routine practice. In 
the Netherlands some laboratories have already converted, despite clinical 
guidelines that prescribe the use of the conventional Pap smear. The third 
research question will therefore be: 
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3. What are the test characteristics of newly developed cytologic technologies for 
cervical cancer screening, and how (cost-)effective are these technologies compared 
to screening with Pap smears? 
Cervical cancer screening is effective in preventing invasive cancers and 
mortality, but it has unfavourable side-effects as well. One of the main 
unfavourable effects is that currently about 3% of screened women have an 
abnormal smear, of whom only a small part would develop invasive cancer in 
the absence of screening. In some countries the proportion of abnormals may be 
as high as 10%, as in the Netherlands until recently. These women will get 
follow-up by a repeat smear or will be referred for colposcopy and treated if 
necessary, whereas only few of them will actually benefit. A considerable part 
of pre-invasive stages of cervical cancer will spontaneously regress to normal, 
and would never have been detected without screening. For the women 
concerned follow-up implies uncertainty and discomfort, which may last for 
more than a year (according to the recent guidelines). 
These unfavourable side effects of screening might be reduced by 
testing women with an abnormal smear for the presence of human 
papillomavirus (HPV). HPV testing can be used as a diagnostic tool to triage 
women for further management [52]. Since the 1980s there is growing 
molecular and epidemiological evidence that some HPV types act as causal 
agents for the development of cervical cancer [137 190]. These high-risk types 
(hr-HPV) have been detected in over 95% of invasive cancers, and in 50-80% of 
the pre-invasive stage cervical intraepithelial neoplasia (CIN). Prospective 
studies have shown that progression of pre-invasive stages was only observed 
in case of 'persistent HPV', in women that tested positive for hr-HPV in the 
screening smear and repeat smears [204]. In women without hr-HPV, 
progression does not occur. However, regression is also observed in women 
with hr-HPV [202]. It therefore remains to be determined whether HPV testing 
is a valuable diagnostic tool in women with abnormal smears, with the aim to 
reduce anxiety and discomfort induced by screening. The fourth research 
question will therefore be: 
4. Can the follow-up of women with abnormal Pap smears be made more efficient by 
human papillomavirus testing? 
HPV testing may also be applied as a primary screening tool and as a 
surveillance instrument in women that have been treated for CIN. These 
possible applications have been evaluated elsewhere, and will not be further 
investigated in this thesis [203 267]. 
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1.4 Analytical tools 
For the analysis of the questions posed so far, we used three existing analytical 
tools that are known as burden of disease (BOD) studies, cost of illness (COl) 
studies and economic evaluation studies. The relationship between these tools 
and the two principal entities they relate to, population health and health care, 
are presented in figure 1.1. BOD and COl studies provide a comprehensive and 
coherent description of population health and health care, respectively, and of 
their distribution across diseases and injuries, risk factors, and other population 
variables. They may be used for comparative purposes to identify differences in 
health and costs (e.g. between groups) or changes over time. Summary 
measures play a key function in BOD studies. Summary measures of population 
health combine information on mortality and non-fatal health outcomes to 
represent the health of a particular population, using time as the common 
numerator [88]. Examples are the quality adjusted life year (QALY) and 
disability adjusted life year (DALY) [194 261 ]. In COl studies, costs can be 
regarded as a summary measure of health care. BOD and COl studies are 
complementary in measuring the societal burden of disease and injury, and 
they could be usefully combined to translate expected dynamics in population 
health into future health care needs. In contrast with BOD and COl studies, 
economic evaluations focus on the dynamic relationship between health care 
and population health, and are a tool to assess the implications of a change in 
health care for population health. 
Burden of disease studies 
Population health can be distinguished into mortality and disability (non-fatal 
health outcomes). Frequently used indicators of mortality are (standardized) 
mortality rates, the number of life years lost, survival rates, and life expectancy. 
Disability is a more complex, multidimensional concept, similar to its positive 
counterpart: health. A conceptual framework for measuring disability is 
provided by the International Classification of Functioning, Disability and 
Health (ICF), which distinguishes between functioning and contextual factors 
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[297]. Functioning encompasses the level of body functions, activities and 
participation in life situations. The impact of disability may be determined by 
contextual factors, the social and physical environment, in addition to personal 
factors, specifically in terms of limitations in social participation such as the 
ability to engage in work or social activities. 
The data requirements of BOD studies are large, particularly for the 
construction of summary measures, and encompass disease-specific 
epidemiological frequency data (incidence, prevalence, mortality), data on 
duration of disease, and disease-specific health status valuations. Complete and 
consistent epidemiological frequency data are often not readily available, but 
are a prerequisite for collecting data on disease severity. Data on disease 
severity are of no use when frequency data with which they must be combined 
are incomplete or inconsistent [78]. Some of the problems with epidemiological 
frequency data may be solved with modelling [139]. 
Severity of disease can be measured with specific instruments for health 
status measurement. Many instruments (read: questionnaires) have been 
developed. A general distinction is between generic instruments and disease- or 
domain-specific instruments. Generic instruments include items on all three 
domains of health: physicat mental and social functioning. These instruments 
are applicable to all diagnoses, and are therefore useful to make comparisons 
among diseases or injuries that may be quite different. Disease-specific 
instrument have a more detailed focus on functional consequences that are 
specific for certain diseases or injuries. As a result they are more sensitive to 
specific changes in health, but cannot be used to make comparisons across very 
different diagnoses. Domain-specific instruments focus on specific types of 
functioning, e.g. pain or depression. 
Despite their large differences, all instruments share common 
characteristics. They capture a number of health items (e.g. mobility, pain) that 
can be associated with specific body functions, activities and social roles, and 
each item can be scored in several response categories. Instruments may differ 
in the items that they include and in the level of detail in response categories. 
An instrument with many items and many response categories may well be 
able to discriminate among health states, but this should be weighed against 
their complexity. 
A general shortcoming of health measurement instruments is that they 
do not enable a judgement which health status is to be preferred, in case one 
health status scores worse on one health domain but better on another domain 
compared to another health status. This requires value judgements on the 
relative severity of health states. These valuations (scores, weights) can then be 
combined with information on the duration of functional sequelae and with 
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other epidemiological frequency data to arrive at a single metric of population 
health. 
Health status valuations can be derived in two ways. The first is by 
describing the functional consequences of all possible diseases and injuries and 
their different disease stages, and subsequent valuation of these descriptions by 
one or several valuation techniques. Considering the wide spectrum of possible 
diagnoses, even within the field of injury, this would at least be time 
consuming. A second, more efficient approach is by describing disease stages 
using a generic measurement instrument, and subsequently converting these 
descriptions into valuations by using existing algorithms. For instance, such 
algorithms are available for the EuroQol and SF-36 generic instruments, based 
on statistical modelling of empirical valuations of a set of key health state 
descriptions [34 65]. This second approach has been followed in this thesis for 
describing non-fatal health outcomes in injury patients. Apart from being more 
efficient, an advantage compared to the first approach is that it provides 
information on the prevalence of restrictions on specific underlying health 
domains, which facilitates the interpretation of health status valuations and of 
metrics that summarize non-fatal health outcomes. 
Cost of illness studies 
Health care can be quantitatively described by numbers of inputs, such as 
labour and equipment, and by outputs, such as hospital bed days. Similar to 
summary measures of population health, costs can be regarded a summary 
measure of health care. In contrast to economic evaluations, cor studies 
provide a cross-sectional description of costs by diseases and injury. Because of 
their cross-sectional design, they do not provide insight into the relationship 
between changes in input (health care) and output (health), and statements on 
the efficiency of health care are therefore not possible. 
There is a considerable variety in cor studies [219]. They may be 
restricted to health care costs, or also include costs to patients and other 
economic sectors (e.g. productivity losses). They may be disease-specific, 
describing the costs of specific diseases, or generic, giving a comprehensive 
overview of costs of the entire spectrum of diseases. A related distinction is 
between top-down and bottom-up studies. Total (health care) costs in a 
specified period can be attributed top-down to specific diseases, injuries and 
risk factors. This has the advantage that a uniform methodology is applied for 
all diseases, and facilitates the comparison of costs. Each euro can be attributed 
only once and double counting of costs is therefore avoided. In a bottom-up 
approach, often used in disease-specific studies, lifetime health care 
consumption (and other costs) of individual patients are aggregated into a total 
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estimate. Disease-specific COl studies may use detailed data sets that are not 
available for generic COl studies, and therefore may give more detailed and 
reliable results. In theory, and assuming a stable population with no changes in 
demography or epidemiology, both approaches should produce the same 
results. Differences often occur because of differences in how costs are 
attributed in patients with two ore more conditions (comorbidity). 
In this thesis generic and disease-specific cor studies have been 
conducted. Total health care costs by diseases and injuries were described using 
a top-down approach, whereas health care costs of injury were estimated 
bottom-up. 
Economic evaluation studies 
In contrast to COl studies, that provide a static description of the relationship 
between population health and health care, economic evaluation studies 
provide insight into the (potential) changes in costs and population health as a 
result of a particular intervention. In other words, they evaluate the impact of 
an intervention in terms of monetary costs and savings, and positive and 
negative health effects. These studies are a powerful tool for health care 
rationing. A more efficient use of resources results when priority is given to 
those interventions with the most favourable balance between costs and health 
effects ('cost-effectiveness ratio'). The findings of economic evaluations are 
often implemented in clinical practice [282]. However, economic evaluations are 
not yet systematically embedded in decisions concerning the financing and 
implementation of health care technologies [239]. 
Different types of economic evaluation exist, namely cost-effectiveness, 
cost-utility, and cost-benefit analysis, depending on whether the effects are 
counted in natural units (e.g. life years lost), quality of life (valuations or 
utilities), or monetary units, respectively. Evaluations of interventions without 
positive or negative health effects are cost-minimization analyses. Because most 
health interventions have multiple health effects, there has been an increasing 
tendency to translate outcomes into summary measures such as quality 
adjusted life years (QAL Y s ). These summary measures facilitate the comparison 
of different interventions in different areas of population health, but should not 
draw too much attention at the expense of important differences on underlying 
health components. In practice, evaluative studies that use utilities as outcome 
measure are often called cost-effectiveness analyses. Cost-benefit analyses 
(CBA) are more strongly rooted into welfare economic theory, but their 
application has not been widespread in the evaluation of health care, and their 
share has also decreased over time [75]. This may be partly because of the 
empirical difficulties that are experienced in deriving monetary values of health 
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benefits through willingness to pay methods (WTP), and because of equity 
concerns [209]. In this thesis, several interventions for the optimization of 
cervical cancer screening have been evaluated with application of cost-
effectiveness analysis. 
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Depending on the decision authority, economic evaluations may be 
conducted from different perspectives. Most economic evaluations support 
national policy decisions and use the societal perspective as a general rule. This 
implies that costs and benefits of all societal parties are accounted for, including 
health care resources, costs to patients (out of pocket expenses, travel costs), 
and costs to other economic sectors, including production losses due to work 
absence, permanent disability, and premature death. In general, non-medical 
costs are more difficult to measure and also their valuation may be contentious. 
This applies for example to time costs of informal care and production losses 
[38131]. Other perspectives from which an evaluation is conducted are a health 
care provider perspective or company perspective. An economic evaluation 
then includes only those components that are relevant from the perspective of 
the decision maker. 
In summary, the three analytical tools as described here- BOD, COl, 
and economic evaluation studies - are strongly related to each other and are 
complementary with respect to informing health care policy and planning. 
Nevertheless, questions remain about their relative contribution, of which this 
thesis presents some examples. This brings us to the fifth and last research 
question: 
5. To what extent do burden of disease studies, cost of illness studies and economic 
evaluation studies provide helpful information for the prioritization of health care? 
1.5 Reading guidance 
The research questions are dealt with in this thesis as follows: chapter 2 
presents a generic COl study for the Netherlands, based on health care 
expenditures in 1994. After this broad picture of where all the money goes, we 
focus on injuries in part I, and start with a detailed, bottom-up cost of injury 
study in chapter 3 (question 1). The basis is formed by a costing model linked to 
an injury surveillance system. Particular attention is paid to the distribution by 
injury diagnosis, demography and type of health care. We continue in chapter 4 
with a review of existing cost of injury studies, in order to determine whether 
the picture that is drawn by cost of injury studies is sufficiently transparent to 
be useful for health care policy and planning. In chapter 5 we shift the focus 
from costs to functional outcome after trauma in a comprehensive population of 
injury patients, including minor and major trauma. This chapter describes how 
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levels of functioning differ by type of injury, and how functioning is 
determined by socio-demographic factors and injury severity (question 2). 
In part II two major evaluative studies of cervical cancer screening are 
described. In chapters 6 and 7 the costs and cost-effectiveness of newly 
developed cytologic tests are determined (question 3). Test sensitivity and 
specificity, and costs per test are the key dimensions in a decision analytic 
framework that is designed with use of a microsimulation model. Current 
evidence on test sensitivity and specificity is confronted with this framework, to 
judge whether these tests can be expected to provide enough 'value for money'. 
In chapter 8 we evaluate the possible role of HPV testing in the triage of women 
with abnormal smears, with help of a decision analysis (question 4). 
In chapter 9 the main conclusions are summarized and discussed, 
including the relative contribution of BOD and COl studies and of economic 
evaluation to the prioritization of health care is discussed (question 5). We 
conclude with a concise answer on each of the research questions and define the 
possible implications for further research and health care policy. 
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Abstract 
Objectives The debate on cost containment in health care mainly concentrates 
on the supply side. The objective of this study is to present data on the demand 
side: the epidemiologic and demographic causes of health care use. 
Design Information on health care use was obtained from all (22) health care 
sectors of the Netherlands. Most important sectors (hospitals, nursing homes, 
inpatient psychiatric care, institutions for the mentally retarded) have registries 
with nation-wide coverage. Total expenditures in a sector are subdivided into 
21 age groups, sex, and 34 diagnostic groups. 
Results After the first year of life, costs per person drop to their lowest levels in 
youth. They rise slowly throughout adult life, and increase exponentially from 
age 50 onwards till the oldest age group (95+). The top 5 causes of health care 
costs are mental retardation, musculoskeletal disease (predominantly joint 
disease and dorsopathy), dementia, a heterogeneous group of other mental 
disorders, and ill-defined conditions. Stroke, all cancers combined, and 
coronary heart disease, the main causes of death, rank 7, 8 and 10, respectively. 
Conclusions The main determinants of health care use in the Netherlands are 
old age and disabling conditions, particularly mental disability. A large share 
of the health care budget is spent on long-term nursing care, which will 
inevitably increase further in an ageing population. Aspecific cost containment 
measures may endanger the quality of care of the old and mentally disabled. 
Meerding WL Bonneux L, Polder JL Koopmanschap MA, van der Maas PJ. 
Demographic and epidemiological determinants of health care costs in 
Netherlands: cost of illness study. British Medical Joumal1998;317:111-5. 
Demographic and epidemiological 
determinants of health care costs in 
Netherlands: cost of illness study 
2.1 Introduction 
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The debate on cost containment in health care is mainly focused on the supply 
side and the financing of health care [1]. Changes in population health status as 
another important determinant of costs play a minor role in the discussion. One 
reason is that the relation between diseases and costs is not straightforward, 
and relevant data are often lacking. This study connects the supply and 
demand side by subdividing total health care costs by health care sector, 
diagnosis, age and sex. Analyzing the Dutch health care budget offers good 
opportunities for this purpose; the country is small, more than 99% of its 
population has full health insurance coverage and, because of a long-standing 
administrative tradition, most health care sectors have excellent registries, of 
which the most important are nation-wide. The completeness of available 
Dutch health care data allows for a comprehensive description of epidemiologic 
and demographic determinants of health care costs. This means that not only 
the acute care sectors are represented, but also those sectors which deliver long-
term care to the disabled. These are rarely included in other studies [9 150 186 
201 ], which as a consequence underestimate the high costs of disabling disease. 
2.2 Methods 
Table 2.1 gives an overview of the health care costs in 1994 for each health care 
sector as presented annually by the Ministry of Health [182]. Additional 
personal expenditures, such as over-the-counter medication and spectacles (6% 
of all costs) are not included. 
For the purpose of this article, the diagnoses of the International 
Classification of Diseases (ICD, 9th revision) [296] were clustered into 34 
diagnostic groups, which can be regrouped into the 17 chapters of the ICD (see 
table 2.2). We defined groups of diagnoses in order to minimise 
misclassification between diagnostic groups and in order that each group be 
large enough to efficiently describe a sufficiently large proportion of health care 
costs. Conditions that could not be related to a specific diagnostic group but 
that are unambiguously related to a specific functional system (cardiovascular, 
respiratory, mental, etc.) were assigned to the remainder group of that specific 
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ICD chapter. ill-defined conditions which could not be related to a specific ICD 
chapter were classified as 'Symptoms and ill-defined conditions' (ICD chapter 
16). Particularly in primary health care this is a relevant category, as patients 
present with problems, not diagnoses. To avoid double counting, we have 
considered only primary diagnoses. Of all health care costs 8.1% could not be 
allocated to any diagnostic group because of insufficient information from some 
smaller health care sectors. Of all health care costs 5.3% are due to health care 
administration, and are not related to specific health problems. Together with 
the living costs in homes for the elderly, these latter costs were assigned to 
aspecific health care costs. 
Table 2.1 Percentage of health care budget spent on different sectors of health care in 
Netherlands, 1994. 
Health care sector 
Hospital care 
Nursing homes 
Old people's homes 
- medical costs 
- living costs 
Psychiatric care 
Institutions for mentally and physically disabled people 
Primary medical and paramedical services (excluding dental care) 
Dental care 
Pharmaceutical care 
Home care and other small sectors 
Health care administration 
%of total* 
32.1 
8.9 
3.7 
5.4 
7.1 
8.6 
5.7 
4.0 
8.8 
10.4 
5.3 
*Health care spending in 1994 was 59.5 billion guilders ($32.7 bn, £21.3 bn), 9.7% of gross 
national product. 
For each health care sector, we identified key variables that are 
representative for health care use in that sector, such as days of stay for nursing 
costs in hospitals and nursing homes, or outpatient visits for costs of outpatient 
hospital care. For a specific sector the distribution of costs by 2 sexes, 21 age 
groups (0, 1-4, 5-9, 10-14, ..... , 95+ years) and 34 diagnostic clusters in 1428 (2 x 21 
x 34) cells is considered equal to the distribution of the key variable for that 
sector. Thus, for each health care sector, costs for each combination of age, sex 
and diagnostic group are equal to the fraction of the key variable in that cell 
times the total costs for that sector. The summation of these cells over all health 
care sectors yields the data presented here. 
The probability distribution of key variables was derived from sector-
specific registries and sample surveys. Detailed information about the registries 
and the key variables used is available elsewhere [219]. 
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Table 2.2 Diagnostic groups used in study and corresponding lCD 9 code [296]. 
lCD chapter 
I Infectious and parasitic diseases 
II Neoplasms 
Ill Endocrine, metabolic and nutritional 
diseases 
IV Blood and blood-forming organs 
V Mental disorders 
VIa Nervous system 
Vlb Sense organs 
VII Circulatory system 
VIII Respiratory system 
IX Digestive system 
Xa Urinary system 
Xb Genital organs 
XI Pregnancy & childbirth t 
XII Skin diseases 
XIII Musculoskeletal system 
XIV/XV Perinatal/congenital conditions 
XVI Symptoms, signs and ill-defined 
conditions 
XVII Accidents 
Diagnostic group 
Infection 
Cancer 
Benign neoplasms 
Diabetes 
Other endocrine diseases 
Blood diseases 
Dementia 
Schizophrenia 
Depression/anxiety 
Alcohol/drugs 
Mental retardation, Down's 
syndrome* 
Other mental disorders 
Neurologic disorders 
Eye disorders 
Ear disorders 
Hypertension 
Coronary heart diseases 
Heart failure 
Stroke 
Other circulatory diseases 
Asthma & COPD 
Other respiratory diseases 
Dental diseases 
Gastro-intestinal diseases 
Liver, gall, pancreas diseases 
Urinary disorders 
Genital disorders 
Pregnancy t 
Skin diseases 
Musculoskeletal diseases 
Perinatal/congenital conditions 
Ill-defined conditions 
Falls 
Other accidents 
Not allocated 
Non-specific :j: 
* Down's syndrome is classified in lCD chapter XV, code 758.0. 
lCD codes 
1-139 
140-208 
210-239 
250 
240-279 
280-289 
290 
295 
296,300 
291-292, 303-
305 
317-319, 758.0 * 
remainder 290-
316 
320-359 
360-379 
380-389 
401-405 
410-414 
428-429 
430-438 
remainder 390-
459 
490-496 
460-489, 497-
519 
520-529 
531-569 
570-579 
580-599 
600-629 
630-676 
680-709 
710-739 
740-779 
780-899 
E880-888 
E800-879, E890-
999 
t Hospital costs of healthy babies (boys and girls) after childbirth were assigned to pregnancy and 
childbirth (women). 
:j: Costs of health care administration and living costs in homes for the elderly. 
2.3 Results 
Total health care costs, representing 9.7% of the Dutch gross national product, 
were $2,124 per capita in 1994,$2,481 for women and $1,760 for men. The 
distribution is strongly age-dependent (figure 2.1). Costs are relatively high in 
the first year of life, reflecting the high costs of perinatal and infant care, but 
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than drop to the lowest levels in youth. During adulthood costs increase slowly 
and after age 50 they start to increase exponentially up to the highest age group 
(95+). The higher share in total costs of women (59%) is predominantly caused 
by their longer life expectancy, the higher prevalence of women in nursing 
homes and homes for the elderly, and the high costs of reproduction (including 
contraconception and diseases of the genital organs). 
Figure 2.1 Total and per capita health care costs by age and sex in the Netherlands, 
1994. Long-term care includes nursing homes, old people's h'omes, institutional care for 
disabled people, and appliances to assist disabled people. In 1994 $1 =Dfl 1.82. 
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Tables 2.3 and 2.4 show the share in total costs of diagnostic groups by 
sex (table 2.3) and by age (table 2.4). Table 2.3 shows the high proportion of 
health care costs caused by mental disorders. Mental retardation ranks 1, 
dementia ranks 3, depression and anxiety ranks 15, schizophrenia 23, alcohol 
and drug abuse 31, and the heterogeneous remainder group of mental disorders 
ranks 4. All mental disorders together cover 28.4% of the health care budget 
that could be allocated to diagnostic groups. Ill-defined conditions, covering 
among others many psychosomatic problems, rank 5. Musculoskeletal diseases 
(predominantly all types of arthritis) rank 2. Dental diseases (predominantly 
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dentists' costs) rank 6. The main causes of death, i.e. stroke, all cancers 
combined, and coronary heart disease, rank 7, 8 and 10, respectively. Among 
women, costs of reproduction rank 6. 
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Table 2.3 Health care costs by diagnostic group and sex, the Netherlands 1994, ranked 
by share (in % of total health care costs). 
Rank Diagnostic group* Men Women Total 
1 Mental retardation, Down's syndrome 11.0 6.0 8.1 
2 Musculoskeletal diseases 5.4 6.4 6.0 
3 Dementia 2.9 7.4 5.6 
4 Other mental disorders 5.4 4.7 5.0 
5 Ill-defined conditions 4.6 5.0 4.8 
6 Dental diseases 4.9 3.8 4.2 
7 Stroke 3.0 3.4 3.2 
8 Cancers 3.7 2.8 3.2 
9 Pregnancy 0.0 4.3 2.6 
10 Coronary heart diseases 3.9 1.5 2.5 
11 Neurologic disorders 2.6 2.3 2.4 
12 Other circulatory diseases 2.8 2.1 2.4 
13 Other respiratory diseases 2.9 1.9 2.3 
14 Other accidents 2.8 1.9 2.3 
15 Depression and anxiety 1.8 2.6 2.3 
16 Falls 1.3 2.4 2.0 
17 Gastro-intestinal diseases 2.4 1.6 1.9 
18 Asthma & COPD 2.4 1.2 1.7 
19 Eye disorders 1.7 1.7 1.7 
20 Liver, gall, and pancreas diseases 1.7 1.6 1.7 
21 Skin dis4eases 1.7 1.6 1.6 
22 Genital disorders 0.9 1.9 1.5 
23 Schizophrenia 2.1 1.0 1.4 
24 Urinary disorders 1.3 1.3 1.3 
25 Infections 1.5 1.2 1.3 
26 Hypertension 1.3 1.3 1.3 
27 Diabetes 1.1 1.4 1.2 
28 Ear disorders 1.4 0.9 1.1 
29 Heart failure 1.1 1.1 1.1 
30 Perinatal I congenital conditions 1.4 0.9 1.1 
31 Alcohol/drugs 1.4 0.4 0.8 
32 Benign neoplasms 0.5 0.9 0.7 
33 Other endocrine diseases 0.4 0.8 0.6 
34 Blood diseases 0.3 0.3 0.3 
Not allocated 7.2 8.8 8.1 
Non-specifict 9.1 11.7 10.7 
Share in total costs(%) 41.0 59.0 100.0 
* For lCD codes of all diagnostic groups, see table 2.2. 
t Costs of health care administration and living costs in homes for the elderly 
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Table 2.4 shows the top 15 diagnostic categories for 5 age groups. In all 
age groups either mental retardation or dementia is the leading cause of health 
care costs. In youth, cognitive disability ranks second but congenital diseases 
also cover many mental disabling conditions. Among younger adults (age 15-
44) the heterogeneous remainder group of mental disorders is second. 
Schizophrenia, depression, and alcohol and drug-related problems all rank 
among the top 15. Musculoskeletal diseases rank among the top 5 in all age 
groups after age 14, and ill-defined conditions rank among the top 6 in all age 
groups. Among the oldest age group (85+) stroke is second and accidental falls 
(predominantly hip fractures) is third. All cancers reach the top 5 only in the 
65-84 age group and coronary heart disease only in middle age (age 45-64). 
Table 2.4 Fifteen diagnostic groups* accounting for highest percentage of health care costs 
for five age groups, Netherlands 1994. 
age 0-14 age 15-44 age 45-64 age 65-84 age 85+ 
Rank Diagnostic group % Diagnostic group % Diagnostic group % Diagnostic group % Diagnostic group 
Perinatal/ conge- 1 0.2 Mental retardation, 16.5 Mental retardation, 9.4 Dementia 9.5 Dementia 
nital conditions Down's syndrome Down's syndrome 
2 Mental retardation, 9.7 Other mental 8.6 Musculoskeletal 8.3 Stroke 6.7 Stroke 
Down's syndrome disorders diseases 
3 Other respiratory 6.3 Pregnancy 8.5 Dental diseases 6.3 Musculoskeletal 5.8 Falls 
diseases diseases 
4 Other mental 6.0 Dental diseases 6.6 Ill-defined 5.8 Cancer 5.6 Musculoskeletal 
disorders conditions diseases 
5 Ill-defined 5.5 Musculoskeletal 6.3 Coronary heart 5.0 Ill-defined 4.6 Ill-defined 
conditions diseases diseases conditions conditions 
6 Ear disorders 5.2 Ill-defined 4.7 Other mental 4.9 Coronary heart 4.0 Heart failure 
conditions disorders diseases 
7 Dental disorders 4.6 Schizophrenia 3.5 Cancer 4.6 Other circulatory 3.9 Cancer 
diseases 
8 Infection 4.0 Depression/anxiety 3.4 Depression/anxiety 3.4 Neurologic 2.9 Other respiratory 
disorders diseases 
9 Neurologic 2.8 Other accidents 3.1 Other circulatory 3.3 Other mental 2.6 Neurologic 
disorders diseases disorders disorders 
10 Other accidents 2.3 Genital disorders 2.3 Gastro-intestinal 2.7 Falls 2.5 Other circulatory 
diseases diseases 
11 Eye disorders 2.2 Skin diseases 2.2 Neurologic 2.7 Asthma & COPD 2.5 other mental 
disorders disorders 
12 Asthma & COPD 2.3 Other respiratory 2.0 Liver, gall and 2.5 Eye disorders 2.3 Liver, gall and 
diseases pancreas diseases pancreas diseases 
13 Musculoskeletal 1.9 Neurologic 2.0 Hypertension 2.5 Diabetes 2.2 Eye disorders 
diseases disorders 
14 Gastro-intestinal 1.6 Alcohol/drugs 1.6 Asthma & COPD 2.2 Gastro-intestinal 2.2 Urinary disorders 
diseases diseases 
15 Skin diseases 1.6 Gastro-intestinal 1.6 Other accidents 2.2 Heart failure 2.1 Other accidents 
diseases 
Share of age groups in 7.9 29.3 20.7 30.6 
total costs 
Share of age groups in 18.4 46.0 22.5 11.8 
population 
*See table 2.2 for lCD codes of all diagnostic groups. 
2.4 Discussion 
In the Netherlands, health care costs are dominated by old age and by 
disability, particularly mental disability and musculoskeletal diseases. The 
share in the health care budget of the main fatal diseases is relatively modest: 
all cardiovascular diseases and all cancers, together 67% of all causes of death, 
cover 17% of all health care costs that could be allocated to a diagnostic group. 
% 
22.2 
6.6 
5.9 
4.3 
3.7 
2.9 
2.1 
2.1 
2.0 
1.7 
1.5 
1.3 
1.2 
1.2 
1.1 
11.6 
1.3 
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Obviously, these results have to be interpreted with caution. The exact 
share of each separate diagnostic group is less trustworthy than the patterns of 
distribution which emerge from this data. Firstly, the key variables used to 
break down costs are generally not collected for epidemiological purposes, but 
in the Netherlands there is no financial incentive to register one diagnosis 
rather than another. Only primary diagnoses are taken into account. It is 
beyond the limits of the method used to assign costs appropriately to the 
primary as well as each secondary diagnosis. Valid information about 
secondary diagnoses is generally lacking or incomplete. As a result, costs of 
diagnoses that are more often registered as secondary or tertiary, such as 
diabetes, are slightly underestimated. However, the registered primary 
diagnosis is generally the more important diagnosis for the health care sector 
concerned, and the main reason why health care is needed: e.g. what the 
internist calls osteoporosis, is for the surgeon a hip fracture, for the ambulance 
an accidental fait and for the nursing home a demented patient. The obvious 
advantage of the used method is that each guilder is allocated to only one 
combination of age, sex and diagnostic group, avoiding double counting. 
Secondly, the key variables used to break down costs for each health 
care sector do not represent exactly equal amounts of resources. Not all days of 
stay in hospitals or nursing homes are equally expensive, some hours of care 
are more labour intensive than others, and outpatient visits or primary care 
consultations can vary in length. As a result, costs of some diagnoses may be 
biased. For example, because hospital nursing costs are broken down by bed 
days without any differentiation, costs of diagnoses for which relatively more 
days are spent in intensive care will be slightly underestimated and vice versa. 
These limitations, however, will not affect the major findings of this 
study, such as the exponential increase by age or the heavy health care burden 
of mental disorders. 
The major strength of the present study is its comprehensiveness. This 
explains why our results seem at variance with a USA-based (Medicare) study 
that shows decreasing costs at the oldest ages [150]. This latter study does not 
include long-term home care for the elderly, and care in elderly homes or 
nursing homes. It is exactly these costs which cause the exponential increase at 
old age. Our findings agree with the American study, as we found that costs for 
acute admissions in hospital decrease at the oldest ages (figure 2.1). Most of 
these patients are already admitted to a nursing home or a home for the elderly, 
and/or are too old or too ill to consider hospital admission useful. A Swedish 
study, which is older and less complete, shows the same results [146]. 
Our findings correspond to a large extent with those of our earlier 
study for the year 1988 [132 133]. Studies that are more or less comparable have 
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been published for England [201], Australia [9] and Canada [186]. These studies 
show basically similar cost patterns, but with lower shares particularly for 
mental retardation and dementia. However, they either did not consider all 
health care, particularly long-term (psychiatric) care [9 201 ], or could not assign 
these costs to diagnoses [186]. Apart from the degree of comprehensiveness, 
many other methodological and country-specific issues may cause differences 
in cost distributions. A serious international comparison of cost-of-illness 
distributions would require specifically designed cross-national studies. 
The present study only considers medical costs; costs of informal care 
are not included. It has been estimated for the Netherlands that if informal care 
is entirely substituted by professional care, this would generate costs that are 
comparable to the current costs of professional home care [98]. Informal care 
mainly substitutes for simple forms of professional care. If these costs had been 
included, the total costs of chronic, disabling conditions (e.g. dementia, 
musculoskeletal disease) would be even more dominant, thus strengthening 
our conclusions. 
It is not surprising that the share of fatal diseases is relatively limited: 
care stops at death. Disability is the main reason why ill people use health care. 
The pattern of epidemiological causes of costs found by us is remarkably 
consistent with the main causes of disability as estimated by Murray and Lopez 
[192 194]. In 1990, in the developed world, they estimated that mental disorders 
(including dementia and hereditary disorders of the central nervous system) 
accounted for 35.5% of life years lived with disability. In the present study, the 
same disorders, including congenital anomalies, caused 28.4% of all health care 
costs that could be allocated to diagnostic groups. Musculoskeletal diseases, 
including arthritis and dorsopathy, caused 7.3% of the allocated health care 
costs, while Murray and Lopez estimated that osteoarthritis covered 6.1% of the 
life years lived with disability in the developed world. 
The costs presented here are grouped cross-sectional figures. Each age 
group mixes persons with low or no costs, and persons with high costs due to 
costly interventions, severe disability or impending death. In higher age groups 
this mixture shifts towards the latter, causing costs per person to rise. Any 
lifetime expected costs that are derived from these data only, assume that 
someone alive today is 'exposed' in the future to currently observed age-
specific health care costs. 
The cost distribution by age is notifying especially for societies that face 
a further ageing of the population. Because the distribution of costs is 
determined by the current prevalence of disease and disability, future health 
care costs will depend (among others) on the evolution of the risk of disability 
and death by age. If it were possible to delay the senescent process as cause of 
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both disability and death, senescence-related costs would be postponed, and 
perhaps curtailed by death. However, as long as the main disabling diseases of 
old age, such as dementia, osteoarthritis and hip fractures, remain more or less 
resistant to prevention and therapy, increasing life expectancy can only result in 
a steep increase in health care needs. 
We conclude that health care costs in the Netherlands are strongly 
determined by old age and disability. In the future, the ageing of the society 
will undoubtedly increase health care needs. When talking about cost 
containment in health care, we should not forget that large shares of the 
budgets are not spent on 'cure', but on 'care'. Long-term care of the old, the frail 
and the mentally disabled will always be labour intensive and expensive, but is 
the hallmark of a civilized society. 
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Part I Injuries 
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Abstract 
Objectives To describe health care costs of injury by its medical and 
demographic determinants. 
Design An incidence based cost model was developed to estimate the lifetime 
costs of injury occurring in a specific period. We defined patient groups that are 
homogeneous in terms of health service use. Health service use per patient 
group was estimated with data from national health care registers and a 
prospective follow-up among 5,755 injury patients. 
Setting Netherlands, 1998. 
Subjects Injury patients presenting at an Emergency Department. 
Measures Health care costs. 
Results Total health care costs due to injury in 1998 are 1.1 billion euro, or 3.4% 
of the total health care budget. Health care costs of injury shows two major age 
peaks: one among males between age 15 and 44 due to high numbers of injury, 
and the second among among females from age 65 onwards due to high costs 
per patient. Costs per injury patient rise linearly up to age 60 and rise 
exponentially thereafter. From age 25 onwards, females account for higher costs 
per patient than males. Hip fracture (21.3%), superficial injury (13.5%), open 
wounds (6.1 %) and skull-brain injury (6.0%) have the highest total costs. 
Superficial injuries rank first among the health care costs of injury up to age 65, 
and is dominated only by hip fracture beyond age 65. 
Conclusions Minor injuries without need for hospitalization account for a 
substantial share of health care costs. 
Meerding WJ, Toet H, MulderS, van Beeck EF. 
Submitted for publication. 
Health care costs of injury in the 
Netherlands 
3.1 Introduction 
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Injuries account for a considerable share in the global burden of disease, 
estimated at 12% for the established market economies and even higher shares 
for other global regions [194]. In addition to their impact on public health, 
injuries are a major cause of health care costs, comparable to the costs of cancer 
and stroke (chapter 2). Because injuries have a very heterogeneous origin, more 
detailed information on health care costs by type of injury may help to identify 
previously unnoticed health problems within this field. Also, such information 
may be a first step in identifying existing inefficiencies in health care and direct 
the development of preventive policies and trauma care. Being a 
unidimensional measure, costs enable rapid comparisons among types of injury 
that differ with respect to severity and health care need [159]. 
Previous studies have identified substantial resources going to patients 
with lower extremity fractures, including hip fracture [10 305]. So far, cost of 
injury studies have been occasional and limited to specific injuries, health care 
sectors and age groups [155 159167 231], or did not distinguish among injury 
diagnoses [275] (see also chapter 2). Therefore it is largely unknown which 
types of injury contribute most to the high medical costs of injury. 
To fill this knowledge gap, we estimated health care costs of injury by 
an incidence-based model linked to an injury surveillance system. With this cost 
model health care costs can be described by type of injury, health sector, basic 
socio-demographic indicators, and multiple external causes. It is comprehensive 
for it covers all injuries and all health care sectors including long-term health 
services. The Netherlands is an ideal setting for such a study, because almost 
100% of the population is covered by health insurance, and most important 
health care sectors have data registries with national coverage. 
3.2 Methods 
Model description 
We developed an incidence-based model [231] to measure and describe the 
lifetime health care costs of injury occurring in a specified period. The present 
paper contains results for 1998. A full description of the model is available 
elsewhere [172]. We considered all injuries of chapter 17 of the international 
34 
classification of diseases (ICD, 9th revision) [296], except injury due to medical 
adverse events (ICD-9 995-999, E870-E879, E930-E949), early complications of 
trauma (ICD-9 958), late effects of injury (ICD-9 905-909), and injuries occurring 
in hospitalized patients. Incidence was restricted to patients who attend a 
hospital Emergency Department (ED), so patients who are fully treated by 
general practitioners or at the injury scene were excluded. 
Table 3.1 Diagnostic groups* used in study and corresponding lCD 9 codes [296]. 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
Diagnostic group 
skull-brain injury 
facial injury 
vertebral column, spinal cord injury 
injury to internal organs 
fractured ribs I sternum 
fractured collar bone I shoulder 
fractured upper arm 
fractured elbow I lower arm 
fractured wrist 
fractured hand I finger 
dislocation I strain I sprain upper extremities 
traumatic amputation I crushing injury upper 
extremities 
pelvis fracture 
hip fracture 
fractured shaft of femur 
fractured knee I lower leg 
fractured ankle 
fractured foot I toes 
dislocation I strain I sprain lower extremities 
traumatic amputation I crushing injury lower 
extremities 
superficial injury (incl. contusions) 
open wound 
burns 
poisoning 
other and non-specified injury t 
lCD codes 
800-01' 803-04, 850-54, 950-51 
802, 870-71' 918 
805-06, 839.0-5, 846-47, 952 
860-69, 900-02, 926, 929 
807.0-3, 809 
810-11 
812.0-3 
812.4-5, 813.0-3, 813.8-9 
813.4-5, 814 
815-17 
831-34, 840-42 
880.2, 881.2, 882.2, 883.2, 884.2, 
885-87' 903, 927 
808 
820 
821.0-1 
821.2-3, 822-23 
824 
825-26 
835-38, 843-45 
890.2, 891.2, 892.2, 893.2, 894.2, 
895-97, 904, 928 
910-17, 919-24 
872-84 (excl. 880.2, 881.2, 882.2, 
883.2, 884.2), 890-94 (excl. 890.2, 
891.2, 892.2, 893.2, 894.2) 
940-49 
960-89 
807.4-6, 818-19, 827-30, 839.6-9, 
848,925,930-39,953-57,959,990-
95 
*Excluded are: late consequences of trauma (ICD-9 905-09), early complications of trauma (ICD-9 
958), and injuries due to medical adverse events (ICD-9 996-99). 
t Includes: other fractures, other strains and sprains, injury to peripheral nerves, injury due to foreign 
body, other injury. 
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We included all health services that are relevant for the treatment and 
rehabilitation of injury patients, except for dental care, aids and appliances, and 
institutions for mentally and physically disabled persons, due to lack of 
information on the cause of injury. 
We calculated lifetime health care costs of injury as a multiplication of 
incidence, transition probabilities (e.g. chance of nursing home admission), 
health care volumes (e.g. length of stay) and unit costs (e.g. costs per day in 
nursing home). Incidence, transition probabilities and health care volumes were 
subdivided by patient groups that are homogeneous in terms of health service 
use. We tested known determinants of health service use: age, sex, location and 
type of the injury, and indicators of injury severity[4 159 179], and patient 
groups were defined accordingly. Injuries were classified by location and type 
into 39 groups (table 3.1 presents an aggregation into 25 groups) after 
consultations with experts in traumatology, orthopedics and rehabilitation. We 
considered hospitalization, number of injuries, and motor vehicle involvement 
to be indicators of injury severity. 
Data sources 
Injury incidence was extracted from the Dutch Injury Surveillance System (LIS) 
for non-hospitalized cases and the hospital discharge register for hospitalized 
cases. LIS is a continuous monitoring system which records all unintentional 
and intentional injury treated at 17 ED's in the Netherlands, resulting in a 
representative 12% sample. The hospital discharge register has national 
coverage. 
For inpatient hospital care, medical procedures, nursing homes and 
rehabilitative services, we estimated health service use (transition probabilities, 
health care volumes) from sector-specific data systems with national coverage 
[198 206 230]. The selection and classification of injury patients from national 
data systems was based on the registered primary diagnosis. In case of multiple 
injuries, we determined the primary injury in LIS by application of an algorithm 
derived from the literature [159]. 
For emergency services and GP services preceding ED treatment we 
used data recorded in LIS. 
We performed a patient follow-up among a sample of 5,755 injury 
patients who attended one of the hospitals of LIS between July 14, 1997 and 
October 18, 1998 in order to collect data on other health services used: intensive 
care, outpatient visits, GP visits after the ED treatment, outpatient physical 
therapy, home care, medication, and aids and appliances. The sample contained 
an overrepresentation of hospitalized patients and severe, less common injuries, 
such as injuries to the vertebrae and spine and skull-brain injury. Victims from 
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self-inflicted injury were excluded. Postal questionnaires were sent two, five 
and nine months after the injury occurrence. As a result, health service use 
estimated from the questionnaires is up to nine months, while health service 
use derived from national data systems can be considered lifetime. 
Data analysis health service use 
For each health care sector for which national data were available, determinants 
of individual health service use were derived by crosstable analysis, and patient 
groups were defined accordingly. Length of stay in nursing homes was 
adjusted for the presence of comorbidity, so days that are not attributable to 
injury are excluded. 
Because the response rates of the patient follow-up were 41.4%, 77.5% 
and 64.2% for the first, second and third questionnaire respectively, data were 
adjusted for non-response using socio-demographic and injury-related 
information from the patient sample. For each type of health service for which 
data from the questionnaires were used, multivariate logistic regression was 
used to estimate the probability of health service use (response variable), and to 
test which determinants of health service use were significantly predictive. We 
used logistic regression because health service utilization appeared to be very 
skewed. Only significant (p<0.05) determinants were included in the final 
models and were used to classify patient groups. The estimated probability of 
health service use multiplied with the average health service use given this 
probability, results in the average health service use specific for each patient 
group and health care sector. 
Unit costs 
For each health care sector we determined costs per volume unit that reflect real 
resource use. All unit costs were estimated according to national guidelines for 
health care costing [210]. We assumed that health care fees were representative 
of real resource use for GP consultations, inpatient medical procedures, home 
care, and rehabilitative treatment. Unit costs of emergency and ordered 
transport, inpatient hospital days (excluding medical procedures), outpatient 
visits, nursing home days, other rehabilitative services, physical therapy, and 
pharmaceuticals were calculated from national production and cost statistics. 
All costs are expressed in 1998 Euros. 
Costs of ED visits were decomposed and estimated as follows. Visit 
duration as recorded in LIS was considered as an indicator of nursing costs. 
Visit duration was entered as a response variable in multivariate linear 
regression analysis, and determinants of health service use were tested as 
predictors. Costs (labour time) of physicians by injury group were determined 
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by expert guesses from two ED physicians. National data on hospital costs were 
used to calibrate the estimated labour costs, and to calculate material, 
diagnostic and overhead costs of ED visits. 
Figure 3.1 Numbers of injury (ED visits), total health care costs of injury (€1 ,000) and 
costs per patient (€) by age and sex, Netherlands 1998. Costs of care include nursing 
homes and home care. 
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Total costs of injury were 1.1 billion euro or 3.4% of total health care costs. Costs 
per capita were Euro 62 for males and Euro 75 for females, and costs per patient 
were Euro 769 for males and Euro 1,380 for females. Total health care costs of 
injury reach a first peak among males aged 15 to 44 due to a high number of 
injuries. An even higher second peak is found among females beyond age 65 
due to increasing costs per injured patient with age and their longer life 
expectancy compared to males (figure 3.1). 
Costs per patient show a linear increase from childhood until age 60, 
and rise exponentially after this age. From age 25 onwards females show higher 
costs per patient than males, which is largely due to more intensive use of home 
care and nursing homes. 
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Table 3.2 Health care costs of injuries by sex, ranked by share (in % of health care costs 
b~ sex1, and inju!J:: freguenc~, ranked b~ share in total freguenc~, Netherlands 1998. 
injury group Costs Incidence 
males females total rank total rank 
14 hip fracture 11.4 29.2 21.3 1 1.2 17 
21 superficial injury 14.6 12.7 13.5 2 34.6 1 
22 open wounds 9.2 3.7 6.1 3 17.1 2 
1 skull-brain injury 7.9 4.4 6.0 4 2.1 11 
16 fractured knee /lower leg 5.7 6.0 5.9 5 1.3 16 
19 lower extremity strain I sprain 5.6 4.4 4.9 6 7.6 3 
17 fractured ankle 3.6 4.4 4.0 7 1.6 13 
9 fractured wrist 2.7 3.9 3.4 8 4.0 7 
8 fractured elbow /lower arm 3.0 3.3 3.2 9 2.3 10 
3 vertebral column I spinal cord 3.7 2.7 3.2 10 0.6 21 
24 poisoning 2.7 3.4 3.1 11 1.6 12 
25 other injury 3.5 2.3 2.8 12 5.1 4 
13 pelvis fracture 1.7 3.3 2.6 13 0.3 25 
10 fractured hand I finger 3.8 1.6 2.6 14 4.1 6 
15 fractured shaft of femur 2.3 2.7 2.5 15 0.4 24 
7 fractured upper arm 1.2 3.2 2.3 16 0.9 20 
2 facial injury 3.2 0.9 2.0 17 4.2 5 
4 organ injury 2.5 1.3 1.8 18 0.4 23 
11 upper extremity strain I sprain 1.9 1.5 1.7 19 2.9 8 
18 fractured foot I toes 2.1 1.3 1.6 20 2.6 9 
23 burns 1.7 1.0 1.3 21 1.5 14 
5 fractured ribs I sternum 1.5 1.1 1.2 22 0.4 22 
12 upper extremity traumatic 2.0 0.5 1.2 23 0.9 19 
amputation/crushing injury 
6 fractured clavicle I shoulder 1.5 0.9 1.1 24 1.3 15 
20 lower extremity traumatic 1.0 0.4 0.7 25 1.0 18 
amputation I crushing injury 
all injury by sex 44.5 55.5 100.0 
Table 3.2 shows the share of injuries in incidence and total health care 
costs by sex. The four injuries with the highest health care costs are hip fracture, 
superficial injury (mainly bruises and abrasions), open wounds and skull-brain 
injury. Hip fracture and skull-brain injury rank 17 and 11 respectively in terms 
of numbers, but result in high medical costs per patient. The high frequency of 
superficial injury and open wounds result in a large proportion of health care 
costs. Of the seven injury groups with the highest total costs, four are lower 
extremity injury. All fractures combined are responsible for 52.8% of total costs 
and 21.3% of total incidence. 
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Table 3.3 Six injury groups accounting for highest percentage of health care costs for 
selected age groups, Netherlands 1998. 
age 0-14 % age 15-24 %age 45-64 %age 75+ % 
1 superficial injury 21.2 superficial injury 21.5 superficial injury 11.7 hip fracture 52.6 
2 fractured elbow I 10.4 lower extremity 9.5 hip fracture 8.0 superficial injury 6.0 
lower arm strain I sprain 
3 open wounds 9.2 open wounds 9.4 skull-brain injury 7.9 fractured knee I 5.8 
lower leg 
4 fractured wrist 8.3 skull-brain injury 8.1 fractured knee I 7.4 pelvis fracture 4.9 
lower leg 
5 skull-brain injury 7.8 fractured knee I 6.0 fractured ankle 6.9 fractured shaft of 3.8 
lower leg femur 
6 fractured hand I 4.5 fractured hand I 4.9 open wounds 6.8 fractured upper 3.7 
finger finger arm 
Superficial injuries dominate costs up to age 65. Beyond this age, hip 
fracture has the highest costs (table 3.3). Up to age 75, open wounds and skull-
brain injury (including concussion) are among the six injuries with the highest 
costs. The importance of injuries to the upper extremities in terms of health care 
costs is relatively high during childhood, but from age 15 onwards injuries to 
the lower extremities (e.g. knee and lower leg fractures, hip fractures) 
increasingly dominate health care costs. 
Table 3.4 Six injury groups accounting for highest percentage of health care costs , and 
share of non-admitted and admitted patients in health care costs of these injuries, 
Netherlands 1998. 
total costs (€ min) admitted nonadmitted 
~atients ~atients 
hip fracture 227.9 99.7% 0.3% 
2 superficial injury 145.2 14.5% 85.5% 
3 open wounds 65.6 21.2% 78.8% 
4 skull-brain injury 64.0 92.6% 7.4% 
5 fractured knee I lower leg 63.2 91.3% 8.7% 
6 lower extremity strain I sprain 52.7 26.3% 73.7% 
Total 1072.2 64.2% 35.8% 
The skewed distribution of health care costs is reflected by the high cost 
share (approximately two-third) of admitted patients, who account for only 
9.4% of total incidence (table 3.4). Their share in costs rises from 37% in age 
group 0-14 to 94% beyond age 85. This pattern reflects decreasing personal 
independence and slower recovery with age giving rise to higher 
hospitalization rates and length of stay. The share of admitted patients in health 
care costs varies among types of injury, and is relatively high among disabling 
conditions such as skull-brain injury and lower extremity fractures. 
Table 3.5 shows the distribution of health care costs by sector of all 
injuries together, and of three injuries that are typical for childhood (fracture of 
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elbow/lower arm), adolescence (skull-brain injury) and old age (hip fracture). 
Hospital costs dominate total health care costs of injury with a share of 68.7%, 
followed by home care (8.8%) and nursing homes (7.7%). The high cost shares 
for ED and outpatient care are typical for fractures of the elbow /lower arm, but 
also in general for childhood injury. Nursing homes, home care and inpatient 
hospital care are the major cost components in hip fracture, but also in general 
among elderly. The share in costs of rehabilitation hospitals that is observed in 
skull-brain injury (9.9%) is only higher for injuries of the spinal cord and 
vertebral column (14.0%), and for crushing injury and traumatic amputations of 
the lower limb (12.1 %). 
Table 3.5 Total costs (min Euro), costs per capita and costs per patient (Euro), and share 
of health care sectors in total health care costs, for selected injury groups and all injuries, 
Netherlands 1998. 
skull-brain hip fracture fractured all injuries 
injury elbow I 
lower arm 
Hospital care 67.6 70.9 70.5 68.7 
-nursing 53.1 59.4 24.1 35.4 
- operations 1.3 7.2 11.5 4.6 
- outpatient 5.5 2.5 19.2 11.2 
- Emergency Department 7.7 1.8 15.7 17.6 
Rehabilitation hospitals 9.9 0.2 0.5 1.8 
Nursing homes 6.1 14.9 6.4 7.7 
General practitioners 1.1 0.3 1.2 1.5 
Ambulance services 5.8 2.5 4.2 5.7 
Physical therapy 2.7 2.3 9.6 5.5 
Home care 6.5 8.8 7.1 8.8 
Pharmaceuticals 0.2 0.1 0.3 0.2 
100.0 100.0 100.0 100.0 
Costs per capita (€) 4.1 14.6 2.2 68.5 
Costs per patient (€) 2,951 14536 1,382 1,019 
Total costs (€ min) 64.0 227.9 34.1 1072.2 
3.4 Discussion 
Substantial parts of health care costs of injury are due to high numbers of 
injury, such as in males between age 15 and 44, superficial injury and open 
wounds, or are due to high costs per patient, such as in females beyond age 65, 
hip fracture and skull-brain injury. Minor injuries without need for 
hospitalization account for more than one-third of health care costs of injury, 
which is almost twice the costs of hip fracture. Costs per patient are higher for 
females than for males from age 25 onwards due to higher costs of care. 
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The biggest strength of our study is that it presents comprehensive 
estimates of health care costs by injury that are fully comparable across all 
output dimensions, and that include most relevant health care sectors and both 
major and minor, intentional and unintentional injury. For those health care 
sectors that are most important for injuries in terms of health care use -hospital 
inpatient care, medical procedures, rehabilitation clinics and nursing homes -
we used registries with national coverage. Nevertheless, one should take into 
account that we included only injuries that are treated at an ED and may be 
hospitalized thereafter. In the Netherlands the total number of injuries on an 
ED is about 1 million per year (6% of the population) and an additional number 
of about 1.3 million are fully treated by a GP or other primary health care 
providers [62]. The vast majority of this second group are patients with minor 
injuries: cuts, abrasions, superficial injuries, dislocations, strains, sprains, small 
bums and poisonings. The associated health care costs will add at most 10% to 
our cost estimate. 
Secondly, for outpatient and primary health services we recorded 
consumption up to nine months after the injury event, and excluded institutions 
for permanently disabled persons. As a result, we underestimated lifetime 
consumption that is particularly relevant for injuries with long-term needs, 
such as permanent brain injury and spinal cord injury. However, for the vast 
majority of injuries all health care needs are in the first year post-injury [134]. 
Thirdly, the response on the patient follow-up was 41% which could 
have biased estimates of outpatient and primary health care. However, 
systematic response bias was accounted for as far as socio-demographic, injury 
and treatment related factors were associated with response. 
Fourthly, to estimate injury-specific health service use, we adjusted for 
comorbidity in nursing home costs by using data on length of stay of patients 
without other disabling conditions. In the patient survey we only asked for 
health care use related to the injury. Hospital costs include additional days 
because of other chronic conditions and complications, but this may be justified 
because the injury was the cause for admission and the additional costs would 
not have occurred without the injury. 
Finally, about 5% of ED patients had multiple injuries. The main injury 
was then identified by an algorithm that was derived from other studies [159 
179], giving priority to spinal cord injury, skull-brain injury and lower 
extremity injury above injury in other body parts, and to fractures above other 
types of injury. Because costs were attributed to the main injury, costs of 
injuries that often occur in combination with more severe injuries were 
underestimated. For hospitalized patients, we used the registered primary 
diagnosis in the hospital discharge register. 
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The comprehensive macro-level approach of the present study makes 
comparisons with other studies difficult. Most cost of injury studies apply to 
specific injuries [167], are restricted to hospitalized patients or specific age 
groups [155 159 161], report only micro-level results or describe costs by injury 
cause [134]. Compared to the study reported in chapter 2, the present study 
estimates higher costs for home care, and higher costs for injuries that do not 
need hospitalization (e.g. superficial injury, upper extremity fractures) which is 
due to the use of an ED-based injury surveillance system and a separate 
operationalization of ED costs. In a classical study from the US [231], medical 
costs of injury were estimated at about $250 per capita (adjusted for inflation up 
to 1998) or about three times the estimate in the present study. Medical costs 
per patient of about $1,030 per patient are similar to our estimate of Euro 1,019. 
However, the US study included all injuries, also those not treated in an ED. 
When this is accounted for, costs per patient in the Netherlands will be about 
half the US estimate. In addition, our study reports a much higher share in costs 
for home care and emergency services, and a lower share for pharmaceuticals. 
Because many other methodogical and country-specific issues may cause 
differences, a full comparison will need a specific study. 
The cost of injury estimates in the present study have shown the impact 
on health care of injuries with a high incidence (e.g. superficial injury) 
compared to injuries that occur far less frequently but have large health care 
needs (e.g. hip fracture). Health care costs by injury not only represent their 
economic impact, but also reflect their impact on population health. This shows 
the potential of cost estimates as a composite population health measure similar 
to disability adjusted life years (DALY). Reasoning that health care costs are to 
some extent the product of injury incidence, degree of disability and the 
duration of this disability, they will rather be associated with the morbidity 
component than the mortality component of the injury burden. Likewise, the 
future distribution of health care costs will among others be determined by 
trends in injury risk, related disability and survival. More research on this 
matter however has to wait for forthcoming estimates of this burden [194]. 
Although the present study demonstrates the substantial impact on 
health care costs of non-hospitalized injury, costs are still unevenly distributed 
with less than 10% of patients (those hospitalized) accounting for almost two-
third of total costs. Due to population aging, and the positive relationship 
between age and hospitalization independent of type of injury, the share of 
admitted injury patients in total costs of injury will be probably enhanced in the 
future. 
Cost of illness studies have been criticized for they do not provide 
enough information to identify health care inefficiency, and they are no aid for 
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prioritizing health care because they do not give information on the 
effectiveness, costs and savings of interventions [45 53]. However, without 
comprehensive burden of disease information, with health care costs (current or 
projected) being just one health measure, the search for cost-effective 
interventions will be a blind search. This search is often susceptible to single 
disease advocacy, whereas comprehensive information on costs of illness 
(injury) will put specific diseases or injuries into perspective and may highlight 
other health problems that receive insufficient policy attention. Moreover, cost 
of illness (injury) studies produce a starting point for cost-effectiveness studies 
by raising insight into health care costs by types of injury, health sectors and 
basic demographic indicators, and therefore where costs might potentially be 
saved or not. For example, when all patients at an ED with minor injury 
(dislocations, sprains, strains, superficial injury, open wounds, small bums, 
poisonings, foreign body injury) who did not need hospitalization and who 
were not referred by their GP were instead treated by their GP, this would 
reduce the number of ED patients by more than 50% and save about 7% of total 
health care costs of injury. 
We did not conduct estimates of production loss due to injury. Because 
of the relatively low hospitalization rates of persons in the productive phase, 
and assumed that minor injuries will often lead to one or more work days lost, 
we hypothesize that the contribution of non-hospitalized patients to production 
losses will be even larger than to health care costs. Future research should 
verify this hypothesis. 
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Abstract 
Objective To compare published cost of injury studies from different countries, 
and increase their usefulness for setting priorities in injury prevention and 
trauma care. 
Design We selected 17 cost of injury studies from Pubmed and our own files, 
that reported on population based estimates of costs of all injuries combined or 
transport injuries. The studies were from 6 countries. We assessed their 
methodology in-depth, and calculated basic economic figures by which results 
could be compared. 
Setting Review of published studies. 
Patients All injuries combined, transport injury. 
Main outcome measures Costs per capita, costs per patient. 
Results Per capita health care costs of all injuries combined ranged from $35-
275, and of transport injury from $2-116 (in PPP 2000 US dollars). These 
differences could partly be attributed to differences in injury incidence, cost 
items and patient groups included. When these factors were accounted for, 
considerable differences in costs per patient remained between countries, with 
high costs in the US and Australia, intermediate costs in the Netherlands, and 
low costs in Sweden, Norway and New Zealand. Productivity costs of injury 
were estimated consistently at about three times the medical costs. 
Conclusions Reported costs of injury could only partially be made comparable 
by accounting for differences in methodology, demography and injury 
incidence. Guidelines for conducting and reporting cost of injury studies are 
urgently needed to better inform health policy and planning, and enable 
meaningful comparisons among injury groups, countries, and time periods. 
Meerding WJ, MulderS, van Beeck EF. 
Submitted for publication. 
Cost of injury studies: do they bring 
us more than confusion? 
4.1 Introduction 
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Injuries are an often neglected though important public health problem. It is by 
far the most important cause of mortality among persons between 15 and 44 
years, and injuries account for 12% of the burden of disease in established 
market economies, and even higher shares in other global regions [194]. 
Information on injury-related health care consumption and costs can be 
complementary to epidemiological data in identifying existing or emerging 
risks and health problems. It might also be a useful tool to prioritize health 
policy and improve trauma care [189]. Being a unidimensional measure, costs 
can be a useful indicator for comparative analysis in a heterogeneous problem 
field ranging from high frequency minor injuries (e.g. superficial injuries) to 
low frequency severe injuries (e.g. polytrauma patients). 
Several population-based cost of injury studies have been conducted 
[177 231 275 293]. They all highlight the economic burden of (specific) injuries. 
However, studies differ notoriously with respect to their methodology, 
including comprehensiveness, matters of definition and classification, and the 
way they measure and value costs. They may consider different patient groups, 
and some studies only consider medical costs whereas others include other 
societal costs and 'human costs' as well [177]. Although such differences may be 
justified by the study objectives, they may create confusion among users such as 
policy makers and health care professionals. They may even attract unjustified 
attention to (specific) injuries at the expense of other health problems, and 
complicate the development of a coherent and efficient health policy. Also, 
artificial differences in cost estimates obscure the genuine causes underlying 
cost differences that are relevant for policy development. 
In this paper, we discuss the most important methodological issues 
concerning cost of injury studies. In a review of studies from different countries 
we assessed their comparability and traced the possible reasons for observed 
differences. 
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4.2 Methods 
Selection of literature 
We conducted a Pubmed search for studies on population-based costs of all 
injuries combined or transport injuries. We only selected English language 
publications from 1995 onwards. To this set we added older key studies, and 
studies from participants of the Burden of Injury Conferences in 2000 and 2002 
that have partly focussed on the economic burden of injury [151 262]. The 
resulting set contained generic cost of illness studies, injury-specific studies 
with population based cost estimates, and studies that primarily focussed on 
costs per injury patient but extrapolated these costs to population level. 
Assessment of studies 
We assessed all studies on pre-specified methodological issues. First, we 
determined the comprehensiveness of studies with respect to included cost 
items: medical cost items, and other societal costs such as material damage, 
costs of the legal system, and productivity losses due to work incapacity. Some 
studies may also monetize premature mortality and lost quality of life ('human 
costs'). 
Second, we determined the case definition in each study, particularly 
regarding external causes and injury diagnoses included, the extent to which 
non-hospitalized patients were considered, and age criteria. 
Third, studies may use either a top-down or bottom-up estimation of 
costs. In a top-down approach total health care costs are broken down by health 
care sector and by (injury) diagnoses, with key variables that more or less 
represent equal amounts of health care resources (e.g. hospital days, outpatient 
visits). In a bottom-up approach costs per injury patient are multiplied with the 
number of injuries. Ideally both approaches should yield similar results, but 
some sources of divergence are known, usually leading to bottom-up costs 
exceeding top-down costs. One of these sources is comorbidity. In top-down 
studies, all costs are attributed to the recorded principal diagnosis, whereas in 
bottom-up studies costs related to comorbid conditions may be attributed to the 
injury when health care consumption do not discriminate sufficiently among 
diagnoses. An important limitation of top-down studies is that key variables 
used to break down total costs may not represent equal amounts of health care 
resources (e.g. normal versus intensive care days). 
Fourth, incidence-based cost studies consider the lifetime costs of 
injuries that have occurred in a given year, whereas in prevalence-based cost 
studies health care consumption in a given year is attributed to injuries that 
have occurred in this or previous years. Again, both approaches may lead to 
differences in outcomes, for instance due to dynamics in the injury 
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epidemiology, the practice of discounting future costs, and incomplete data on 
long-term costs. 
Fifth, costs can be calculated as charges or as real costs, the opportunity 
costs of using resources. Charges may differ from actual resource use. For 
instance, in the US charges are deliberately set at a higher level because they 
partly cover the medical care of uninsured persons [180]. How costs should be 
calculated depends on the study perspective (e.g. societal, insurance company). 
Sixth, we assessed the most important data sources that were used. 
These may be data from health surveys, administrative data (e.g. hospital 
discharge registers), follow-up interviews of injury patients, etcetera. The 
possible limitations of these data are numerous, and are more extensively 
described elsewhere [44 235]. Surveys and follow-up interviews may suffer 
from recall bias, may not distinguish injury-specific health care consumption, 
may exclude specific populations (institutionalized persons, severely impaired 
patients, etc.), and may have incomplete information on long-term health care. 
Emergency department based systems may not be representative and may have 
less than optimal practices of data collection and codification [256]. 
A seventh issue concerns the measurement and valuation of 
productivity losses due to work days lost. Here two approaches prevail that 
conflict with regard to their account of long-term labour incapacity and death. 
According to the human capital method (HCM), the costs of work absence, 
disability and death are equal to the stream of future production that would 
have been generated without the disease. The friction cost method (FCM) 
assumes that in a situation of unemployment sick workers will be eventually 
replaced by others, thereby limiting the long-term productivity losses [131]. 
Any losses are limited to the friction period, i.e. the period up to the 
replacement of the sick worker by a new person, and include also the costs of 
recruiting and training the new worker. 
Data analysis 
We have standardized the results of studies by distinguishing among medical 
costs and other reported costs. Medical costs were calculated per capita, per 
injury patient, per hospitalized injury patient and per non-hospitalized injury 
patient. We converted all costs to year 2000 US dollars, first accounting for 
inflation with use of nominal price indices, and than converting national 
currencies to US dollars by common exchange rates and by exchange rates 
adjusted for international differences in purchasing power (PPP). Nominal price 
indices, exchange rates and PPP adjusted exchange rates were taken from the 
OECD Health Data [207]. If possible, costs were age-adjusted by direct 
standardization to the US population of 1997. 
48 
4.3 Results 
We included 17 studies that were published between 1980 and 2002, of which 
11 considered all injuries, 2 considered unintentional injuries, and 13 reported 
costs of transport injuries (table 4.1). Seven studies were from the US. Half the 
studies included all patients irrespective of where they were treated, four 
studies were limited to ED patients [134 147 218] (and chapter 3), and four 
studies considered hospitalized patients only [105 141155 158]. The majority of 
studies adopted a bottom-up, incidence based approach. 
Six studies included productivity costs in addition to medical costs [22 
104147 231275 293], and four studies included one or more of the following 
non-medical cost items: home modifications, vocational rehabilitation, legal 
costs, and administrative costs for health and car insurance [22 104 231 293]. As 
for medical costs, six studies included hospital costs only [105 134141147155 
218]. Of the remaining studies, two excluded nursing home care [103 178], one 
excluded community health services and ambulance services [164], and two 
excluded aids and appliances [164] (and chapter 3). In addition, one study 
regarded administrative costs for public and private health insurance as part of 
medical costs [164], whereas four studies mentioned earlier classified these 
under non-medical costs. 
The basic quantitative results have been summarized in table 4.2. We 
maximized the comparability by presenting health care costs per capita and per 
patient in US dollars of 2000. In general, accounting for price level differences 
had a larger impact than demographic standardization. For example, health 
care costs of injury in Australia are $111 per capita, $145 when adjusted for 
price level differences, and $147 when subsequently standardized for 
population demographics. In the following, we will concentrate on the 
unstandardized results in $PPP. 
Per capita health care costs of all injuries ranged from $35-275. Between 
country differences are larger than within country differences. Costs per capita 
are highest in the US [178 231], which is about double the costs in Australia [164 
293], and about triple the costs in the Netherlands [275] (see also chapters 2 and 
3). The high costs in the US are partly explained by a high incidence (e.g. 1.6 
times the incidence in the Netherlands). However, costs per patient in Australia 
are comparable [164] or even higher ($1,390) [293] than in the US ($1,150) [231]. 
Interestingly, the Australian bottom-up study [293] generates about 
40% higher cost estimates compared to the top-down study [164], whereas the 
definitions of cases and costs are comparable. Within the US, per capita costs of 
injury are highest in the Rice-study. The studies of Miller and Harlan do not 
include institutionalized persons (e.g. nursing homes) and do not fully capture 
long-term health spending. The Harlan-study is rather outdated and 
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adjustment for price level could be insufficient. The studies of MacKenzie have 
low estimates but consider only hospitalized patients [155 158]. 
The estimates for Sweden [147] and Norway [134] exclude intentional 
injury and, together with the study of New Zealand [218], include hospital costs 
only. Even then cost estimates in these countries can be considered low: costs 
per ED patient are almost $300 (New Zealand), $500 (Norway) and $600 
(Sweden), which is far below the estimate for the Netherlands (total costs 
$1,180, hospital costs $840, see chapter 3). 
Table 4.3 Proportions of medical costs, productivity costs and other costs in total costs 
of in"u 
Study hospital costs8 medical costs other direct 
as% of as% of total costs as% of 
medical costs costs total costs 
Harlan eta/. (1990) 96 100 0 
Rice eta/. (1989) 63 25 4c 
Miller and Lestina (1996) 73 100 0 
van Beeck et a/. ( 1997) 67 b 22 (HCM) 0 
58 (FCM) 
Meerding eta/. (1998) 59 100 0 
Watson eta/. (1997) 69 29 1 d 
Mathers eta/. (1998) 71 100 0 
Phillips eta/. (1993) 100 100 0 
Meerding eta/. (1999) 71 100 0 
Lindqvist eta/. (1996) 100 23 0 
Kopjar (1997) 100 100 0 
MacKenzie eta/. (1988) 99 100 0 
MacKenzie eta/. (1990) 100 100 0 
Hartunian eta/. (1980) 9 26 7e 
NHTSA (2002) 9 22 22 1 
Hendrie eta/. (1994) 9 100 100 0 
Lan£!1e:i eta/. ~1993l 9 100 100 0 
HCM = human capital method, FCM =friction cost method. 
a Includes emergency department services, physicians' hospital services and inpatient 
rehabilitation. 
b Hospital costs are exclusive inpatient rehabilitation. 
productivity 
costs as% 
total costs 
0 
72 
0 
78 (HCM) 
42 (FCM) 
0 
71 
0 
0 
0 
77 
0 
0 
0 
67 
56 
0 
0 
c Included are home modifications, vocational rehabilitation, and administrative costs for health and 
car insurance. 
d Included are among others income-support. 
e Included are administrative costs for insurance and legal costs. 
f Included are administrative costs for insurance, legal costs, police and fire services, and 
vocational rehabilitation. 
g Transport injuries only (see table 4.1 ). 
The majority of studies concerned transport injuries (whether or not in 
public roads) and a minority focussed on motor vehicle crashes only (table 4.1). 
The international cost pattern is similar to that of all injuries combined. By far 
the highest costs per capita ($116) were reported by NHTSA [22], a 50% higher 
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estimate than in Rice's study that ranks second with $75 per capita [231]. We 
could not find an explanation for this large difference. Hartunian [104] reported 
much lower results for the US, but these could be too outdated. Again, the high 
per capita costs in the US are partly due to a relatively high incidence and 
partly due to high costs per patient. 
Compared to the US estimate in Rice's study, per capita costs of 
transport injury are 60% lower in Australia [293], and 80% lower in the 
Netherlands [275] (see also chapters 2 and 3). The difference with Australia can 
largely be explained by a 50% lower incidence in Australia, unadjusted for case 
definition. The incidence in the Netherlands is 25% lower than the US incidence 
(1,700 vs 2,200 per 100,000 person years), and the largest part of the difference 
in per capita cost is therefore accounted for by much lower costs per patient in 
the Netherlands. The lowest per capita costs were reported for Norway ($2) 
[134] and Sweden ($11) [147]. Both studies included hospital costs only, but 
even then the estimates can be regarded low. Costs per patient in Sweden is half 
the estimate in the Netherlands and doubles the Norwegian estimate, despite 
similar case definitions. Per capita costs in New Zealand [141] are higher than 
that reported for Australia [293] considered that the former study was restricted 
to hospitalized patients and hospital costs. The higher costs in New Zealand are 
due to a much higher incidence of hospitalized patients (550 and 160 per 
100,000 person years in New Zealand and Australia respectively) that 
outweighs the lower costs per hospitalized patient ($5,450 versus $12,500). Late 
consequences of injury were not included by Phillips, which largely explains 
the difference between both studies from New Zealand [141218]. 
In studies that aimed to include all medical costs, the proportion of 
hospital costs in all medical costs ranged from 59% to 99% (table 4.3). The 
variation could only partly be explained by differences in casemix. 
Some studies added non-medical direct costs, e.g. vocational 
rehabilitation and administrative costs for insurance, and productivity costs. 
The former represent 1-7% of total costs (here including medical and non-
medical direct costs, and productivity costs), except for the NHTSA-study in 
which the non-medical direct costs (inclusive administrative costs for insurance, 
legal costs, police and fire services, and vocational rehabilitation) equal the 
medical costs. Productivity costs about triple the medical costs of injury in 
studies that adopt the HCM, but are less than the medical costs when estimated 
according to the FCM [275]. 
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4.4 Discussion 
Summary of results 
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The international comparability of cost of injury studies is poor, largely due to 
differences in cost items and patient groups included, and to a lesser extent due 
to differences in approaches for estimating costs: bottom-up or top-down, 
incidence- or prevalence-based. After accounting for the major methodological 
differences, substantial differences in per capita and per patient costs remained 
between countries, and to a lesser extent between studies within the same 
country. It was however impossible to estimate the proportions of variance 
explained by specific causes. 
Added value of cost of injury studies 
Cost estimates provide a composite measure of health care demand that enables 
rapid comparison among very different types of injury, such as minor injuries 
with a high incidence (e.g contusions, open wounds) and less frequent injuries 
with substantial health care needs (e.g. hip fracture, skull-brain injury). In 
addition to epidemiological indicators, cost estimates may help to identify 
specific injuries as canditates for intervention. 
International comparisons of health care costs by injury potentially 
provide opportunities for identifying underlying determinants of cost 
differences. Apart from injury incidence, case mix, and demography, 
particularly differences in health systems may be an important factor. 
Comparative studies on total health spending have shown that countries with 
primary care "gatekeepers" and with capitation systems instead of fee-for-
service payment systems for physicians had lower costs [93]. Similarly, 
international comparisons of costs of injury may help to identify system 
characteristics that improve the efficiency and effectiveness of trauma care. 
However, the current lack of transparency obstructs this development. E.g. the 
high costs per ED patient in the Netherlands compared to Norway and Sweden 
could be due to more comprehensive cost data, but also to differences in injury 
severity and health system efficiency. 
Cost of illness (COI) studies have often been criticized as being of little 
relevance to health policy [45 53]. Because they do not give information on the 
incremental costs and health effects of interventions, they would be useless for 
resource allocation decisions. However, similar to other indicators of the 
burden of injury, costs are important for the health intelligence function of 
governments. Comprehensive cost estimates subdivided by type of health care, 
injury diagnoses and external causes show at a glance where costs might 
potentially be saved or where interventions are most needed. Without such 
comprehensive estimates the search for cost-effective interventions will be a 
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blind search. Moreover, these estimates may highlight previously unidentified 
health problems and risks, whereas others are put into perspective, and so help 
to avoid unjustified single disease advocacy. In other words, COl studies are 
part of the 'public health accounts' similar to what the national accounts are for 
macro-economic policy, and nobody would question the utility of the latter. 
Some opponents argue that COl studies might shift resources towards health 
problems with the largest resource use ('circularity problem'), but nobody has 
ever advocated such a practice. Cost-effectiveness information is critical for 
such resource allocation decisions. 
Some cost of injury studies included estimates of production losses. 
These are a contentious issue because they may exceed medical costs by far, and 
available methods for measuring these costs need further validation. The 
human capital method has been argued to overestimate production losses from 
a societal perspective (see Methods) [131]. Empirical research is needed to 
measure the actual production loss in case of work absence, and should 
consider possible compensation of work loss by colleagues or after return to 
work [243], and the occurrence of catastrophic events with high costs in case of 
unexpected sick leave. Apart from validation, including productivity costs 
introduces an equity problem, giving priority to injuries occurring in the 
working population. It should be investigated whether this is in line with 
societal values and beliefs. 
Two studies considered the monetary value of lost quantity and quality 
of life due to injury [22 177]. Such values have been derived from willingness to 
pay (WTP) estimates for health care or reductions in health risks. Although the 
WTP method is more firmly rooted into the standard welfare economic 
framework than population health measures, there are concerns about its 
validity. A major concern is its insensitivity to the size of the good that is 
valued, i.e. the phenomenon that respondents are unwilling to pay more for 
(much) larger health gains [209]. This compromises the use of WTP values as a 
descriptive measure of population health. Also, WTP estimates appear to be 
very sensitive to study design and framing [92 209], and often exceed by far the 
costs per QAL Y thresholds that are commonly used as rules of thumb in health 
care rationing [108]. Others put forward that WTP values will be positively 
related to the wealth of the individual and negatively to remaining life 
expectancy [66]. 
Towards comparable cost of injury studies 
The policy relevance of COI studies as discussed above is compromised by lack 
of standardization and transparency. The between and within country 
comparability of results can be increased by the development of guidelines for 
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conducting and reporting research. These guidelines should particularly focus 
on the cost items to be included (medical and non-medical), the classification of 
injuries, the measurement of productivity losses, and reporting. Comparability 
will already be greatly enhanced when detailed data would be reported for 
medical costs only, with crosstabulations of costs by type of health care, injury 
diagnoses and/or external causes. More detailed results could be put on a 
website in addition to the published key figures. In addition, some basic 
demographic and epidemiologic indicators should be added to nationwide cost 
estimates to facilitate interpretation and comparability, e.g. age-specific costs 
per capita, and population rates for ED visits and hospitalizations. Such practice 
would facilitate greatly the research into the underlying causes of international 
differences in health care costs of injury, that are of interest for health policy 
making. 
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Table 4.1 Selected cost of injury studies: major characteristics. 
Study External causes Patient group Country Year Method Productivity costs 
All injuries 
Harlan eta/. (1990) all 1 all us 1980 BU, prevalence-based no 
Rice eta/. (1989) all all us 1985 BU, incidence-based yes 
Miller eta/. (1996) all 1 all us 1987 BU, prevalence-based no 
van Beeck eta/. (1997) all all Netherlands 1988 TD, prevalence-based yes 
Meerding eta/. (1998) all all Netherlands 1994 TD, prevalence-based no 
Watson eta/. ( 1997) all all Australia: Victoria 1994 BU, incidence-based yes 
Mathers eta/. ( 1998) all all Australia 1994 TD, prevalence-based no 
Phillips eta/. (1993) all ED N-Zealand: Dunedin 1990 BU, incidence-based no 
Meerding eta/. (2000) all 2 ED Netherlands 1998 BU, incidence-based no 
Lindqvist eta/. ( 1996) unintentional ED Sweden: Motala 1983 BU, incidence-based yes 
Kopjar ( 1997) unintentional 2 ED Norway: Stavanger 1992 BU, incidence-based no 
MacKenzie eta/. (1988) all hospitalized 3, US: Maryland 1983 BU, incidence-based no 
all 2 
age 16-45 
MacKenzie eta/. (1990) hospitalized us 1985 BU, incidence-based no 
Transport injuries 
Hartunian eta/. (1980) mva all us 1975 BU, incidence-based yes 
Rice eta/. (1989) mva all us 1987 BU, incidence-based yes 
NHTSA (2002) mva all us 2000 BU, incidence-based yes 
van Beeck eta/. (1997) transport all Netherlands 1988 TO, prevalence-based yes 
Meerding eta/. (1998) transport all Netherlands 1994 TO, prevalence-based no 
Watson eta/. ( 1997) transport all Australia: Victoria 1994 BU, incidence-based yes 
Mathers eta/. (1998) transport all Australia 1994 TD, prevalence-based no 
Phillips eta/. (1993) transport 2 ED N-Zealand: Dunedin 1990 BU, incidence-based no 
Meerding eta/. (2000) transport 2 ED Netherlands 1998 BU, incidence-based no 
Table 4.1 Selected cost of injury studies: major characteristics. 
Study External causes Patient group 5 Country Year Method Productivity costs 
Lindqvist eta/. (1996) transport 4 ED Sweden: Motala 1983 BU, incidence-based yes 
Kopjar (1997) road traffic 2 ED Norway: Stavanger 1992 BU, incidence-based no 
Hendrie eta/. (1994) road traffic hospitalized W. Australia 1988 BU, incidence-based no 
Langley eta/. (1993) mvta hospitalized N-Zealand: Dunedin 1989 BU, incidence-based no 
mva = motor vehicle accidents, mvta = motor vehicle traffic accidents 
1 Excluding institutionalized 
2 Excluding late consequences of injury. 
3 Includes surviving patients who have been hospitalized for >1 night, and who have not been transferred to another acute care facility. 
4 Traffic injuries during work time are not included. 
5 All= patients treated in primary care facility or ED; ED= patients treated in ED. 
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Table 4.2 Cross-national comparison of incidence (per 100,000 person years) and medical costs of injury (year 2000 US$). 
Study Country Patient group incidence, health care health care costs health care costs health care costs 
standardized a costs per capita per capita (PPP) per capita (PPP), per patient (PPP) 
standardized a 
All injuries 
Harlan eta/. (1990) us All -- 139 139 143 
Rice eta/. (1989) us All 23,599 275 275 275 1,150 
Miller and Lestina (1996) us All -- 219 219 226 
van Beeck eta/. (1997) Netherlands All -- 65 77 
Meerding eta/. (1998) Netherlands All 15,100 [62] 62 74 77 481 
Watson eta/. (1997) Australia All 10,320 111 145 147 1,389 
Mathers eta/. (1998) Australia All -- 81 105 107 
Phillips eta!. (1993) N-Zealand ED -- -- -- -- 266 c 
Meerding eta/. (2000) Netherlands ED 6,983 67 79 80 1,182 
Lindqvist et a/. ( 1996) Sweden ED 11,889b 73° 70° -- 582° 
Kopjar (1997) Norway ED 7,137 42 c 35 c 33 c 493 c 
MacKenzie eta/. (1988) us Hospitalized d 856 b 81 81 -- 9,478 
MacKenzie eta/. (1990) us Hospitalized 895 70 c 70 c 71 c 7,867 c 
Transport injuries 
Hartunian eta/. (1980) us All 1,977 b 46 46 -- 2,337 
Rice eta/. (1989) us All 2,194 75 75 72 3,355 
NHTSA (2002) us All 1,887 116 116 -- 6,144 
van Beeck eta/. (1997) Netherlands All -- 12 15 
Meerding eta/. (1998) Netherlands All 1,700 [62] 12 15 15 870 
Watson et a/. ( 1997) Australia All 1 '111 23 30 30 2,645 
Mathers eta/. (1998) Australia All -- 14 18 17 
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Table 4.2 Cross-national comparison of incidence (per 100,000 person years) and medical costs of injury (year 2000 US$). 
Study Country Patient group incidence, health care 
standardized a costs per capita 
Phillips eta/. (1993) N-Zealand ED 
Meerding eta/. (2000) Netherlands ED 957 13 
Lindqvist eta/. (1996) Sweden ED 1,525 b 12° 
Kopjar (1997) Norway ED 704 3 c 
Hendrie eta/. (1994) Australia Hospitalized -- --
Langley eta/. (1993) N-Zealand Hospitalized 551 b 20 c 
a Figures are age-standardized by using the US 1997 population as the standard population. 
b Not age-standardized 
health care costs 
per capita (PPP) 
15 
11 c 
2c 
--
30 c 
c Includes hospital costs only. 
d Includes surviving patients between 16-45 years and who have been hospitalized for >1 night. 
health care costs health care costs 
per capita (PPP), per patient (PPP) 
standardized a 
15 1,569 
-- 727" 
2c 326 c 
--
3,523 c 
--
5,452 c 
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Abstract 
Background Insight into the distribution and determinants of both short- and 
long-term disability can be used to prioritize the development of prevention 
policies and to improve trauma care. We report on a large follow-up study in a 
comprehensive population of injury patients. 
Methods We fielded a postal questionaire in a stratified sample of 4,639 
nonhospitalized and hospitalized injury patients aged 15 years and older, at 2, 
5, and 9 months after injury. We gathered sociodemographic information, data 
on functional outcome with a generic instrument for health status measurement 
(EuroQol EQ-5D+), and data on work absence. 
Results The response rates were 39%, 75% and 68% after 2, 5, and 9 months, 
respectively. The reported data were adjusted for response bias and 
stratification. The 2-month health status of nonhospitalized patients was 
comparable to the general population's health when measured by the EQ-5D 
summary score, although considerable prevalences of restrictions in usual 
activities (24.0%) and pain and discomfort (34.8%) were reported. Hospitalized 
patients reported higher prevalences of disability in all health domains. Their 
mean EQ-5D summary score increased from 0.62 at 2 months to 0.74 at 5 
months but remained below the population norm at 9 months, particularly for 
patients with a long hospital stay. Patients with injuries of the spinal cord and 
vertebral column, hip fracture and other lower extremity fractures reported the 
worst health status, also when adjusted for age, sex and educational level. Age, 
sex, type of injury, length of stay (LOS), educational level, motor vehicle injury, 
intensive care unit admission, medical operation, and number of injuries were 
all significant predictors of functioning. Nonhospitalized and hospitalized 
injury patients lost on average 5.2 and 72.1 work days, respectively. Of 
nonhospitalized patients, 5% had not yet returned to work after 2 months, and 
39%, 20% and 10% of hospitalized patients had not yet returned to work after 2, 
5, and 9 months, respectively. In a multivariate regression analysis, LOS, type of 
injury, level of education, and ICU admission appeared to be significant 
predictors of absence duration and return to work 
Conclusions Injury is a major source of disease burden and work absence. Both 
hospitalized and nonhospitalized patients contribute significantly to this 
burden. 
Meerding WJ, Looman CWN, Essink-Bot ML, Toet H, MulderS, van Beeck EF. 
Distribution and determinants of health and work status in a comprehensive 
population of injury patients. J Trauma 2004;56:150-61. 
Distribution and determinants of 
health and work status in a 
comprehensive population of injury 
patients 
5.1 Introduction 
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Injury patients are a heterogeneous population with respect to physicat 
emotional and social functional sequelae, in both the short term and the long 
term. A uniform comparison of functional consequences after injury is therefore 
a difficult and challenging task. Insight into the distribution and predictors of 
both short and long-term disability can be used to prioritize the development of 
prevention policies and to improve trauma care. Additional monitoring of 
changes in health will then be supportive of the evaluation of injury control and 
trauma care. 
Several follow-up studies on levels of functioning or disability have 
already been performed among more or less comprehensive, broadly defined 
populations of serious trauma patients [95 109 110 157 159 166] or specific 
serious injuries [123 154 156 223]. In these studies, many predictors of 
functioning could be identified, such as age, sex, maximum Abbreviated Injury 
Scale (AIS), serious extremity injury, spinal cord injury, length of stay (LOS), 
and intensive care unit (ICU) admission. More recently, posttraumatic stress 
and depression were found to significantly predict physical and social 
functioning [109 110 223]. Return to (household) work is a more specific 
indicator of disability and has appeared to be significantly determined by 
educational level, job type, income, age, body region affected (particularly 
extremity injury), presence of a supportive network, and nation- specific 
income replacement services [95156]. 
So far, studies have concentrated on severely injured, hospitalized 
patients up to age 64 and have used different time intervals and measurement 
instruments. As a result, existing information on disability is difficult to 
compare across patients with different types of injury, and little is known with 
respect to elderly patients and the large number of nonhospitalized injury 
patients. The latter are likely to have minor disability levels with short 
durations, but there are large numbers of them, so the total disease burden 
might still be significant. 
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To fill these significant gaps, we report on a large follow-up study of a 
comprehensive population of injury patients aged 15 years and older, both 
hospitalized and nonhospitalized. We aim to answer the following questions: 
How are the levels of functioning and work status distributed across patient 
groups in the first year after the injury? How does the health status of injury 
patients compare with the general population? What personal, injury and 
health care factors are predictive for levels of functioning and work status? 
5.2 Patients and methods 
Survey 
We conducted a patient survey in a sample of 4,639 injury patients aged 15 and 
older, who had visited one of the hospital emergency departments (EDs) of the 
Dutch Injury Surveillance System (LIS) between July 14, 1997, and October 18, 
1998. The LIS is based in 17 hospitals in The Netherlands (approximately 15% 
coverage), in which all unintentional and intentional injuries are recorded. 
These hospitals are geographically spread across the country; include both 
academic and nonacademic hospitals, trauma centers and nontrauma centers; 
and cover representative amounts of urban and rural populations. As a result, 
the recorded injury incidence in the LIS is regarded representative for the total 
population. The sample was stratified such that severe, less common injury 
groups and hospitalized patients were overrepresented in the survey in order to 
get high enough numbers of patients to analyze differences in functional 
outcome by type of injury. On average, hospitalized patients were sampled 
approximately 10 times more than nonhospitalized patients. Hospitalization is 
decided by the treating physician on the ED and is based on medical needs for 
the majority of patients; for a small minority it is also based on social needs 
(e.g., an elderly woman with a concussion living alone). Persons younger than 
age 15, victims of self-inflicted injury, and institutionalized persons were 
excluded. 
After a pilot test, postal questionnaires were sent 2, 5, and 9 months 
after the injury, of which the first was posted by the hospital. All hospitals gave 
permission for the study before the questionnaires were fielded. Before 
questionnaires were sent, it was verified whether patients were still alive. 
Reminders could not be sent. The questionnaire was designed to collect 
information on functioning and work absenteeism, sociodemographic and 
injury characteristics, and health care use. Of 4,639 persons addressed, 1,806 
(39%) responded on average 2 weeks later, giving an average interval of 2.5 
months. Because the majority of nonhospitalized patients have minor injuries 
that need a relatively short recovery period, only hospitalized responders were 
sent repeat questionnaires, of which 75% and 68% responded after 5 and 9 
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months, respectively. The response rates are quite common to similar surveys in 
The Netherlands. 
Functional outcome 
We used the EuroQol (EQ-5D) generic instrument for measuring functional 
outcome [260]. In this instrument, health is defined along five dimensions: 
mobility, self-care, usual activities (such as work, study, housework, and leisure 
activities), pain/discomfort, and anxiety/depression. Each dimension has three 
levels: no problem, moderate problem, or severe problem. To capture 
consequences of head injury, we added a question on cognitive ability (EQ-5D+) 
[138]. In the second part of the EuroQol instrument, respondents recorded their 
health status on a visual analogue scale (VAS), between 0 (worst imaginable 
health state) and 100 (best imaginable health state). We selected the EQ-5D+ 
because it covers the main health domains that are affected by injury. It was 
therefore thought to describe well a heterogeneous injury population and to 
discriminate among specific injuries. In addition, a scoring algorithm, based on 
empirical valuations from the UK general population and subsequent statistical 
modeling is available by which each health state description can be expressed 
into a summary score [65]. This summary score ranges from 1 for full health to 0 
for death, and can be interpreted as a judgement on the relative desirability of a 
health status compared with perfect health. The validity and reliability of the 
EuroQol instrument have been extensively tested [33 79 265]. It can well be self-
administered and takes only 2 minutes to complete [77]. It has been fielded in 
the general population in several countries and in many specific patient groups. 
So far, the EuroQol instrument has not been applied to a comprehensive 
population of injury patients. We compared our estimates with EuroQol data 
from the Swedish general population [43]. 
Work status 
We added questions relating to work absence, absence duration and return to 
work (RTW) only in people with paid jobs, to capture one of the more 
important socioeconomic consequences of health problems. The questions on 
work absence and RTW strongly relate to the "usual activities" dimension of 
the EuroQol instrument but are more detailed. 
Sociodemographic, injury, and health care characteristics 
From the literature, potential determinants of health and work status were 
identified [86 95 109 110 156 157159 168]. These can be grouped into 
sociodemographic (age, sex, and education) and injury-related characteristics 
(type of injury, number of injuries, motor vehicle crash, hospitalization, LOS, 
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admission to the ICU, and medical operation). Injury-related factors can be 
regarded as proxy indicators of injury severity. Educational level was used as 
an indicator of socioeconomic status. The type of injury was picked from the 
LIS surveillance system, in which up to three injuries can be recorded by type 
and body region. The diagnosis of hospitalized patients was verified with 
information from the hospital discharge register (according to the International 
Classification of Diseases, ninth revision). In discordant cases, the hospital 
discharge diagnosis replaced the ED diagnosis. The principal injury was 
classified by body region, with additional categories for extremity fractures, 
superficial injury (abrasions and contusions) and open wounds, burns, and 
poisonings. In case of multiple injuries, the main injury was determined by an 
algorithm derived from MacKenzie et al. [159]. By this algorithm, priority was 
given to spinal cord injury over skull/brain injury (except concussion), hip 
fracture, and other lower extremity fractures, respectively. Age and sex could 
be drawn from the LIS surveillance system, and these were verified by the 
questionnaire. 
Statistical analysis 
A nonresponse analysis was performed by forward stepwise multivariate 
logistic regression separate for the 2-, 5-, and 9-month measurement. We tested 
age, sex, socioeconomic status, type of injury, type of injury event, motor 
vehicle injury, ambulance transport, number of injuries, health status (EQ-5D 
summary score) and hospitalization as possible determinants of nonresponse. 
Only significant variables (p < 0.05) were used to adjust for response bias. 
Subsequently, the respondents were weighted with the inverse probability of 
response resulting from the final modeL In addition, the data were adjusted for 
the sample stratification. The resulting weighted data (adjusted for nonresponse 
and stratification) were representative for the original patient population with 
injury presenting at an ED in terms of basic demographics, injury cause and 
type of injury. Further statistical analyses were performed on the weighted 
data. 
We performed regression analyses on the weighted data of each follow-
up measurement with the following response variables: the EuroQol summary 
score and VAS (continuous variables), probability of work absence 
(dichotomous variable), number of work days lost (continuous variable), overall 
RTW and RTW of persons who reported work absence (dichotomous variable), 
and number of work days lost of persons who had returned to work within the 
2-month interval (continuous variable). The number of work days lost was 
corrected for small differences in the follow-up time by assuming a constant 
RTW hazard over time. In case the reported work absence duration was longer 
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than the time interval , the reported work absence was interpreted as calendar 
days and was subsequently converted to work days. Eleven percent of 
responders did not report on one or more health domains of the EQ-5D. 
Because the summary score can only be computed in case of complete 
information on all health domains, the missing values were estimated by 
hotdeck imputation in case only one or two domains were not reported, using 
the reported values of persons with similar scores in the health domains that 
were reported [238]. 
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The sociodemographic and injury-related characteristics were tested as 
significant predictors of functional outcome and work status in forward-step 
multivariate regression analyses. They were all entered as categorical variables. 
We included an injury by hospitalization interaction term, in order to test 
whether the distribution of functioning and work status by type of injury was 
significantly different between persons who were not hospitalized or were 
hospitalized for a short (<7 days) or long (?:7 days) time. The extreme unequal 
weighting of the data due to the nonresponse analysis and adjustment for 
stratification could influence the identification of significant independent 
variables. To avoid this we used bootstrap analysis [176 226]. This is a socalled 
resampling technique by which a specified number of population samples are 
drawn from the data (iterations), given the distribution of the population across 
the variables that are tested. The distribution of the drawn populations across 
the variables provides information about the significance of each variable. We 
performed 100 iterations to test the significance levels of the independent 
variables. We calculated overall p values using the covariance matrix resulting 
from the bootstrap replicas. The most significant variable was entered into the 
model, and the other variables were subsequently entered. This procedure was 
repeated until none of the remaining variables was significant. The 95% 
confidence intervals of the variables in the univariate and final multivariate 
models were determined by using the 2.5% lowest and highest percentiles of 
500 iterations. 
5.3 Results 
Study population 
Because of stratification, severe injuries such as lower extremity fractures 
(26.5%) and skull/brain injury (9.9%), female sex (45.2%), and persons aged 65 
and older (27.4%) were overrepresented in the study sample (table 5.1). The 
proportion of traffic injury was twice as high (26.1 %) as in the Dutch Injury 
Surveillance System (13.2%). Home and leisure injuries, occupational injuries 
and intentional injuries represent 66%, 13%, and 6%, respectively, of all ED 
attendances and were slightly underrepresented in the study population. 
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Persons with a lower chance to respond were young (15-34 years old) and 
elderly (75+ years old), males, less educated, nonhospitalized, reported a good 
health status (EQ-5D summary score) at the previous measurement, victims of 
home injury and violence, and/or had the following injuries: intoxication, 
foreign body injury, spinal cord injury, eye injury, concussion, bums, and 
ankle/knee strain or sprain. These determinants were all significant (p <0.05) in 
a multivariate analysis. 
Table 5.1 Stud~ population by a~e, sex, injury, and hospitalization. 
Dutch Injury Study Respon- Respondents 
Surveillance sample* dents t working 
System, populationt 
1997 
n=106,318 n=4,639 n=1,806 n=896 
age % % % % 
15-24 26.8 19.2 18.4 20.4 
25-44 42.5 32.8 31.8 50.1 
45-64 18.7 20.6 25.0 29.5 
65-74 5.4 9.0 11.7 
75-84 4.4 11.0 9.0 
85+ 2.2 7.3 4.0 
100.0 100.0 100.0 100.0 
sex 
male 60.2 54.6 50.6 66.0 
female 39.8 45.4 49.4 34.0 
100.0 100.0 100.0 100.0 
type of injury 
skull/brain 1.9 9.9 8.9 10.2 
facial injury 5.3 4.1 2.9 3.6 
spine, vertebrae 0.6 5.8 6.8 7.0 
internal organs 1.0 6.7 6.9 7.4 
upper extremity, fractures 10.9 10.4 12.8 11.6 
upper extremity, other injury 4.2 6.4 6.2 8.4 
hip fracture 1.5 8.0 6.6 1.5 
lower extremity, other fractures 6.3 18.5 21.0 19.4 
lower extremity, other injury 10.7 7.5 8.3 10.4 
superficial, open wounds 49.4 13.7 13.6 14.0 
burns 1.5 2.4 1.8 2.5 
poisonings 1.6 3.2 1.6 1.1 
other 4.9 3.4 2.8 3.1 
100.0 100.0 100.0 100.0 
hospitalization 
no 91.0 37.4 33.1 35.4 
yes, <7 days 4.7 32.2 37.2 40.4 
yes, >=7 days 4.3 30.4 29.7 24.2 
100.0 100.0 100.0 100.0 
* Hospitalized patients and patients with skull/brain injury, injuries to the spine or vertebral column 
were overrepresented. 
t Response to the 2-month questionnaire. 
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Table 5.2 Prevalence (95% Cl) of moderate or severe problems after 2 months in the EQ-50 health domains and cognitive ability (in%), 
and mean EQ-50 summary score and VAS by key indicators. 
mobility self-care usual pain, anxiety, cognitive EQ-50 summary VAS 
activities discomfort deeression abilit~ score 
Total 17 (14, 22) 7 (5, 11) 28 (22, 35) 37 (31, 45) 12 (9, 16) 5 (3, 9) 0.86 (0.84, 0.88) 82 (79, 84) 
hospitalization 
no 14 (10, 20) 5 (3, 9) 24 (17, 32) 35 (27, 43) 10 (7, 15) 4 (1, 7) 0.88 (0.86, 0.90) 83 (80, 85) 
yes, <7 days 31 (27, 37) 15 (12, 19) 50 (46, 55) 56 (51, 62) 27 (22, 32) 18 (14, 23) 0.73 (0.70, 0.75) 77 (75, 79) 
yes, >=7 days 79 (76, 83) 50 (45, 55) 84 (81, 87) 76 (71, 79) 44 (39, 49) 32 (27, 38) 0.51 (0.48, 0.53) 63 (61, 66) 
age 
15-24 9 (5, 16) 10 (3,21) 18 (9,31) 29 (17, 43) 12 (5, 27) 3 (1, 6) 0.89 (0.85, 0.94) 86 (82, 90) 
25-44 18 (9, 27) 1 (1, 2) 30 (18,44) 39 (27,49) 9 (5, 16) 5 (2, 12) 0.88 (0.85, 0.91) 83 (77, 87) 
45-65 13 (9, 19) 8 (5, 11) 25 (15, 36) 39 (27, 51) 10 (5, 19) 3 (1, 4) 0.86 (0.82, 0.90) 79 (71, 85) 
65-74 35 (19, 51) 18 (10, 32) 38 (23, 63) 43 (28, 70) 14 (9, 26) 12 (4, 25) 0.80 (0.66, 0.87) 78 (68, 86) 
75-84 66 (51, 83) 35 (25, 49) 58 (44, 79) 58 (44, 75) 43 (28, 59) 21 (14, 33) 0.63 (0.52, 0.77) 66 (60, 72) 
85+ 74 (57, 90) 67 (50, 88) 74 (53, 93) 60 (41, 77) 45 (30, 61) 52 (30, 73) 0.46 (0.27, 0.61) 45 (38, 54). 
sex 
males 12 (7, 19) 6 (3, 12) 24 (16, 35) 29 (21, 38) 4 (3, 6) 3 (2, 5) 0.90 (0.87, 0.92) 84 (80, 87) 
females 25 (19, 33) 9 (7, 11) 32 (24, 45) 49 (40, 60) 22 (16, 31) 9 (5, 15) 0.81 (0.76, 0.84) 79 (75, 82) 
type of injury 
skull/brain injury 17 (10, 23) 8 (4, 15) 32 (23, 47) 44 (32, 60) 22 (15, 29) 31 (23, 43) 0.80 (0.70, 0.85) 77 (72, 81) 
facial fracture, eye injury 1 (0, 5) 0 (0, 0) 8 (1, 27) 9 (3, 20) 3 (1, 8) 2 (0, 5) 0.96 (0.94, 0.98) 83 (76, 90) 
spine, vertebrae 41 (31, 51) 25 (16, 35) 56 (44, 67) 69 (60, 79) 29 (18, 42) 21 (13, 31) 0.64 (0.56, 0.73) 68 (61, 73) 
internal organ injury 24 (16, 31) 10 (3, 17) 41 (28, 50) 60 (48, 69) 20 (12, 29) 9 (4, 14) 0.77 (0.74, 0.82) 74 (71, 78) 
upper extremity fracture 5 (2, 10) 18 (12, 31) 34 (25, 49) 57 (44, 72) 12 (7, 21) 4 (1, 9) 0.78 (0.70, 0.83) 80 (74, 85) 
upper extremity, other 2 (0, 4) 19 (11, 27) 41 (29, 53) 54 (42, 66) 19 (10, 29) 6 (1, 12) 0.81 (0.77, 0.84) 77 (73, 82) 
hip fracture 90 (84, 94) 68 (58, 77) 92 (87, 96) 74 (65, 83) 45 (33, 56) 40 (29, 52) 0.45 (0.40, 0.50) 56 (51, 61) 
lower extremity, other fractures 57 (49, 68) 14 (10, 18) 51 (41, 63) 56 (45, 67) 19 (13, 27) 8 (5, 13) 0.74 (0.69, 0.78) 79 (74, 83) 
lower extremity, other injury 44 (33, 63) 5 (1, 13) 39 (25, 54) 54 (38, 70) 19 (9, 33) 0 (0, 1) 0.80 (0.74, 0.85) 83 (79, 87) 
superficial injury, open wounds 9 (1, 17) 4 (0, 12) 23 (9, 35 31 (17, 45) 9 (4, 17) 5 (1, 11) 0.90 (0.87, 0.94) 83 (78, 88) 
burns 0 (0, 1) 0 (0, 0) 0 (0, 1) 5 (1, 15) 5 (1, 14) 0 (0, 1) 0.98 (0.96, 0.99) 87 (81, 90) 
poisonings 12 (3, 22) 4 (0, 12) 6 (0, 16) 9 (0, 19) 20 (6, 38) 17 (4,29) 0.84 (0.73, 0.94) 85 (78, 93) 
other inju!l 27 ~5, 57l 3 ~1, 8l 15 ~3, 42l 34 !7, 58l 4 ~2, 9l 2 ~1, 6l 0.88 !0.81,0.94l 86 ~79,91l 
Cl, confidence interval; VAS, visual analogue scale; EQ-50, EuroQol questionnaire. 
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Figure 5.1 EQ-50 summary score (95% Cl) by age and hospital admission. The injury 
patients data are 2 months after the injury occurred for patients 15 years and older. Data 
are adjusted for selective nonresponse and stratification. The injury patients data are 
from the present study, the data for the Swedish general population are from Burstrom 
(2001 ). Notice that the age groups have unequal lengths, in order to enable comparison 
with the Swedish population. 
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The presented results are all adjusted for response bias and sample 
stratification. Two months after the injury, the health status of nonhospitalized 
patients was similar to the general population's health when measured by the 
EQ-5D summary score (figure 5.1). In contrast, the health status of hospitalized 
patients was lower in all age groups, and significant in most groups. The 
decrease in health status by age in both hospitalized and nonhospitalized injury 
patients was similar to what has been observed in the general population. 
Nevertheless, a significant proportion of nonhospitalized persons 
reported restrictions in usual activities (24.0%) and pain and discomfort (34.8%) 
(table 5.2). Hospitalized patients reported higher prevalences of disability in all 
health domains than nonhospitalized patients, and even much higher in case of 
long-term hospital stay. All injury patients combined, the highest prevalences 
of disability were reported for pain and discomfort (37.4%), restrictions in usual 
activities (27.6%), and mobility (17.2%). 
Patients with injuries of the spinal cord and vertebral column, hip 
fracture and other lower extremity fractures reported the worst health status as 
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measured by the EQ-5D summary score. Patients with bums, facial injury (eye 
injury, fractures), or superficial injury (contusions, wounds, and abrasions) 
reported the best health status. The health status as measured by the VAS was 
lower at the higher end of the spectrum compared with the EQ-SD summary 
score, and higher at the lower end, but the ordering by type of injury was 
almost similar. 
Figure 5.2 EQ-50 summary score by type of injury and hospitalization. The point 
estimates represent predicted values from a statistical model. The model includes age, 
sex, injury, hospital admission, a injury times hospital admission interaction term, and 
education as determinants of health status. The presented figures are for age 15-19, 
males, and lowest educational level. The size of the dots represent the number of 
observations. 
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In the multivariate regression analysis, personal background 
characteristics (age, sex, and educational level), type of injury, injury severity 
(measured by motor vehicle involvement and number of injuries) and health 
care-related factors (hospitalization, LOS, and medical operation) were all 
significant predictors of health status (EQ-5D summary score, table 5.3). All 
coefficients had the expected sign, among which were a positive correlation 
between health status and a higher educational level and a better health status 
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for men compared with women. When adjusted for age, sex, and education, the 
ranking of type of injury in terms of quality of life remained the same, but the 
difference between hip fracture and all other injuries became smaller (summary 
score changes from -0.45 to -0.30 with respect to superficial injury). The 
distribution of functioning by type of injury differed significantly between 
nonhospitalized patients and hospitalized patients with a short or long LOS 
(figure 5.2). For example, among shortly hospitalized patients a relatively 
favorable health status was found in patients with skull/brain injury and facial 
injury; among patients with a long LOS, a relatively bad health status was 
found in patients with extremity fractures and injuries of the spinal cord and 
vertebral column. The average health status of nonhospitalized patients was 
similar to the general population, but patients with injury to the vertebral 
column appeared to be the most unfavorable exception to this rule. 
Table 5.3 Determinants of health and work status after 2 months and their p values by 
multivariate regression analysis. 
Age 
Sex 
Hospital LOS 
Type of injury 
Hospital LOS times 
type of injury 
Admittance to ICU 
Medical operation 
Education 
Motor vehicle 
involvement 
EQ-50 
summary score 
<0.0001* 
<0.001* 
NA 
NA 
<0.05* 
0.07 
<0.05* 
<0.01* 
<0.05* 
absence 
probability 
0.62 
0.38 
NA 
NA 
<0.0001* 
<0.001* 
0.32 
0.71 
0.54 
absence 
duration 
<0.01* 
0.19 
NA 
NA 
<0.0001* 
<0.01* 
0.64 
<0.0001* 
0.61 
return to work 
probability 
0.40 
0.98 
<0.0001* 
<0.0001* 
0.96 
<0.05* 
0.32 
<0.01* 
0.50 
Number of injuries <0.05* <0.0001 * 0.52 0.43 
NA, not applicable; LOS, length of stay. 
*significant. Significance levels are for models including all other significant variables. 
We specifically addressed the impact of a second injury on level of 
functioning, as was observed in 4.3% of nonhospitalized patients and 18.4% of 
hospitalized patients. A second or third injury had a relatively large negative 
influence in patients with lower extremity fractures (except hip fracture), upper 
extremity fractures, facial fractures, and internal organ injury (table 5.4). 
For hospitalized patients, the mean EQ-5D summary score increased from 0.62 
at 2 months to 0.74 at 5 months and remained stable up to 9 months, whereas 
the mean VAS score was 70 at 2 months, and increased to 74 and 76 at 5 and 9 
months, respectively (table 5.5). Particularly in patients with a long LOS (?:.7 
days) health status remained below general population norms [43], as well as in 
patients below age 60 (data not shown). 
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Table 5.4 Functional outcome after 2 months by type of injury as single injury or with 
multiple injury.* 
single injury multiple injury 
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skull/brain injury -0.090 (-0.260, 0.021) -0.092 (-0.173, -0.028) 
facial fracture, eye injury 0.041 ( -0.006, 0.097) -0.139 ( -0.232, 0.003) 
spine, vertebrae -0.198 (-0.295, -0.092) -0.258 (-0.455, -0.065) 
internal organs -0.084 (-0.147, -0.021) -0.224 (-0.334, -0.114) 
upper extremity fracture -0.083 (-0.160, -0.015) -0.212 (-0.336, -0.123) 
other upper extremity injury -0.089 ( -0.159, -0.026) -0.176 ( -0.271, -0.1 06) 
hip fracture -0.306 (-0.401, -0.199) -0.306 (-0.444, -0.168) 
other lower extremity fracture -0.115 ( -0.166, -0.064) -0.407 ( -0.480, -0.328) 
other lower extremity injury -0.095 (-0.170, -0.023) 0.003 (-0.722, 0.169) 
superficial injury, open wounds 0.0 -0.091 (-0.217, 0.046) 
burns 0.071 (0.012, 0.124) 0.097 (-0.107, 0.184) 
poisonings -0.064 (-0.183, 0.043) 0.061 (-0.008, 0.156) 
other injury -0.040 ( -0.129, 0.036) -0.271 ( -0.405, -0.126) 
* Coefficients (95% Cl) from a multivariate linear regression model with the EuroQol-50 summary 
score as dependent variable, adjusted for age, sex and educational level. 
Table 5.5 Health and work status in the first year after injury: mean (95% Cl) EQ-50 
summary score, VAS, work absence and return-to-work rate after 2, 5, and 9 months. 
N* 2 months 5 months 9 months Work 
all injury 
not hospitalized 
hospitalized 
<7 days 
~7 days 
all injury 
not hospitalized 
hospitalized 
<7 days 
~7 days 
EQ-5D summary score 
1806 0.86 (0.84, 0.88) NA 
598 0.88 (0.86, 0.90) NA 
1408 0.63 (0.61, 0.66) 0.74 (0.70, 0.77) 
671 0.73 (0.70, 0.75) 0.82 (0.80, 0.84) 
537 0.51 (0.48, 0.53) 0.65 (0.59, 0.70) 
VAS 
1806 82 (79, 84) 
598 83 (80, 85) 
1408 71 (69, 73) 
671 77 (75, 79) 
537 63 (61, 66) 
Return to work rates 
NA 
NA 
74 (72, 75) 
77 (75, 79) 
71 (68, 73) 
NA 
NA 
0.74 (0.67, 0.78) 
0.85 (0.80, 0.90) 
0.62 (0.54, 0.69) 
NA 
NA 
76 (73, 78) 
82 (80, 84) 
70 (65, 74) 
days 
lost 
all injury 896 0.93 (0.88, 0.96) NA NA 11.2 
not hospitalized 317 0.95 (0.89, 0.99) NA NA 5.2 
hospitalized 579 0.63 (0.58, 0.67) 0.80 (0. 76, 0.85) 0.90 (0.86, 0.94) 72.1 
<7 days 362 0.76 (0.71, 0.82) 0.92 (0.88, 0.96) 0.96 (0.91, 0.99) 52.6 
~7 days 217 0.37 (0.30, 0.44) 0.61 (0.51, 0.69) 0.84 (0.74, 0.90) 101.4 
Cl, confidence interval; VAS, visual analogue scale; EQ-50, EuroQol questionnaire; NA, not applicable. 
* Response to the 2-month questionnaire. 
In a multivariate regression analysis, age, sex (women), and hospital 
LOS appeared to have a significant (p < 0.05) negative association with health 
status in hospitalized patients at each interval, and type of injury appeared a 
significant (p < 0.0001) predictor of short-term health status only (table 5.6). In 
contrast to the analysis of health status in nonhospitalized and hospitalized 
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patients combined (table 5.3), ICU admittance appeared to have a significant (p 
= 0.04) negative correllation with health status after 2 months, and offset 
medical operation, motor vehicle crash, and number of injuries as significant 
predictors of health status. 
Table 5.6 P values resulting from multivariate regression analysis of health status (E0-
50 summary score) at 2, 5, and 9 months. 
age 
sex 
education 
hospital LOS 
type of injury 
admittance to ICU 
medical operation 
2 months 
<0.0001* 
<0.001* 
<0.01* 
<0.0001* 
<0.0001* 
0.04* 
0.34 
5 months 
<0.0001* 
<0.01* 
0.08 
<0.0001* 
0.29 
0.61 
0.14 
9 months 
<0.01* 
0.03* 
<0.01* 
<0.0001* 
0.66 
0.14 
0.17 
motor vehicle involvement 0.07 0.34 0.08 
number of injuries 0.15 1.00 0.16 
LOS, length of stay. 
* Significant. Significance levels are for models including all other significant variables. 
Table 5.7 Functioning and work status after 2 months for patients aged 15 to 64 with 
skull/brain inju!}::. 
EQ-50 VAS cognitive return to work t 
summary disability* 
score 
N mean mean % N % 
concussion 71 0.83 79 26 48 96 
not hospitalized 14 0.85 79 18 10 100 
hospitalized 57 0.81 79 39 38 90 
<7 days 50 0.82 80 39 33 93 
?.7 days 7 0.74 73 41 5 69 
skull fractures, 64 0.75 73 38 43 59 
intracranial injury 
not hospitalized 11 0.85 78 20 8 72 
hospitalized 53 0.68 71 51 35 50 
<7 days 18 0.84 77 31 12 89 
?.7 days 35 0.59 68 61 23 30 
all injury 1359 0.88 83 4 896 93 
not hospitalized 495 0.89 83 3 317 95 
hospitalized 864 0.70 76 17 579 63 
<7 days 549 0.75 78 16 362 76 
?.7 da~s 315 0.59 70 20 217 37 
* Minor or severe limitations in cognitive function. 
t Including nonabsentees. 
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Table 5.8 Mean (95% Cl) rates of work absence and return to work within 2.5 months by 
key indicators. 
Absence Return to work Return to work 
erobabilit:[ {rate 2 {rate 2 * {rate} t 
Total 0.57 (0.47, 0.68) 0.88 (0.80, 0.94) 0.93 (0.88, 0.96) 
age 
15-24 0.56 (0.33, 0.75) 0.76 (0.47, 0.94) 0.86 (0.66, 0.97) 
25-44 0.55 (0.42, 0.71) 0.93 (0.87, 0.96) 0.96 (0.93, 0.98) 
45-65 0.62 (0.45, 0.80) 0.89 (0.80, 0.94) 0.94 (0.87, 0.97) 
sex 
males 0.53 (0.40, 0.67) 0.88 (0.75, 0.95) 0.94 (0.85, 0.98) 
females 0.63 (0.45, 0.79) 0.89 (0.81, 0.95) 0.93 (0.87, 0.97) 
type of injury 
skull/brain injury 0.80 (0.64, 0.99) 0.86 (0.78, 0.93) 0.88 (0.81, 0.94) 
facial fracture, eye injury 0.65 (0.26, 0.93) 1.00 (0.97, 1.00) 1.00 (0.99, 1.00) 
spine, vertebrae 0.79 (0.65, 0.90) 0.57 (0.40, 0.71) 0.67 (0.54, 0.80) 
internal organs 0.88 (0.74, 0.98) 0.71 (0.60, 0.84) 0.75 (0.62, 0.84) 
upper extremity fracture 0.85 (0.68, 1.00) 0.78 (0.60, 0.95) 0.82 (0.65, 0.95) 
other upper extremity injury 0.69 (0.52, 0.84) 0.87 (0.77, 0.96) 0.91 (0.85, 0.96) 
hip fracture 0.99 (0.99, 1.00) 0.42 (0.18, 0.70) 0.42 (0.15, 0.74) 
other lower extremity fracture 0.75 (0.62, 0.90) 0.73 (0.60, 0.82) 0.80 (0.70, 0.87) 
other lower extremity injury 0.72 (0.52, 0.90) 0.92 (0.81, 0.99) 0.94 (0.85, 0.99) 
superficial injury, open wounds 0.44 (0.33, 0.64) 0.90 (0.69, 1.00) 0.96 (0.85, 1.00) 
burns 0.36 (0.16, 0.64) 1.00 (0.97, 1.00) 1.00 (0.99, 1.00) 
poisonings 0.60 (0.27, 1.00) 1.00 (1.00, 1.00) 1.00 (1.00, 1.00) 
other injury 0.64 (0.29, 0.94) 0.94 (0.82, 0.98) 0.96 (0.90, 0.99) 
hospitalization 
No 0.54 (0.44, 0.67) 0.91 (0.83, 0.97) 0.95 (0.89, 0.99) 
Yes 0.95 (0.92, 0.98) 0.61 (0.56, 0.65) 0.63 (0.58, 0.67) 
<7 days 0.93 (0.88, 0.98) 0.75 (0.68, 0.79) 0. 76 (0. 71, 0.82) 
'i:!7 da_ls 0.99 ~0.97, 1.001 0.36 ~0.30, 0.421 0.37 ~0.30, 0.441 
* Return to work rates of those who reported work days lost. 
t Return to work rates including those who did not report work days lost. 
General and cognitive functioning of patients with skull/brain injury 
For patients with skull/brain injury, we specifically analyzed both general and 
cognitive functioning. In this analysis, we excluded the elderly to eliminate 
cognitive dysfunction resulting from other causes. Two months postinjury, 26% 
of patients between the ages of 15 and 64 with concussion and 38% of those 
with skull fractures and/or intracranial injury had minor or severe cognitive 
limitations, compared with 4% on average (table 5.7). Nonhospitalized patients 
with skull/brain injury performed slightly worse than average in terms of 
overall functioning (EQ-5D summary score and VAS), and cognitive limitations 
were much more prevalent (18-20%) than average (3%). In contrast, although 
hospitalized patients with skull/brain injury had much higher prevalences of 
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cognitive limitations, they performed at least average in terms of overall 
functioning and return to work. When stratified for hospitalization and LOS, no 
significant differences exist between patients with concussion and those with 
more severe skull/brain injury in terms of health and work status, except for 
patients with skull fractures and/or intracranial injury with a long LOS, who 
had much lower levels of general and cognitive functioning and a worse return 
to work rate. 
Figure 5.3 Absence duration by injury and hospital admission. The point estimates 
represent predicted values from a statistical model. The model includes injury, hospital 
admission, a injury times hospital admission interaction term, and education as 
determinants of work absence. The presented figures are for the lowest educational 
level. The size of the dots represent the number of observations. 
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Work status 
Among patients with paid jobs, an average of 11.2lost work days were reported 
to have been caused by the injury: 5.2 work days among nonhospitalized 
patients and 72.1 work days among hospitalized patients (table 5.5). Because 
nonhospitalized patients account for approximately 90% of all injury patients, 
the total number of work days lost is comparable among both patient groups. 
Work absence was reported by 54% of nonhospitalized patients and 95% of 
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hospitalized patients (table 5.8). After 2 months the proportion of hospitalized 
patients who had returned to work was much lower (61 %) compared with 
nonhospitalized patients (95%). For hospitalized patients, this proportion 
increased to 80% and 90% after 5 and 9 months, respectively (table 5.5). Patients 
with a long LOS had considerably worse return-to-work rates than those with a 
short LOS. Hospitalized patients with lower extremity fracture (excluding hip 
fracture) had the lowest return-to-work rates: 38%, 64%, and 83% had returned 
to work within 2, 5, and 9 months, respectively. 
Table 5.9 Odds ratio's (95% Cl) by type of injury for work absence and return to work within 
2.5 months after the injury, adjusted for educational level. 
absence duration absence probability 
(work days)* (rate) 
type of injury 
skull/brain injury 9.5 (5.5, 16.0) 5.4 (1.8, 156.9) 
facial fracture, eye injury 1.9 (0.8, 4.3) 2.6 (0.6, 26.1) 
spine, vertebrae 13.6 (7.6, 22.6) 5.4 (2.0, 28.3) 
internal organs 11.6 (6.6, 19.9) 10.3 (3.5, 99.3) 
upper extremity fracture 13.0 (7.2, 22.5) 9.8 (3.4, >1 000) 
other upper extremity injury 7.3 (4.0, 12.3) 2.8 (0.9, 12.4) 
hip fracture 26.2 (13.2, 49.3) 178.4 (118.2, >1000) 
other lower extremity fracture 9.5 (5.6, 15.6) 4.2 (1.5, 17.4) 
other lower extremity injury 5.0 (2.4, 9.5) 3.9 (1.3, 23.2) 
superficial injury, open wounds 1.0 1.0 
burns 1.2 (0.4, 2.9) 0.6 (0.1, 3.0) 
poisonings 2.1 (0.5, 5.6) 2.2 (0.4, 23.1) 
other inju!};: 5.0 ~1.4, 10.82 2.5 ~0.5, 30.02 
* An odds of 2.0 means an absence duration two times the base category. 
t Return-to-work rates of those who reported work days lost. 
return to work 
(rate) t 
0.7 (0.3, 1.3) 
2.7 (0.8, 9.1) 
0.3 (0.1, 0.6) 
0.5 (0.2, 0.8) 
0.5 (0.2, 1.3) 
0.8 (0.3, 1.5) 
0.2 (0.0, 0.5) 
0.4 (0.2, 0.8) 
1.1 (0.3, 2.6) 
1.0 
2.5 (0.7, 16.5) 
3.9 (1.5, 11.6) 
1.3 ~0.4, 3.12 
In a multivariate analysis, lower educational level, hospitalization and 
LOS, ICU admittance, and specific types of injury were positively associated 
with work absence (duration and probability), and negatively with RTW (table 
5.3). Age was significantly predictive for work absence duration, but a linear 
age pattern could not be identified (data not shown). Long-term work absence 
in hospitalized patients was predominantly associated with educational level 
and hospital LOS. The highest numbers of lost work days were reported by 
patients with hip fracture, injuries of the spinal cord and vertebral column, and 
upper extremity fractures, also when adjusted for educational level (table 5.9). 
We adjusted for educational level because this is an indicator of job-related 
factors that mediate RTW, and it appeared to be significantly related to absence 
duration and RTW. Patients with lower extremity fractures had a lower RTW 
probability within 2 months than those with upper extremity fractures, but 
among the latter group a larger share reported work absence. For work absence 
duration and probability, the hospitalization times type of injury interaction 
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term appeared statistically significant, indicating that there were significant 
differences among types of injury within nonhospitalized and hospitalized 
patient groups. This is illustrated in figure 5.3. For instance, among 
nonhospitalized and shortly hospitalized patients by far the most work days 
lost were observed in upper extremity injuries, whereas among patients with a 
long hospital LOS the highest number of work days lost were reported by 
patients with injuries to the vertebral column and spinal cord. 
5.4 Discussion 
It can be concluded that 2 months after injury, the EQ-5D summary score of 
nonhospitalized injury patients was almost similar to general population 
norms, and 95% of those with paid work had returned to work. The main 
unfavorable exceptions were patients with injuries to the vertebral column and 
to the extremities. In contrast, hospitalized patients had a significantly lower 
EQ-5D summary score in all age groups, especially patients with hip fracture, 
injuries of the vertebral column and spinal cord and other lower extremity 
fractures (adjusted for age and sex). Mean health status of hospitalized injury 
patients improved up to 5 months, but stabilized thereafter at suboptimal 
levels, predominantly in patients with long LOS. Of all hospitalized patients 
working before the injury, significant portions (39%, 20%, and 10%) had not yet 
returned to work after 2, 5, and 9 months, respectively. 
Methodological issues 
A major limitation of our study was the relatively low response rate (39% 
overall, 42% in hospitalized patients on the 2-month questionnaire). This is 
largely due to the use of postal questionnaires and the very heterogeneous 
population, and because it was not feasible to use reminders. However, relevant 
information on the nonrespondents was available from the Injury Surveillance 
System, which enabled us to perform an extensive nonresponse analysis in 
which the role of personal, injury related and health care factors was 
investigated. As a consequence, we were able to adjust for major determinants 
of nonresponse. Particularly young adults, elderly and patients with minor 
injuries showed significantly lower response rates. It was not possible to 
consider socioeconomic status and work status prior to the injury as 
determinants of nonresponse to the 2-month questionnaire. These are generally 
found to be positively related to response, and appeared to be positively related 
to health status. This might have caused our results to be relatively favorable. 
On the other hand, we found that injury severity was negatively associated 
with response. It could be that we have insufficiently adjusted for injury 
severity, for instance when the relatively less severe injuries within an injury 
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group were less responding. This might have caused our results to be relatively 
unfavorable, particularly the 9-month data. 
One of the major issues in the measurement of functional outcome is to 
determine the appropriate time intervals. The measurement moment should be 
representative for a specific stage within the recovery process. The number and 
length of these stages will differ between specific injuries, and so will the 
appropriate measurement intervals, but uniform guidelines do not exist. 
Although the time interval in this study was the shortest feasible, it appears to 
be too long for nonhospitalized patients (90% of the original population), 
because the majority of these patients had returned to normal health. Because 
these injuries can be temporarily quite disabling, it can be concluded that 
follow-up of these minor injuries should take place a few weeks after the injury. 
In addition, because no further increase in the EQ-5D summary score 
was observed after 5 months, we may conclude that the 2- and 5-month interval 
were sufficiently remote for measuring an improvement in health status, also in 
specific age and injury groups, whereas the 5- and 9-month measurements 
could have been too close. On the other hand, there are other possible 
explanations for the stabilizing aggregate health status after 5 months. First, a 
significant number of the patients might have achieved their maximum level of 
functioning, leaving no room for further improvements. Second, we observed a 
non-significant decrease in health status in elderly beyond age 85, who 
constitute about 10% of hospitalized injury patients. Although this might be 
due to remaining nomesponse bias after the adjustments we made, a 
deteriorating health status in the long term is generally observed in the very 
elderly, particularly after specific injuries [90]. Third, we used a generic, non-
disease specific instrument for measuring health status (EuroQol) that might 
have been insufficiently sensitive for aggregate changes in health after 5 
months. However, its validity and reliability has been extensively tested and 
are prerequisites for the measurement of functioning. Moreover, the short 
completion time, the possibilities for making comparisons with other patient 
groups, and the possibilities for computing a summary score are major 
advantages. 
The EQ-5D+ appeared to be a feasible and valid instrument for the 
measurement of functioning and disability in injury patients. The domains 
discriminated well among different patient groups. Hospitalized patients with 
skull/brain injury scored relatively favorable on the EQ-5D summary score, 
although 55% reported minor or severe cognitive limitations after 2 months. 
This indicates that the EQ-5D captures the specific health consequences of 
skull/brain injury insufficiently, and underlines the previously indicated 
usefulness of the additional question on cognitive ability [138]. 
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We compared the EQ-5D summary score with the averages in the 
general Swedish population [43], which revealed a striking similarity of the age 
gradient. The age gradient in the general population is a reflection of the 
prevalence of disability and chronic conditions. For the purpose of the present 
study, it therefore seems a valid way to adjust for age-specific comorbidity, to 
identify the injury-specific contribution to loss of health-related quality of life. 
However, this hypothesis should be confirmed with other research in which 
direct information on comorbidity is available. 
The rank ordering of patient groups was similar between the EQ-5D 
summary score and the VAS. However, patients with relatively high levels of 
functioning scored systematically lower on the VAS scale than on the EQ-5D 
summary score, and vice versa. This socalled end aversion bias is a general 
observation in visual analogue scales [257]. 
Other issues and comparison with other studies 
The present study has clearly shown the explanatory value of the 
sociodemographic factors age, sex, and socioeconomic status with respect to the 
variance in functional outcome, in addition to the type of injury and severity. 
The role of other factors next to injury-related impairments has been assumed 
in earlier studies on post-injury functioning [154], and particularly age has been 
shown a significant term in later studies on long-term disability [5 109]. 
Sociodemographic factors can be regarded as distal factors, to be distinguished 
from more proximal factors that are more directly related to disability, and that 
(partly) mediate the relation between distal factors and disability. An increased 
understanding of these proximal factors may help improve trauma care and 
patient recovery, especially those factors that may be amenable to intervention. 
Examples of proximal factors are comorbidity including mental health, social 
support, propensity to complain, and the perception of disease and disability. 
Specific job characteristics will mediate the relationship between educational 
level and return to work. The importance of preinjury health and social support 
has been indicated in studies on long-term disability [5 183], and particularly 
(acquired) poor mental health, post-traumatic depression, and stress, receive 
increasing attention and appear to have a major impact on overall health status 
[109 175 223]. 
Our observation that educational level is positively related to RTW 
confirms findings in other studies [95156]. We did not identify a relationship 
with age, contrary to what has been found in these studies, particulary for 
persons aged 45-64 years [35 95156]. However, other factors that have been 
associated with faster RTW were not investigated in the present study, such as 
job characteristics, the presence of a social network, and income. In the 
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Netherlands, work absentees generally receive complete income compensation 
in the first year after injury, thus neutralizing income-related incentives for 
return to work. However, much remains unclear about the independent 
contribution of these factors (e.g., specific job characteristics need to be 
identified for the development of focussed measures that stimulate persons to 
resume work). 
We found that LOS, motor vehicle involvement, and number of injuries 
were all independently and significantly predictive for postinjury levels of 
functioning, even when adjusted for age, hospitalization, and type of injury. 
ICU admission appeared to be a significant predictor of absence duration and 
RTW, and functional status in hospitalized patients. These results indicate that 
these proxy measures for injury severity could be useful for predicting 
functional recovery and RTW, especially in situations were injury severity is not 
routinely recorded with classifications such as the AIS and the Injury Severity 
Score [12]. Particularly the maximum AIS related to extremity and spinal cord 
injury has been previously identified as a good predictor of functional status 
and RTW [157 159], whereas Glancy et al. found a significant relationship 
between RTW and the Injury Severity Score [95]. Of the proxy measures in the 
present study, only LOS and ICU admission have been identified previously as 
good predictors of functioning and RTW [109157]. We found that a second 
injury deteriorates levels of functioning, especially when the principal injury 
was a lower extremity fracture (excluding hip fracture), upper extremity 
fracture, internal injury, or facial fracture. Previous research has shown similar 
findings for patients with lower extremity fractures, especially in combination 
with head injury [123]. Our findings give rise to future research on this matter, 
to identify specific combinations of injuries that are particularly disabling. 
In previous studies with comprehensive patient populations, spinal 
cord injury and extremity injury have been identified as being particularly 
disabling also after several months [109 157159]. This has given rise to other 
studies on these particular injuries [123 154]. We found that particularly lower 
extremity fractures and injuries to the vertebral column and spinal cord had the 
most negative impact on levels of functioning, also when adjusted for 
sociodemographic variables. 
Because among the injuries to the vertebral column and spinal cord in 
our sample only few patients (7 of 270) had spinal cord injury, injuries to the 
vertebral column such as strains, sprains, and fractures without damage to the 
spinal cord have a significant impact on levels of functioning. In terms of work 
days lost, upper extremity fractures and skull/brain injury can be added to the 
injuries with the highest impact. This confirms findings reported previously, 
although these concern results 1 year after injury [159]. 
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We found that significantly more patients had returned to work after 9 
months (90%) than in the study by MacKenzie et al. after one year (57%) [159]. 
Similarly, we found that 38% of hospitalized patients with lower extremity 
injury (excluding hip fracture) had returned to work after 2 months, which is 
higher than found elsewhere (26% after three months) [156]. The discrepancies 
are likely because of differences in case mix, and possibly also because we 
included persons who had only partly returned to work 
In the present study persons with burn injury showed a relatively good 
functional status. However, our sample is not representative for burn injuries, 
because patients with severe burn injury are treated in one of the three burn 
centres in The Netherlands, and these were not included in the study. Previous 
research has shown the severe difficulties with community integration for 
patients with major burns [76]. 
If we take into account the age composition of hospitalized injury 
patients in the Netherlands, the observed EQ-5D summary scores after 5 and 9 
months (0.74) are still below the population norm of 0.79 calculated with 
Swedish data [43]. However, our results compare favorably with the average 
Quality of Well-being scores of 0.63 and 0.67 that were found in hospitalized 
patients after 6 and 12 months, respectively, by Holbrook et al. (population 
norm of Quality of Well-being score, approximately 0.80) [109]. This is at least 
partly due to the more severe patient mix in the study by Holbrook et al.: 62% 
were traffic injuries, compared with only 29% in Dutch hospitals. 
Until now, studies describing and predicting injury-related disability 
have concentrated on trauma center patients between 16 and 65 years old. The 
present study is the first which has been designed to measure levels of 
functioning and work status after injury in a comprehensive sample of 
hospitalized and nonhospitalized patients presenting at an ED. In The 
Netherlands the total number of injuries on an ED is approximately 1 million 
per year (6% of the population), of whom approximately 10% are hospitalized, 
and an addional number of approximately 1.3 million injuries are treated only 
by a general practitioner or other primary health care providers [62]. The vast 
majority of this group are patients with minor injuries: cuts, abrasions, 
contusions, strains, sprains, and small burns. Although the duration and level 
of dysfunction reported by nonhospitalized injury patients are relatively 
modest, the total burden of injury may still be high because of the large 
numbers of patients. Similarly, the average number of work days lost was more 
than 10 times as high for hospitalized patients (72.1 days) compared with 
nonhospitalized patients (5.2 days up to 2 months after the injury), but the latter 
constitute 90% of the injuries. This justifies further study on functional outcome 
and factors determining RTW in injuries that are generally considered minor. 
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We conclude that injury is a major source of disease burden and work absence. 
Both hospitalized and nonhospitalized patients contribute significantly to this 
burden. 
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Part II Cervical cancer 
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Abstract 
Objective To assess the difference in costs between P APNET -assisted and 
conventional microscopy of cervical smears when used as a primary screening 
tooL 
Study design We performed time measurements of the initial screening of 
smears by four cytotechnicians in one laboratory. Time was measured in 816 
conventionally screened smears and in 614 smears with P APNET-assisted 
screening. Data were collected on the shares of initial screening, clerical 
activities and other activities in the total work time of cytotechnicians in the 
routine situation, and on resource requirements for both techniques. 
Results P APNET saved on average 22% on initial screening time per smear. 
Due to costs of processing and additional equipment, the costs of P APNET-
assisted screening are estimated to be $2.85 (and at least $1.79) higher per smear 
than conventional microscopy. The difference in costs is sensitive to the rate of 
time saving, the possibility to save on quality control procedures and the share 
of the initial screening time in the total work time of cytotechnicians. 
Conclusion Although P APNET is time saving compared with conventional 
microscopy, the associated reduction in personnel costs is outweighed by the 
costs of scanning the slides and additional equipment. This conclusion holds 
under a variety of assumptions. Using PAPNET in stead of conventional 
microscopy as a primary screening tool will make cervical cancer screening less 
cost-effective, unless the costs for P APNET are considerably reduced and its 
sensitivity and/or specificity are considerably improved. 
Meerding WJ, Doomewaard H, van Ballegooijen M, Bos A van der Graaf Y, 
van den Tweel JG, van der Schouw YT, Habbema JDF. Cost analysis of 
P APNET -assisted vs. conventional Pap smear evaluation in primary screening 
of cervical smears. Acta Cytologica 2001;45:28-35. 
Cost analysis of P APNET -assisted 
versus conventional Pap smear 
evaluation in primary screening of 
cervical smears 
6.1 Introduction 
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The P APNET system [162] is one of various techniques that are being 
developed to improve on the conventional microscopic examination of Pap 
smears. It assists the cytotechnician by scanning the slide and selecting through 
neural network technology those cells on the slide that are most likely to be 
neoplastic. These cells are represented by 128 images and stored on a digital 
tape. The images are presented to the cytotechnician on a monitor. If desired, 
the selected cells can be traced on the original slide under the microscope by 
use of X/Y coordinates. The automated scanning of slides can be remote or in 
the review laboratory. 
Several studies have assessed the effectiveness [28 69 83 136 237] or 
have explored the cost implications [99] and the cost-effectiveness [113 143 227 
228 241] of the P APNET system. These studies all refer to a situation where 
P APNET is used as a rescreen instrument, and use anecdotal information 
concerning resource implications. Recently the P APNET system has been 
evaluated when used as a primary screening tool. It turned out to have similar 
diagnostic performance as conventional microscopy, and as a consequence will 
be equally effective in terms of health benefits [ 68]. Given this result, P APNET-
assisted screening will only be more cost-effective when costs per smear are 
lower than with conventional microscopy. 
It has been reported that the screen rate is 3-4 times faster with 
PAPNET compared to conventional microscopy [83 120]. However, these 
studies compare rescreening in a study situation with routinely used 
conventional microscopy, and only consider the video image assessment 
exclusive additional microscopy. In addition, the initial screening of slides is 
only part of the entire laboratory process of smear examination. 
In this paper we present the results of a cost analysis of P APNET 
compared with conventional microscopy that was executed parallel to the 
evaluation of the diagnostic performance [68]. We gathered empirical data on 
the time involved in screening smears in a study situation using both methods, 
and on how cytotechnicians spend their total work time in the routine situation. 
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We also assessed the required resources for conventional microscopy and 
P APNET -assisted screening. 
6.2 Materials and Methods 
P APNET versus conventional microscopy 
On the one hand P APNET -assisted screening may save screening time, and 
thereby reduce the number of cytotechnicians, microscopes, and housing costs. 
On the other hand the PAPNET technology requires additional investments in 
review stations and involves costs for scanning of slides and for training. We 
assume that the introduction of P APNET will have no implications for the 
amount of work by the pathologist, senior cytotechnician or secretariat. This is 
reasonable because it has been indicated that the rate of potentially positive 
smears does not change when P APNET is used as a primary screening tool [ 68]. 
Other studies have suggested that the rate of potentially positive smears 
increases [28 69 83136 237]. However, these concern situations in which 
P APNET is used as a rescreen instrument, which by definition increases the rate 
of positive smears. 
Cytotechnicians' work time activities 
In order to evaluate the impact of P APNET cytotechnicians' work time, we 
distinguished three main activities: 
1. Initial screening of smears. Using conventional microscopy this includes 
smear examination, review of the clinical and pathologic history, and 
reporting of results on paper. Using P APNET this includes examination of 
the images, additional microscopy (quick scanning, X/Y coordinates or total 
screening) in case of technical problems or smear abnormalities following a 
protocol [68], review of the clinical and pathologic history, and electronic 
reporting of results. 
2. Clerical activities. This includes colouring and filing of slides, data entry of 
screen results in the computer, and follow-up of women with positive 
smears. These activities do not change when P APNET is introduced. 
3. Other activities. These are a mixture of quality control activities and 
aspecific work time (telephone calls, staff meetings and personal time). 
Quality control comprises multiple screening of high risk smears, screening 
of marked cells, and rescreening of previous smears in case of positive 
smears. In routine practice, these activities may happen during initial 
screening and bilateral and multilateral team discussions among 
cytotechnicians or with the pathologist. In this study however, we strictly 
separate initial screening from other activities. 
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We made this distinction in activities in order to take into account that a 
reduction in the initial screening time through P APNET for instance by 50% 
does not imply that the number of smears processed per cytotechnician can be 
doubled. Quality control and clerical activities are largely related to the number 
of smears processed and as a result their shares in the total work time will 
increase when the number of smears per cytotechnician increases. 
Materials 
The cost analysis was part of a larger study on the accuracy of the P APNET-
system using archival smears from 1988 [68]. Time measurements were 
performed on a random sample of these smears. Because the study considered 
an enriched sample of smears (11.0% were assessed SIL+), we calculated the 
average screening time according to the mix of negative and positive smears in 
the Dutch screening programme in the same laboratory in 1988 (1.8% SIL+). 
For P APNET, smears containing suspicious cells or other specific 
characteristics, were manually reviewed either rapidly or more detailed 
according to a protocol [ 68]. 
Time measurements 
Of all four cytotechnicians participating in the study we measured the initial 
screening time per smear for each screening technique. All cytotechnicians were 
experienced in conventional microscopy and had gone through the standard 
P APNET training before the start of the study, but they had never worked with 
PAPNET routinely. In order to capture possible learning effects in PAPNET-
assisted screening, the measurements took place on two occasions, three and 
nine months after the start of the study. The screening for the study took place 
in a separate room, without the disturbances common to a routine situation, 
creating equal circumstances for both screening techniques. Time was clocked 
and registered manually for conventional microscopy and electronically (using 
the system-integrated time clock) for P APNET -assisted screening. In P APNET-
assisted screening, any additional microscopy of a smear took place 
immediately after the video image assessment and was included in the initial 
screening time measured. The screening times were linked with the cytologic 
result. 
To know the share of initial screening activities within total work time, 
we combined the results of this study with a recent time measurement during 
routine practice in the same laboratory. During a week all cytotechnicians 
(including the four cytotechnicians in the study) had registered time spent on 
screening and other activities combined and clerical activities, as well as the 
number of smears screened. The difference between the total time per smear for 
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screening and other activities combined in this recent time measurement and 
the initial screening time per smear as measured in this study generates the 
time per smear for ;other activities;. 
Resource requirements 
In our assessment of the resources needed for P APNET -assisted screening and 
conventional microscopy we made the following assumptions. For a workload 
of 40,000 smears per year, process costs for P APNET are at least $2.82 per 
smear. This includes only scan station lease costs, technical service, software 
upgrades, two review stations and training for two cytotechnicians and two 
scan station operators. When additional review stations and training of 
cytotechnicians are needed this involves extra investments. We assumed one 
review station for two cytotechnicians plus one extra review station to handle 
peak workloads. 
For each full time cytotechnician we assumed 200 effective work days 
per year, one microscope, 10 square metres for housing ($180 per m2 I month), 
and $1,067 per year for central management, administration and travelling 
costs. All costs are expressed in 1997 US dollars using an exchange rate of $0.51 
per Dutch guilder. 
6.3 Results 
Time measurements in the study 
The crude average initial screening time was 232 seconds (sd = 80 sec) for 
conventional microscopy and 189 seconds (sd = 109 sec) for PAPNET-assisted 
screening (table 6.1). The average initial screening time with PAPNET was 
significantly lower in the second time measurement (t=9 months) than in the 
first one (t=3 months): 183 vs. 203 seconds (p=.02). We considered the results of 
the second time measurement representative for a routine situation. As 
expected, for both screening techniques the average initial screening time 
increased with the degree of cytologic abnormality (table 6.1). PAPNET was 
time saving for normalsmears only. This reflects the utility of the PAPNET 
system as an instrument that accelerates the selection of a relatively small 
sample of abnormal smears from the large pool of screening smears. When 
corrected for the share of abnormal smears in the Dutch screening programme, 
the average screening time changes slightly for P APNET only. This indicates 
that the sample of smears has been representative for a routine screening 
situation. 
The learning effect with P APNET as reflected in the reduction of the 
initial screening time between month 3 and 9 of the study period was mainly 
related to a reduced usage of the microscope next to the video image 
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assessment. During the first time measurement only 25% of smears passed 
without additional microscopy, while this increased to 39% during the second 
time measurement. Additional microscopy increased the average screening 
time considerably from 100 seconds per smear screened without microscopy up 
to 291 seconds per smear with full microscopy. 
Table 6.1 Time measurement: average initial screening time in seconds per smear (n), 
by cytologic result and screen technique. 
Conventional PAPNET: PAPNET: 
151 and 2nd time 
measurement* 
2nd time 
measurement* 
Unsatisfactory 
Negative 
ASCUS 
SIL 
157(42) 
219(620) 
303 (82) 
301 (72) 
Total 232 (816) 
Total, adjusted t 232 (816) 
* Including manual microscopy. 
172 (16) 
169 (499) 
279 (41) 
300 (58) 
189 (614) 
187 (614) 
159 (11) 
164 (365) 
304 (20) 
307 (37) 
183 (433) 
186 (433) 
t Adjusted to mix of negative and positive smears in the national screening programme in 1988 in 
the same laboratory: unsatisfactory 0.2%, negative 84.1 %, ASCUS 13.9%, SIL 1.8%. 
Table 6.2 Time measurements: average time in seconds per smear (n) of initial 
screening and of initial screening plus 'other activities', by cytotechnician and screen 
techni ue. 
Cytotechnician A B c D Mean 
A. Initial screening: study situation 
Conventional * 182 (196) 260 (222) 233 (199) 246 (199) 230 
PAPNET*t 116(100) 235(122) 178(102) 192(109) 180 
Reduction by PAPNET -36% -9% -24% -22% -22% 
B. Initial screening plus 'other activities': routine situation 
Conventional 429 (109) 675 (76) 432 (25) 459 (78) 499 
C. Share of initial screening in total work time:j: 
Conventional 36% 33% 46% 45% 
* Adjusted to mix of negative and positive smears in the national screening programme. 
t 2nd measurement only. 
:j: Calculation: (A I B) x 85%, because 15% of total work time is spent on clerical activities. 
39% 
Compared to conventional microscopy, the average initial screening 
time was reduced by 9% to 36% for P APNET depending on the cytotechnician 
(table 6.2). We took the average of 22% as baseline estimate. The relative 
differences in the average screening time among the cytotechnicians were larger 
with P APNET compared to conventional microscopy, but the ranking of the 
cytotechnicians in terms of speed was the same. 
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Time measurements in the routine situation 
It was observed in the routine situation time measurement that initial screening 
and 'other activities' taken together accounted for 85% of total work time of 
cytotechnicians. Per smear this was 499 seconds for the cytotechnicians 
participating in the study and 621 seconds for all cytotechnicians (40 smears per 
full work day of 8 hours), so the cytotechnicians participating in the study were 
20% faster on average. Combining these findings with the time measurement in 
this study, it can be concluded for the cytotechnicians participating in the study 
that the share of initial screening in total work time was 39% on average (range 
33%-46%, table 6.2), leaving 46% for 'other activities', and 15% for clerical 
activities (114 seconds per smear). 
Number of smears per cytotechnician; cost calculations 
In table 6.3 the baseline and alternative assumptions are summarized for 
calculating the number of smears with the P APNET -system in a routine 
practice. We were able to capture only the initial screening time of smears for 
both screening techniques. Our baseline assumption is that P APNET only saves 
on the initial screening. In a sensitivity analysis we accounted for the possibility 
that P APNET -assisted screening will streamline quality control activities or 
reduce aspecific work time, which has been translated to a time reduction of 
'other activities' analogous to initial screening. In addition we varied the rates 
of time saving according to the observed differences among the cytotechnicians. 
A third assumption is a 50% increase in initial screening time for conventional 
microscopy, holding total work time per smear constant, accounting for the fact 
that the measured initial screening time per smear might have been biased 
downward due to the study situation. We assumed P APNET does not save time 
on clerical activities. 
Table 6.3 Assumptions underlying the calculation of number of smears per 
cytotechnician and costs per smear. 
Assumptions 
1. Rate of time saving by PAPNET 
2. PAPNET saves time on 
3. Initial screening time per smear for 
conventional microscopy 
Baseline 
22% 
initial screening only 
286 sec 
Sensitivity analysis 
9% (low), 36% (high) 
initial screening and 
other activities, but not 
on clerical activities 
430 sec (+50%) 
In table 6.4 the baseline calculations are presented with regard to the 
increase in number of smears per cytotechnician and the change in costs due to 
P APNET. When P APNET only saves time on initial screening (baseline), this 
will lead to a 9% increase in smears per cytotechnician per year and a decrease 
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in cytotechnician's costs by $0.36 per smear. However, due to the PAPNET costs 
(review stations and scanning), total costs per smear increase by $2.85. 
Table 6.4 Baseline results: screen time, smear production and cost per smear for 
conventional microscopy and PAPNET-assisted screening. * 
Cytotechnicians' time per smear (sec): 
-initial screentime (sec) 
-clerical activities (sec) 
-other activities (sec) 
-total work time (sec) 
Smears per cytotechnician/yr 
Cytotechnicians 
Costs per smear: 
- cytotechnicians costs 
- microscopes and housing 
- PAPNET costs 
- all other costs 
-total 
Conventional PAPNET t 
microscopy 
286 (39%) t 
114(15%) 
335 (46%)'U 
735 (100%) 
7840 
5.1 fte 
$4.36 
$1.32 
$10.62 
$16.30 
224 
114 
335 
673 
8560 
4.7 fte 
$4.00 
$1.28 
$3.25 § 
$10.62 
$19.15 
* Results have been calculated for a laboratory size of 40,000 smears per year. 
t Baseline assumptions: PAPNET only saves on initial screening, and with a rate of -22% with 
respect to conventional microscopy. 
:f: Initial screentime = 230 sec x 1.25 = 286. The factor 1.25 is because all laboratory 
cytotechnicians taken together were on average 25% slower than the cytotechnicians participating 
in the study. 
'I! Other activities = 621 sec- initial screentime. 621 sec has been measured in the routine situation, 
and includes both initial screening and other activities, excluding clerical activities. 
§ Processing fee (scanning, technical service, software upgrades, two review stations, training for 
two cytotechnicians and two scan station operators) $2.82, processing time $0.22, extra training 
$0.06, extra review stations $0.15. 
Table 6.5 Results sensitivity analysis (see table 6.3): cost difference per smear using 
PAPNET relative to conventional microscopy.* 
1. PAPNET reduction in screen time 
2a. PAPNET saves on initial screening only 
2b. PAPNET saves on initial screening and on 
other activities ( excl. clerical activities) 
3. Initial screening time per smear contentional 
microscopy 50% higher 
-9% 
+$3.08 
+$2.88 
+$2.99 
-22% 
+$2.85 
+$2.38 
+$2.65 
* Results have been calculated for a laboratory size of 40,000 smears per year. 
-36% 
+$2.58 
+$1.79 
+$2.24 
In table 6.5 results are presented for the sensitivity analysis. Results for 
P APNET are presented as a difference to the conventional microscopy situation. 
In case P APNET also saves on' other activities' (excluding clerical activities), 
costs per smear increase less, namely by $2.38 (range $1.79-2.88 depending on 
the rate of time saving). When initial screening time in a conventional 
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microscopy situation is 50% higher than observed, savings on cytotechnician' s 
costs per smear are also higher than in the baseline situation, but not enough to 
outweigh the additional costs for the PAPNET technology. 
6.4 Discussion 
We conclude that personnel cost savings are likely with PAPNET, but that they 
are outweighed by the additional investments in review stations and scanning 
costs under a broad range of assumptions. The costs for P APNET were assessed 
for a best case situation in which a scanning station is available in the 
laboratory, avoiding the packing and unpacking of slides and transportation 
cost. 
How do our results compare with other studies? Only one 
cytotechnician reached a screen rate that was 2 times faster than with 
conventional microscopy, which is still considerably lower than rates of 3-4 
times faster as published elsewhere [83 120]. Crucial however, is that we 
included additional microscopy in our time measurements of P APNET -assisted 
screening, compared Papnet and conventional microscopy in a comparable 
study situation, and considered abnormal smears in a proportion observed in a 
routine screening population. We observed an average initial screening time of 
100 seconds if no additional microscopy was required (normal smears), which is 
in line with other observations of 1-2 minutes [120]. In addition, although the 
cytotechnicians in the study were relatively unexperienced with P APNET, we 
only observed a small (10%) decrease in average initial screening time between 
month three and nine of the study through learning effects (mainly reduced 
usage of microscopy). Each cytotechnician had screened several hundreds of 
smears inbetween these two points of time. In the sensitivity analysis we 
included a 50% reduction in screening time amongst the four cytotechnicians, 
but this did not change our results significantly. Above all, we not only 
included initial screening in our assessment, but all other cytotechnicians' 
activities as well. In our baseline calculation, intial screening is 40% of their total 
working time. 
P APNET -assisted screening would be more time saving when the 
usage of microscopy could be reduced. For instance, in case absence of 
endocervical cells (ecc-) would not require additional microscopy (quick 
scanning) as is debated in most countries, P APNET -assisted screening would be 
30% faster (160 seconds on average) per smear than conventional microscopy, 
leading to additional cost savings of $0.10-0.35 per smear. However, a further 
reduction in the usage of microscopy, as was already observed during the 
study, might be compensated by a more extensive and thus longer assessment 
of the P APNET video images. Besides, any further shortening of screening time 
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may rather influence the sensitivity and specificity of P APNET -assisted 
screening than increasing the screen rate. 
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The time measurement for P APNET was necessarily done in a study 
situation. Therefore, the time measurement of conventional microscopy was 
also done in the same study situation, making the initial screening time fully 
comparable between both techniques. It is however possible that the deviation 
from routine practice will be larger for conventional microscopy. In reading 
through a microscope, a lively work environment may cause quite some 
interruptions, including the need for repetitive reading of smears. This is 
different for P APNET -assisted screening: communication and other 
environmental factors may be less disturbing for screening activities, which 
increases efficiency. (Note that in this study we classified all aspecific work time 
during initial screening under 'other activities'). Beyond this, P APNET might 
streamline other smear processing activities, including quality control , but in 
order to capture this fully, both screen techniques have to be compared in a 
routine situation and preferably in the same laboratory. We doubt however that 
the rate of time saving due to P APNET for initial screening and 'other activities' 
taken together is much larger than the highest rate assumed in the sensitivity 
analysis (-36%). We calculated that the number of smears per cytotechnician 
would have to be about threefold the number for conventional microscopy, in 
order to neutralize the extra costs for equipment and scanning. 
We considered a situation were P APNET -assisted screening would be 
introduced as a primary screening tool for smears from the national screening 
programme. Can the conclusions be generalized to repeat smears and other 
follow-up smears? The assessment of these smears differs from smears in 
asymptomatic women without a recent positive test. They generally take more 
time, not only for screening the smear but also due to necessary communication 
with clinicians. P APNET will not change the related time-consuming 
administrative procedures, and as a result will have a smaller impact on 
working time. 
Our calculations relate to a laboratory size of 40,000 smears per year, 
because we assume that by this size any scale effects favouring either P APNET 
or conventional microscopy are fully captured. A smaller laboratory will only 
be less favourable for P APNET -assisted screening, among others because of 
underuse of review stations and transporting slides to and from the scanning 
station which will then be remote. 
In a hypothetical situation where scanning costs of P APNET are 
sufficiently reduced and costs of PAPNET -assisted screening are about equal to 
those of conventional microscopy, additional considerations apply to the 
decision whether or not P APNET -assisted screening might replace conventional 
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microscopy. PAPNET-assisted screening might be preferred to conventional 
microscopy by cytotechnicians because part of the boring and tedious work 
(screening of predominantly normal smears) is reduced. When cytotechnicians 
may be difficult to recruit, as is already occurring in the Netherlands, attractive 
and varied work circumstances gain importance. On the other hand, 
cytotechnicians' preferences will not only be based on differences in 
attractiveness of work, but are also related to their trust in the used technology 
and therefore to its performance in reducing system error. 
In this study it is shown that P APNET is less cost saving when the 
average initial screening time per smear for conventional microscopy is low 
(assuming that P APNET does not save on clerical activities and' other 
activities'). A low initial screening time per smear characterizes a situation of 
relatively high work load, as in the United States where minimum workloads of 
80 smears per day are not uncommon, and more than once provoked by 
financial pressures [129]. When a negative relationship between screen rate and 
diagnostic effectiveness is hypothesized, the relative diagnostic performance of 
P APNET may be higher in this situation. Conversely, in a situation with 
relatively low workloads (as in the Netherlands), the possibility to save on 
personnel costs with P APNET -assisted screening is higher, but it might be more 
difficult to improve on the diagnostic effectiveness. This latter has been 
indicated in our evaluation of the P APNET system when used as a primary 
screening tool [68]. It turned out to have similar diagnostic performance as 
conventional microscopy, and as a consequence will be equally effective in 
terms of health benefits. Given this performance, costs for using P APNET 
(equipment, scanning and training) have to be reduced from the current $3.25 
(given an optimal laboratory size) to around $0.50 per slide (baseline) or $1.50 
per slide (best case for P APNET presented here) to reach cost-effectiveness 
levels similar to conventional microscopy when used as a primary screening 
tool. Because this seems highly unrealistic, similar cost-effectiveness can only be 
achieved when the sensitivity and/or specificity of P APNET is considerably 
improved. 
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Abstract 
Objective To analyze for which test characteristics and costs new cytologic tests 
for cervical cancer screening would be at least as cost-effective as the Pap test. 
To compare the results with evidence about recently developed technologies. 
Methods With the validated microsimulation programme MISCAN for the 
evaluation of cervical cancer screening policies, we calculated the rncremental 
number of cervical rntraepithelial neoplasms (CIN) detected, rnvasive cancers 
prevented, life years gamed, and rncremental costs and cost per life year gamed 
for different combrnations of test sensitivity, specificity, and unit cost per new 
screening test, compared with current Pap test screening. We calculated the unit 
cost threshold of any screening test, given its test characteristics, for which this 
test would be equally cost-effective as the Pap test. We conducted one-way 
sensitivity analyses to translate the findrngs to alternative screening settings. 
We conducted a literature review to determrne the test characteristics and costs 
of automated screening systems and liquid based cytology (LBC). 
Results With cancer incidence, screening policy (5-yearly screenrng between age 
30 and 60) and attendance as observed ill the Netherlands, and 80% Pap test 
sensitivity, the unit cost of a cytologic screening test with 100% sensitivity and 
specificity can be up to €9.00 more expensive than the Pap test to be at least as 
cost-effective as the Pap test. In settings with more rntensive screening this unit 
cost threshold is lower, whereas ill settings with lower Pap test sensitivity this 
unit cost threshold is higher. A literature review revealed that there is weak 
evidence that the ThinPrep™ LBC system, and the automated systems 
AutoCyte™ SCREEN and AutoPap™ are more sensitive than the Pap test, at 
the loss of some specifidty, whereas they are €2.50 to €7.00 per test more costly 
than the Pap test. 
Conclusion None of the current automated and LBC cytologic screening systems 
is more cost-effective than the conventional Pap test, except ill situations where 
Pap test accuracy and adequacy is low. 
This chapter has been partly published ill: 
Meerdrng WJ, van Ballegooijen M, Habbema JDF. Performance and cost-
effectiveness of liquid based cytology. Histopathology 2002:4l(Suppl. 2):494-
505. 
When will new cytologic tests for 
cervical cancer screening be cost-
effective? 
7.1 Introduction 
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There is convincing evidence that routine cervical cancer screening with the Pap 
test has significantly reduced mortality due to cervical cancer [116 140]. 
However, there are continuous worries and debates on the accuracy of the 
conventional Pap test [6135 197]. In the US these debates are intensified by 
dissatisfaction about the reimbursements by insurers that would put pressure 
on cytotechnologists' workload, and by legal implications of false negative 
diagnoses [236]. 
In recent years, new cytologic technologies have been developed that 
claim to improve the sensitivity of the Pap test. Automated systems increase the 
efficiency of the initial screening of slides and the rescreening of normal slides, 
such as the AutoPap™ 300QC (rescreening) or Primary Screening system, 
Papnet™ (initial screening and rescreening), and AutoCyte™ SCREEN (only 
initial screening). In liquid based "monolayer" systems such as ThinPrep™ and 
SurePath™ (formerly AutoCyte™ PREP), the cell material is prepared and 
filtered before it is transferred to a glass slide for interpretation. Other systems 
are designed to support conventional microscopy (Pathfinder™, AcCell™ 
Series 2000), but these have not been considered in this study. A brief 
description of the systems is given in the Appendix. 
We investigated how much a new improved cytologic test may cost if it 
should not be less cost-effective than the Pap test. We analyzed the relationship 
between test sensitivity, specificity and cost-effectiveness for population-based 
cervical cancer screening, and calculated threshold values for combinations of 
test sensitivity, specificity and unit cost per test for which any cytologic 
screening test would be as cost-effective as the conventional Pap test. Also, we 
conducted an extensive sensitivity analysis to translate the results to different 
settings. The outcomes can be seen as a decision analytic framework for the 
assessment of any cytologic test for cervical cancer screening. Subsequently, we 
assessed published trials of new cytologic technologies and collected available 
cost information. Tentative conclusions were drawn on the (cost-)effectiveness 
of considered technologies compared with Pap test screening. 
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7.2 Materials and methods 
Model description 
With the MISCAN rnicrosimulation model [102] for the evaluation of screening 
policies individual life histories are simulated. The course of these life histories 
is determined by model assumptions on demography (e.g. birth, death from 
other causes), incidence of preinvasive lesions, the natural history of cervical 
cancer (e.g. duration of screen-detectable preclinical stages), and the impact of 
screening (e.g. test sensitivity and specificity, attendance). 
The model structure and assumptions are given in Table 7.1. Preclinical 
disease (i.e., the stage at which the disease is present but not yet detected) is 
subdivided into four stages: a preinvasive stage (corresponding to cervical 
intraepithelial neoplasia (CIN), and including carcinoma in situ) and three 
preclinical invasive stages (International Federation of Gynecology and 
Obstetrics definition IA, IB, and II+). The duration of these screen-detectable 
preclinical stages of cervical cancer and the sensitivity of the Pap test have been 
estimated with screening data from British Columbia [287]. The mean duration 
and standard deviation of the different stages are 11.8 2.2 years for CIN, 2.0 
0.9 years for preclinical invasive stage IA, and 1.9 0.9 years for preclinical 
invasive stage IB and II+ combined. The variation of the duration of these stages 
between women is described by a Weibull-distribution. Not all preinvasive 
lesions progress to cancer. The proportion of lesions that regress to normal 
decreases with age [287]. The model has been validated by comparison with 
interval cancer data at different screening intensities [116 286]. We adapted the 
model to the demographic and epidemiological situation in the Netherlands, 
and it has been found to satisfactorily reproduce the incidence and mortality of 
cervical cancer from 1968 to 1992 in this country, a period that includes the start 
of mass screening [267]. A more elaborate description of the model has been 
given elsewhere [277]. 
Simulated screening represents organized screening for women aged 30 
to 60 years at 5 year intervals, which is the current policy in the Netherlands 
and Finland. Screening is assumed to occur between 1993-2020 (28 years). In 
most western countries centrally organized or spontaneous screening for 
cervical cancer already occurs, and reduces the effects of current screening 
rounds. Therefore we assumed previous screening activities before 1993 in the 
baseline model, that were estimated with Dutch survey data [60 80 267]. 
Screening attendance is 80%, as observed in the Dutch screening practice. 
Attenders have a 50% higher probability of attending the next screening round 
than non-attenders. 10% of the target population are persistent nonattenders 
and are also at higher risk for cervical cancer. Future costs and health effects are 
discounted by a annual rate of 3% [96]. 
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Table 7.1 Structure and assumptions of the MIS CAN microsimulation model for the 
evaluation of cervical cancer screening. 
baseline 
Cumulative lifetime incidence of cervical cancer .0106- .0235* 
Mean (SD) duration preclinical stages in years 
Cervical neoplasia (CIN) 
Micro invasive (FIGO lA) 
Macro invasive (FIGO IB) 
Sensitivity conventional Pap test 
False positive women who are kept under 
surveillance with repeat smears 
False positive women who are diagnosed 
normal (no CIN) after referral for colposcopy. 
Specificity conventional Pap test 
Inadequate screening smears 
11.8 (2.2) 
2.0 (0.9) 
1.9 (0.9) 
CIN 80% 
FIGO 185% 
FIGO II+ 90% 
14/1,000 
1.2/1,000 
98.5% 
1.0% 
sensitivity analysis 
.0212- .0458 
60% 
70% 
80% 
99.0% 
70% 
77.5% 
85% 
90.0% 
Screening policy: lifetime screenings (interval in 
years) age group 
7 (5) 30-60 10 (5) 20-65 (UK) [200] 
(NL) 17 (3) 18-66 (US) [264] 
27 (2) 18-70 (Aus) [63] 
Screening attendance 
Persistent nonattenders 
Attendance subsequent round, attenders 
Attendance subsequent round, nonattenders 
Discounting costs and health effects 
Cost per screening (€) 
invitation 
sampling 
cytologic examination t 
other (patient costs, administration) 
Fixed programme costs per year (€ min) 
Cost of diagnosis and treatment (€) 
cytologic surveillance and no CIN 
referral and no CIN 
CIN 
FIGO lA 
FIGO IB 
FIGO II+ (screen-detected):j: 
FIGO II+ (clinically detected):j: 
Cost of treatment and palliative care for 
advanced disease (€) 
80% 
10% 
94.4% 
44.4% 
3% 
31.53 
0.99 
9.14 
15.38 
6.01 
3.40 
58 
499 
2,006 
5,468 
11,596 
10,932 
9,991 
<50 years 31,704 
50-70 years 22,598 
> 70 years 9,620 
60% 
0%,5% 
39.22 
23.07 
* Cumulative background incidence for progressive preinvasive cervical cancer develops from 
0.0229 for those born between 1889-1918, 0.0235 for those born between 1919-1928, 0.0128 for 
those born between 1929-1938, 0.0106 for those born between 1939-1948, and 0.0148 for those 
born from 1949 onwards. 
t The costs of cytologic examination decrease with laboratory size, and therefore with the number of 
screening smears. The figure represents the average costs in the simulated screening period. 
+The difference in costs between screen-detected and clinically diagnosed stages II+ cervical 
cancer relates to the less favourable stage-distribution of the latter, with its associated lower number 
of radical hysterectomies and higher number of (cheaper) radiotherapeutic treatments. 
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Costs 
Costs of screening (organization, invitations, smear taking and review), 
diagnosis and treatment by disease stage are based on real resource use. Details 
on the data sources and calculation were presented elsewhere [267 271 272 277]. 
We collected costing information of liquid based cytology (LBC) and automated 
screening systems from chapter 6 and the literature [20 40 83 99113142174187 
236 241 252]. 
Costs are presented in € of the year 2002 (€ = $0.95 in 2002 and $PPP 
1.08 in 2001). 
Model simulations, test sensitivity, specificity, and adequacy 
Test sensitivity is equal to 1- false negative rate, and is defined as the 
probability that an underlying preclinical lesion is detected by screening and 
subsequently treated. We distinguished stage-specific Pap test sensitivities: 80% 
for the preinvasive stages cervical neoplasia (CIN), 85% for the micro-invasive 
(FIGO IA and IB) and 90% for the macro-invasive stage (FIGO II+). These 
sensitivities resulted from an analysis of screening data from British Columbia 
[287], and are consistent with the findings of a recent meta-analysis [197]. Test 
specificity is equal to 1- false positive rate. False positives include women with 
an abnormal screening smear but ultimately do not need to be referred for 
colposcopy, and women who are referred for colposcopy and have a normal 
histological diagnosis. In the Netherlands, these groups constitute 14 and 1.2 
out of 1,000 screened women, respectively, corresponding to a 98.5% test 
specificity (derived from the Dutch Network and National Database for 
Pathology, P ALGA). 
We simulated a situation without screening, a situation with Pap test 
screening, and a screening situation with a new test. We optimized the 
sensitivity of the new test from 80% to 100% in five equal steps, representing a 
reduction in false negatives of 20%, 40%, 60%, 80% and 100%. In a separate 
analysis we optimized the test sensitivity only for the preclinical invasive 
stages, to account for the finding that new technologies might particularly do 
better in detecting invasive cancer [130]. The specificity of the Pap test and a 
new screening test are similar at baseline, and were varied from 99% to 90% in 
concordance with the proportions of mildly abnormal smears currently 
observed in several European countries with population based screening [117]. 
A lower or higher false positive rate of a new screening test will result in lower 
or higher costs, respectively, because of induced diagnostics, apart from the 
anxiety and discomfort for false positive women. 
For each combination of test characteristics we calculated the 
incremental number of detected CIN, invasive cancers, life years gained, 
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screening smears, diagnostic and therapeutic procedures, and incremental 
costs, compared with current Pap test screening. The health effects are counted 
until all women who could have benefited from the screening programme have 
died. Because for each life history the transitions from one disease stage to 
another are modelled as realizations of a probability distribution, the model 
outcomes are subject to random fluctuation, that has been reduced by 
simulating a large population of 45 million women. 
Cost-effectiveness thresholds 
We calculated the unit cost threshold of any new cytologic test for which the 
incremental cost-effectiveness (C/E) of screening with the new test compared 
with Pap test screening would be equal to the incremental C/E of Pap test 
screening. The incremental C/E of a new test is equal to the difference in costs of 
screening with the new test compared with Pap test screening, divided by the 
difference in life years gained [96]. The incremental C/E of Pap test screening 
was calculated as the difference in costs and life years gained of the baseline 
screening policy (7lifetime screenings in women aged 30-60 years at 5 year 
intervals) compared with a slightly less intensive screening policy with 6 
lifetime screenings in the same age group (6 year intervals). The incremental 
C/E of alternative screening policies in the sensitivity analysis (see also below) 
was derived from the incremental C/E of efficient screening policies with a 
similar number of lifetime screenings, published by Van den Akker et al. [277]. 
This study showed that the incremental cost per life year gained increases with 
the number of lifetime screenings offered. For instance, the incremental C/E of a 
screening policy with 7lifetime screenings offered at an efficient schedule is 
about $17,000 per life year gained compared with 6 lifetime screenings, and is 
about $35,000 per life year gained for a screening policy with 15 compared with 
12 lifetime screenings. These values have been interpreted as an acceptable C/E 
threshold for implementing a new screening test. Alternatively, we made 
calculations with arbitrarily chosen C/E thresholds for each simulated screening 
policy. 
Sensitivity analysis 
In a one-way sensitivity analysis, we varied a number of crucial parameters that 
were expected to influence the results, and that describe alternative 
epidemiological or screening situations, such as cervical cancer incidence, Pap 
test accuracy, screening policy, and screening attendance. We reduced Pap test 
sensitivity for CIN to 60% and 70% (baseline 80% ), in line with the outcomes of 
a large meta-analysis of Pap test accuracy [82]. A lower Pap test sensitivity will 
increase the number of missed cases, that might be detected by screening with a 
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more sensitive test. Because the Dutch screening policy is conservative 
compared with most western countries, we also simulated current screening 
policies and recommendations with more lifetime screenings offered at shorter 
intervals and in broader age ranges. The potential health benefit of a new 
screening test is determined by the programme sensitivity, or the ability to 
detect an abnormal lesion with repeated screenings, rather than by the single 
test sensitivity. Some missed cases may be detected timely at the next screening 
round, thereby reducing the unfavourable consequences of a single false 
negative test. The programme sensitivity will be higher with more intensive 
screening. 
Literature review 
We assessed the diagnostic accuracy of available new cytologic screening tests 
by a literature review. We selected studies that were included in recent meta-
analyses on the cost-effectiveness of new cytologic methods [37 40 71196 197]. 
Because these meta-analyses included studies until October 1999, we searched 
Medline for published studies until September 2003 with keywords 'vaginal 
smears', 'cervical intraepithelial neoplasia' or 'cervix dysplasia', in combination 
with 'diagnostic errors' or 'sensitivity and specificity', and in combination with 
'papnet', 'autopap', 'thin prep', 'autocyte', 'liquid based', 'monolayer' or 
'pathfinder'. We also searched the websites of the manufacturers for additional 
published studies. Duplicate publications with interim results of the same trial 
and studies that were described in abstract format only were discarded. We 
included studies in which a) conventional Pap test screening and another 
screening modality were compared, b) histological follow-up or an expert panel 
of cytotechnologists or pathologists was used as reference test, and c) the same 
reference test was used for both screening modalities. 
Studies were assessed on the following key characteristics: study 
population, study design, reference test used, blinding protocol, length of the 
follow-up period, possible sources of verification bias, and results. In all but 7 
studies [16 50 68 85 225 244 245] (a random sample of) negative smears were not 
verified, and absolute sensitivities and specificities could therefore not be 
calculated in all studies. Therefore, relative sensitivity (sensitivity new 
screening test I sensitivity Pap test) and relative specificity (specificity new 
screening test I specificity Pap test) were calculated if possible, assuming that 
non-verified smears are negative. We calculated the relative sensitivity and 
specificity for two diagnostic thresholds of the screening test and the reference 
test: low-grade (LSIL+ orCIN 1+) and high-grade squamous intraepithelial 
lesions (HSIL+ orCIN 2+). For trials with a between subjects design, in which 
the screening tests are applied in different study arms, relative sensitivity was 
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calculated in two ways if possible: as a ratio of both sensitivities with the 
respective number of verified cases in the numerator, and as a ratio of the 
detection rates, with verified test positive cases in the numerator and the 
respective populations in the denominator. The between subjects design is to be 
distinguished from the more superior within subjects design, by which both 
screening modalities are applied to the same women. Both designs can be used 
for the evaluation of monolayer systems. In case of a within subjects design a 
split-sample technique is used for material collection, by which the remaining 
cells are used for a monolayer slide. The within subjects design is common for 
the evaluation of AutoPap and Papnet, because the same smear can be used for 
conventional and automated screening. 
Table 7.2 Health effects and costs (€) per 1,000,000 women per year of screening: Pap 
test (baseline assumptions) and optimal test sensitivity. Screening is for women between 30 
and 60 years at five year intervals, from 1993-2020. Numbers between () are absolute 
differences with baseline results. 
Screening with Screening with new test 
Pa test 
baseline 1 00% sensitivity for 100% sensitivity for 
assumptions * invasive stagest pre-invasive and 
invasive stagest 
Effectiveness 
screen-detected CIN 765 765 (+0) 864 (+99) 
screen-detected invasives 8.5 9.9 ( +1.4) 6.8 ( -1.8) 
clinically detected invasives -76.6 -78.0 (-1.4) -83.1 (-6.5) 
life years gained 811 823 (+12) 888 (+78) 
life years gained (3% 243 247 (+4) 266 (+22) 
discounting) 
Costs (€ min) 
screening and surveillance 2.62 2.62 (O.OO):j: 2.62 (-0.01 ):j: 
diagnosis and primary 1.53 1.53 (0.00) 1.73 (+0.20) 
treatment CIN 
diagnosis and primary 0.07 0.08 (+0.01) 0.05 (-0.01) 
treatment screen-detected 
invasive cancers 
diagnosis and primary 
treatment clinically detected -0.82 -0.83 ( -0.01) -0.89 (-0.07) 
invasive cancers 
palliative and terminal care -0.72 -0.73 (-0.01) -0.78 (-0.07) 
total costs 2.69 2.68 ( -0.01) 2.73 (+0.04) 
total costs ~3% discountin~~ 2.17 2.16 (-0.01) 2.24 (+0.07l 
* Pap test sensitivity is 80% for preinvasive stages (CIN), 85% for the micro-invasive stages (FIGO lA 
and I B) and 90% for the macro-invasive stages (FIGO II+). Baseline results are reported as differences 
to a situation without screening. 
t Test specificity is similar to Pap test. 
:j: If the optimal screening test is as costly as the baseline test. 
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7.3 Results 
Incremental costs and health outcomes of increased test sensitivity 
An increase in test sensitivity for preinvasive stages prevents much more 
cancers and gain much more life years than an increase in test sensitivity for 
invasive stages only (table 7.2). The incremental number of life years gained 
increases less than proportionate with test sensitivity. In case of optimal 
sensitivity (100%) for preinvasive stage CIN, test sensitivity increases with 25% 
(=20/80%), the number of screen detected CIN increases with 13% (+98.6 per 
1,000,000 women per year of screening) and the number of life years gained 
increases with 10% (+78 per 1,000,000 women per year of screening). This is 
because the programme sensitivity of Pap test screening is higher than the 
single test sensitivity. The number of women with CIN that are additionally 
detected by a more sensitive screening test is larger than the number of 
prevented invasive cancers, mainly because most neoplasms will not progress 
to cancer. The remaining invasive cancers with optimal test sensitivity are a 
mixture of cancers in women who are too young or too old for screening, 
interval cancers (fast growing neoplasms), and cancers in women who did not 
attend the former screening round or who never attend screening. 
Figure 7.1 Combinations of sensitivity, specificity, and extra unit costs for which a new 
screening test would be as cost-effective as Pap test screening. The false negative rate 
is decreased for all preclinical stages and for preclinical invasive stages, respectively. 
Screening is for women aged 30 to 60 at 5 year intervals. Future costs and life years 
gained have been discounted at 3%. The shaded areas are the observed ranges of 
sensitivity (LSIL +/HSIL +threshold, see table 7.5) and unit costs for Thin Prep ™ and 
AutoPap™. 
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The cost increase due to the increased detection of preinvasive lesions 
that need further diagnosis and treatment slightly outweighs the cost savings 
due to prevented invasive cancers. However, when future costs are discounted 
the cost increase is much higher, because the costs (management of preclinical 
stages) precede the savings (prevented cancers) with several years. 
Figure 7.2 Combinations of sensitivity, specificity, and various levels of extra unit costs 
for which a new screening test would be as cost-effective as Pap test screening. The 
false negative rate is decreased for all preclinical stages. Screening is for women aged 
30 to 60 at 5 year intervals. Future costs and life years gained have been discounted at 
3%. 
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* Corresponds to a test sensitivity for CIN of 80%, 84%, 88%, 92%, 
96% and 100%, respectively. 
Unit cost thresholds of a new screening test 
The incremental cost-effectiveness (C/E) of the baseline screening policy (7 
lifetime screenings) is about €19,000 per life year gained compared with a 
programme with 6lifetime screenings ((€2.17- €1.93 million) I (243- 231life 
years gained) = €19,000; figures are per 1,000,000 women per screening year). In 
figure 7.1 the unit cost threshold of a new screening test is plotted against an 
increased test sensitivity (reduced false negative rate). In case of 100% 
sensitivity (0% false negatives) for all preclinical stages, a new screening test is 
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allowed to be €7.70 more expensive than the Pap test, and €2.80 more expensive 
if the 100% test sensitivity only applies to preclinical invasive stages. 
Figure 7.2 shows isocurves representing combinations of test sensitivity 
and specificity for which a new cytologic screening test would be as cost-
effective as the conventional Pap test, for different unit costs per new screening 
test. For example, a new test with similar costs but a specificity of 96.0% should 
compensate this with a 25% reduction of false negative smears in women with 
preclinical stages of cervical cancer, to be as cost-effective as Pap testing. Each 
percentage decrease in test specificity would decrease the unit cost threshold of 
a new screening test with €0.80, and vice versa. So if the current test specificity 
deteriorates from 98.5% to 90.0% by implementing a new screening test (as in 
some current situations), this would decrease the unit cost threshold of a new 
screening test with about €7. 
Sensitivity analysis 
A number of assumptions were varied in the sensitivity analysis (table 7.3). The 
potential health impact of a more sensitive screening test decreases with a more 
intensive screening policy, but the incremental C/E of this policies would be 
higher. As a result, the unit cost threshold of a new screening test with 100% 
sensitivity and similar specificity is slightly higher for the UK screening policy 
compared with the baseline policy, but lower for the more intensive policies in 
the US and Australia (17 and 27lifetime examinations, respectively). 
In table 7.4, the unit cost thresholds of a new screening test are 
presented for arbitrary C/E thresholds in stead of the C/E thresholds of current 
Pap test screening in table 7.3. For any given threshold, the unit cost threshold 
for a new screening test decreases with the intensity of screening. Similarly as in 
table 7.4, in figure 7.3 the unit cost thresholds for a new screening test are given 
for different levels of test sensitivity and incremental cost per life year gained. 
For instance, at a threshold of €20,000 per life year gained, a new screening test 
can be up to €3.50 more expensive than the Pap test if the false negative rate can 
be decreased with 40% for all preclinical stages (88% sensitivity for CIN). 
The unit cost threshold for a new screening test increases to €13.80 and 
€10.60 if the current Pap test sensitivity would be 60% or 70% for CIN, 
respectively (table 7.3). However, when the current Pap test sensitivity is lower, 
a reduction in false negatives as used in the calculations corresponds with a 
higher absolute increase in test sensitivity. All other alternative assumptions 
have a relatively modest impact on the results. 
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Table 7.3 Sensitivity analysis. Extra costs of diagnosis and treatment and additional life 
years gained per 100,000 screenings, and incremental cost per smear for which new 
cytologic techniques are equally cost-effective as conventional cytology. Future costs and 
life years gained are discounted at 3%. Baseline and alternative model assumptions 
(table 7.1 ). 
Model assumptions Pap test Screening with optimal test b 
screening a 
Incremental Net Incremental Unit cost 
cost per life incremental life years threshold, 
year gained costs of gained (3) difference with 
(€) (1) diagnosis and Pap test (€) c 
treatment of 
(pre )clinical 
stages 
(€1000) (2) 
Baseline assumptions 19,000 d 155 49.9 +7.70 
Screening 20-65 years at 27,100 e 157 37.0 +8.20 
5-year intervals (UK) 
[200] 
Screening 18-66 years at 57,300 e 65 12.5 +6.30 
3-year intervals (US) 
[264] 
Screening 18-70 years at 122,400 e 31 5.1 +5.80 
2-year intervals 
(Australia) [63] 
Cancer incidence twofold 10,900 d 318 99.6 +7.50 
Pap test sensitivity 60% 13,900 d 343 126.7 +13.80 
Pap test sensitivity 70% 15,800 d 246 84.5 +10.60 
Screening attendance 13,200 d 164 65.1 +6.70 
60% 
Discounting 0% 7,400 d 63 119.5 +8.00 
Discounting 5% 31,900 d 253 30.6 +7.00 
Unscreened population 13,600 d 190 68.3 +7.20 
a Pap test sensitivity is 80% for preinvasive stages (CIN), 85% for the micro-invasive stages (FIGO 
lA and I B) and 90% for the macro-invasive stages (FIGO II+). 
b Test sensitivity 100% for all preclinical (pre)invasive stages, specificity similar to Pap test. 
c Calculation: ((1) x (3)- (2) x 1 000) I (1 00,000 x (1 + 0.010 + 0.015 x 1.16)). Proportion of 
inadequate screening smears= 0.010, proportion of false positive screening smears= 0.015, 
average number of repeat smears per woman = 1.16. 
d Incremental C/E ratio of screening between 30-60 years with 7 lifetime screenings (5 year 
intervals) compared with screening between 30-60 years with 6 lifetime screenings (6 year intervals). 
e Corresponding to the incremental C/E ratio of efficient screening policies with corresponding 
numbers of lifetime screenings in Van den Akker-van Marie eta/. [277]. 
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Figure 7.3 Incremental costs per life year gained of a new screening test compared to 
Pap test screening, for different combinations of test sensitivity and extra costs per 
screen test (no change in test specificity assumed). Screening is for women aged 30 to 
60 at 5 year intervals. Future costs and life years gained have been discounted at 3%. 
ro 
c 
(!) 
E 
(!) 
u 
-~ 
10000 
+€0 
0+-------r------,~-----.-------.------~ 
0% 20% 40% 60% 80% 
reduction in false negatives* 
* Corresponds to a test sensitivity for CIN of 80%, 84%, 88%, 92%, 
96% and 100%, respectively. 
100% 
Table 7.4 Unit cost threshold (difference with Pap test) of a new screening test (in €), for 
different cost-effectiveness thresholds and screening policies. 
Screening policy* Cost per life year threshold 
€20,000 €50,000 €1 00,000 
100% reduction in false negativest 
7 (5) 30-60 (NL, Finland) +8.20 
10 (5) 20-65 (UK) [200] +5. 70 
17 (3) 18-66 (US) [264] +1.80 
27 (2) 18-70 (Australia) [63] +0. 70 
* Lifetime screenings (interval in years) age group 
+22.80 
+16.50 
+5.50 
+2.20 
+47.00 
+34.50 
+11.50 
+4.70 
t 100% sensitivity for all preclinical stages. Pap test sensitivity is 80% for preinvasive stages (CIN), 
85% for the micro-invasive stages (FIGO lA and I B) and 90% for the macro-invasive stages (FIGO 
II+}. 
Literature review 
Of the studies on the accuracy of new cytologic tests that were identified, 15 
considered ThinPrep™ (LBC) [25 46 50 64 85100 114184187 213 214 234 244 245 
295], 7 considered SurePath™ (LBC) [1619 21107181187 288], 1 considered 
AutoCyte™ SCREEN [181],4 considered AutoPap™ [49 216 255 299], and 8 
considered Papnet™ [29 68120 127136 225 237 246]. ThinPrep™ slides have a 
higher sensitivity than conventional Pap tests in most studies, at each 
diagnostic threshold (table 7.5). The relative sensitivity ranges from 0.95 to 1.22 
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for the LSIL+/LSIL+ threshold (screening test I reference test), and from 0.97 to 
1.12 for the LSIL+/HSIL+ threshold when only split-sample studies are 
included. The higher test sensitivity should be weighed against a lower 
specificity as reported in most studies. The relative sensitivity of SurePath TM 
slides ranges from 0.93 to 1.00 at the LSIL+/HSIL+ diagnostic threshold when 
only split-sample studies are considered. In studies with a between subjects 
design the observed relative sensitivity was generally (much) higher. However, 
in the far majority of LBC studies the results were possibly biased in favour of 
the monolayer systems due to flaws in the study design. First in three split-
sample studies consensus opinion on cytology was used as a gold standard and 
not (or partly) histology [107184 245]. Therefore, it is not known whether the 
additional detected cytologic abnormalities would have been confirmed by 
histological assessment. Second, the histological verification was not blinded in 
all but one study in those with histology as reference test [85]. In one study even 
the smear assessment was not blinded between both modalities [244]. Third, in 
none of the studies with a between subjects design were participants randomly 
allocated to the study arms. The prevalence rates may therefore differ, which 
may completely explain the higher detection rates by LBC. The incomparability 
of the study arms is confirmed by the high differences in detection rates in these 
studies. Also, in those studies that used consensus cytology as reference test, 
blinding with respect to the screening modality was not possible by definition. 
Fourth, in studies with histology as reference test, verification bias [229] may 
have occurred when histological follow-up is only available for a (small) 
proportion of positive smears, or when the follow-up rate was lower for LBC 
than for conventional microscopy. Fifth, when cytologic examination with the 
new technology takes place in a different laboratory, or even in a different 
country [114], a comparison of results is seriously hampered because of possible 
differences in laboratory performance. And lastly, in one study the relative 
specificity could not be calculated, in order to check whether the increased 
sensitivity was associated with a loss of specificity [245]. Two split-sample 
studies with sufficient blinding and complete histological follow-up reported a 
higher [85] and lower test sensitivity [50], respectively, for ThinPrep™. In the 
UK Pilot a higher detection rate (+24%) for histology confirmed HSIL+ was 
observed in regions with ThinPrep™ compared with the previous year. This 
increased rate was observed in age group 20-34 only, and might be due to 
increased uptake of previously unscreened women [187]. 
In several retrospective rescreen studies by which the Papnet™ system 
was evaluated, the so-called 'rescreen effect' [32] has likely favoured the test 
performance of Papnet™ relative to conventional screening. [29 120 127 136 
237]. The rescreen effect means that the detection of abnormal smears is 
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increased when the assessment does not have clinical consequences, and/or 
when samples are used with a relatively high proportion of abnormal smears, 
resulting in a higher alertness. An evaluation of Papnet™ has indicated that the 
rescreen effect fully explains the increased detection of abnormal smears [268]. 
Trials on Papnet™ with designs that excluded rescreen effects reported similar 
sensitivities [68 225] or even a lower sensitivity [246] for Papnet™ compared 
with conventional Pap tests. 
Three out of four studies reported slightly higher sensivitities for 
AutoPap™ compared with conventional screening (relative sensitivity up to 
1.12, LSIL+/HSIL+ threshold) [49 216 299]. From one of these studies the relative 
specificity could be calculated (1.005) [299]. In one study only the sensitivity of 
rescreening normal smears was given [216]. Therefore the relative sensitivity for 
the initial screening and rescreening procedure combined could not be 
determined but was greater than one. The three studies were rescreen studies, 
and the rescreen effect might have biased the results in favour of AutoPap™. In 
all AutoPap TM trials expert judgement of cytology was used as a reference test 
instead of histology. In two studies the sensitivity refers to the system 
sensitivity, which is the proportion of smears that were assessed abnormal by 
the expert panel and that were subsequently identified by the system [49 216]. 
This system sensitivity is considered an upper bound for the subsequent 
manual screening. 
One study evaluated the AutoCyte™ SCREEN system, and found a 
relative sensitivity of 1.44 at the cost of a small loss in specificity [181]. 
However, also in this study the rescreen effect has likely influenced the results 
in favour of AutoCyte™ SCREEN. 
Costs of new cytologic screening tests 
Of the costing data that were collected, the minimum difference in cost per test 
compared with the Pap test are reported here. For the ThinPrep™ 2000 system 
€2.70 higher costs per slide have been reported for a large-scale laboratory, 
including €2.45 for consumables and an assumed 30% increase in slides that can 
be read per day [174]. The recent UK Pilot reported €6.95 and €6.61 higher lab 
costs per slide for the ThinPrep™ 2000 and 3000 system, respectively, including 
savings due to more efficient reading, whereas savings of 1 (€0.92) to almost 5 
minutes (€4.34) per slide were reported for smear taking [187]. For SurePath™ 
$2.33 [19] and €3.10 [187] higher costs per slide have been reported, accounting 
for more efficient reading of slides. The difference in costs of Papnet™ was 
estimated at $2.85 when used as a primary screening tool (chapter 6) and at 
$6.80 when used as rescreening tool and assuming $5.00 for processing per slide 
[99]. AutoPap™ is $3.30 per slide more expensive when used as rescreening 
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tool, and $3.15 when used as primary screening tool, including product costs of 
$4-5 per slide [99]. No cost information was found for the AutoCyte™ SCREEN 
system. 
Integration of results 
The observed relative sensitivities up to 1.12 for ThinPrep™ (split-sample 
studies) and AutoPap™ if we assume an LSIL+/HSIL+ threshold, would 
correspond to a test sensitivity of up to 90% (=1.12 x 80%). We take this 
diagnostic threshold because HSIL+ lesions are reason for treatment, and LSIL+ 
smears get follow-up in most countries (the definition of ASCUS smears is too 
aspecific for cross-study comparison). It can then be derived that these 
technologies would only be cost-effective on the lower range of the observed 
unit costs, and when the maximum observed sensitivity is assumed (figure 7.1). 
This does not yet account for the fact that ThinPrep TM showed worse specificity 
in most studies, whereas this could not be determined for AutoPap™. 
7.4 Discussion 
We analyzed the relationship between test accuracy, life years gained and unit 
cost per test for cervical cancer screening to compare the possible cost-
effectiveness of new screening tests with that of the conventional Pap test. We 
used a validated simulation model that describes the natural history of cervical 
cancer. Within a realistic range of assumptions we calculated the diagnostic 
accuracy and cost levels at which any cytologic screening test would be 
acceptable for population based screening compared with the conventional Pap 
test. There is weak evidence that ThinPrep™ smears and the AutoPap™ system 
provide higher sensitivity than conventional Pap tests, whereas the impact on 
specificity is uncertain. However, even with favourable assumptions, their 
diagnostic accuracy appears to be below acceptable cost-effectiveness 
thresholds. 
Limitations 
Apart from avoided mortality from cervical cancer, new screening tests may 
also influence quality of life. A possible reduction in the number of invasive 
cancers has to be weighed against the increased diagnosis and treatment of 
preinvasive lesions. (There are no indications that current new technologies will 
reduce the number of false positive smears and associated anxiety and 
discomfort.) However, the balance between positive and negative effects of 
screening is yet undetermined because no valid estimates are available on the 
quality of life implications of surveillance, referral, treatment and invasive 
cervical cancer. 
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In the present study we only considered screening tests with better 
characteristics than the conventional Pap test, analogous to the claims of newly 
developed technologies and the debate on the limitations of the conventional 
Pap test. However, it is possible that a screening test with worse test 
characteristics than the Pap test but with a much lower price, similar to e.g. 
visual examination, would be attractive for screening policies in low resource 
settings. 
We calculated cases detected and life years gained assuming a 
screening test sensitivity up to 100%, to calculate an upper bound for acceptable 
costs per test. However, a test sensitivity of 100% is unrealistic because new 
tests may avoid that relevant cells are overlooked (screening error) or 
misinterpreted (interpretation error), but they cannot solve the problem of 
sampling error. 
The model sensitivity of the Pap test for the preinvasive stages is 
comparable to the findings of a recent meta-analysis on Pap test accuracy, who 
found a median sensitivity of 83% at a cytologic LSIL+ threshold for the 
detection of HSIL+ lesions [197]. In the Netherlands, these diagnostic thresholds 
have clinical relevance for follow-up and treatment respectively. Our baseline 
sensitivity of 80% was derived from screening data of British Columbia, and 
resulted in the best model fit with the screening data. Nevertheless, we also 
assumed a lower Pap test sensitivity of 60% or 70%, that comes closer to the 
findings of another meta-analysis [82]. Pap test sensitivity might vary among 
countries and even laboratories, and the contribution of a more sensitive 
screening instrument may therefore be higher in some settings than in other. 
We calculated combinations of test characteristics and cost per slide for 
which the incrmental C/E of a new cytologic screening test would be similar to 
that of current Pap test screening. The C/E of current cervical cancer screening 
will be an important normative threshold for any policy change, whether being 
a change in the screening schedule, specific policies for high-risk women, or the 
implementation of a new screening instrument. This approach is different from 
Myers [196] and Brown [40], who calculated the incremental C/E of new 
screening instruments given their costs and test accuracy, but without 
considering this normative threshold. 
Comparisons with other studies 
Are the outcomes comparable with other studies? Brown calculated the 
incremental C/E ratios for AutoPap™ (rescreening), Papnet™ (rescreening) and 
ThinPrep™ (primary screening), with favourable results for AutoPap™ [40]. An 
important reason for this favourable outcome is a high estimate of the 
sensitivity of AutoPap™, that was based on results from one trial [49]. Brown 
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multiplied the sensitivity of AutoPap™-assisted rescreening with the assumed 
false-negative rate of the Pap test (20%) in the model instead of the much lower 
false-negative rate in the trial (12.8%). When estimated correctly, the sensitivity 
of AutoPap™-assisted rescreening will be 1.11 (relative sensitivity in the trial, 
20% rescreening cut-off) x 80% (model sensitivity)= 89% instead of the 95.4% 
estimated by Brown. Moreover, the trials from which the test accuracy of 
AutoPap™, ThinPrep™ and Papnet™ was derived, showed serious flaws in 
study design that could have biased the results in favour of the new screening 
technologies [29 49120 136144 237 244 247]. Of the trials with unbiased study 
designs, three have shown similar test sensitivities for ThinPrep™ and 
Papnet™ compared with the Pap test [50 68 225], and one study showed a 
higher test sensitivity [85]. 
A second reason for the favourable outcome for AutoPap™ in Brown et 
al. is that some model assumptions were favourable for a more sensitive test. He 
assumed an exponential distribution of the duration of preclinical stages [73]. 
Compared with a Weibull-distribution as in our model, this generates more 
rapid growing lesions. These lesions have only one opportunity to be detected 
by screening, and an exponential distribution is thus favourable for a more 
sensitive test. However, a Weibull distribution gave a better fit with screening 
data [287]. Other assumptions of Brown et al. were no previous screening, no 
hysterectomies, and a higher background incidence of invasive cancer, that all 
result in higher estimates of life years saved (table 7.3). When we applied 
similar assumptions, but used a Weibull-distribution of the duration of 
preclinical stages, we estimated an increase in life expectancy of 0.21 days by 
using AutoPap™ compared with 0.96 days in Brown et al., for a three year 
screening interval (3% discounting). 
Myers [196]. estimated the cost per life year gained of the Pap test and a 
hypothetical screening test, with 51% and 99% sensitivity, respectively, and 
equal unit costs, at $2,853 and $2,919, respectively, for 5-yearly screening 
between age 15 and 85 compared with no screening. The Pap test sensitivity of 
51% is rather low compared with our own estimate and findings reported 
elsewhere [40 82 197]. The cost per life year gained are lower than our estimates, 
which can partly be explained by more favourable assumptions for screening: a 
longer average duration of the preinvasive stage (about 20 years compared with 
11.8 years in our model), higher costs of cancer treatment, a previously 
unscreened population, and 100% screening attendance including women at 
high-risk of cervical cancer. 
Smith [252] predicts that primary screening with AutoPap™ saves 
costs, despite $4.50 higher cost per test, assuming 9.4% additional test 
sensitivity for all preclinical stages and lifetime screening. Their results are 
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counterintuitive, because in their model health benefits and net cost savings of 
AutoPap™ accumulate with increasing screening intensity, whereas it is 
expected that at higher screening intensities a more sensitive test will prevent 
less additional cancers and save less costs. 
Schechter [241] estimated cost per life year gained for Papnet™ at 
$12,194 in a situation of screening women 20-64 years at 5 year intervals, 
assuming 3-5% additional sensitivity for SIL, a lower test specificity, and $7 
incremental cost per test. Their results compare favourably with ours. This can 
partly be attributed to assumptions favourable for screening, such as a 
previously unscreened population, and 100% screening attendance. 
Other considerations 
Trials and tentative calculations on the cost-effectiveness of new screening 
technologies [113] use intermediate end points (e.g. abnormal cytology or 
histology) as a proxy for outcome, because mortality as an outcome measure 
would need huge trials and a long follow-up period. The present study is a 
clear example that simulation modelling can help to translate these 
intermediate measures into mortality reduction, taking into account the natural 
history of cervical cancer, screening attendance, individual test sensitivity, and 
programme sensitivity. Moreover, modelling is a tool by which (cost-
)effectiveness of screening can be calculated for any screening context. 
It has been argued that liquid based cytology (LBC) will reduce the 
proportion of inadequate smears, and therefore save costs and discomfort [187]. 
The evidence on this matter is equivocal, with some studies reporting higher or 
similar proportions of inadequate smears, and some studies reporting lower 
proportions with LBC [124]. Moreover, the proportion of inadequate smears is 
generally low, and in most countries with population based screening even 
lower than our baseline assumption of 1.0% [117]. Therefore, any cost savings 
will generally be relatively modest. A decrease in the inadequate rate from 1.0% 
(as currently in the Netherlands) to 0% would increase the unit cost threshold of 
a new test with only €0.32 (1% of Pap test unit cost). A major exception to this 
rule is the United Kingdom, where the proportion of inadequate smears was 
about 10%, and cost savings were a major argument to introduce LBC in their 
national screening programme [199]. Considered the large international 
variation in Pap smear quality, it would be important to assess introduction of 
LBC in comparison with other means to improve Pap smear quality, such as 
training of smear takers. 
The reported cost estimates of LBC do not account for any additional 
costs for postal services because of special transport requirements and that may 
be substantial (about €1 per slide). In addition, the costs of consumables in a 
Chapter 7. When will new cytological tests be cost-effective? 
situation where LBC is applied on a large scale is uncertain, and the reported 
costs should therefore be regarded as indicative. 
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Our findings have important implications for current screening 
programmes, because in several countries liquid based or automated systems 
are considered or used already for population based screening. Because in 
many countries screening is offered at 3 or 2 year intervals, and considered that 
the incremental C/E of these systems deteriorates with screening intensity 
(higher programme sensitivity), this implies considerable existing or potential 
health system inefficiencies. 
A precise estimate of the incremental cost-effectiveness of liquid based 
and automated screening systems has partly been inhibited because unbiased 
estimates of test accuracy are rare. Because unbiased estimates of test accuracy 
were lower than in studies with weak study designs, lessons should be learned 
for any future trials for the evaluation of new tests for cervical cancer screening. 
Human papilloma virus testing (HPV) is increasingly being considered 
as an alternative to cytologic screening [55]. HPV testing has been found to be 
more sensitive than the Pap test, but at the expense of a decrease in test 
specificity. As a result, the screening interval may be extended for women who 
are (repetitively) HPV negative, but a much larger number of screened women 
will need additional surveillance and diagnosis. However, a quantitative 
deliberation of the pros and cons of HPV testing in primary screening, either as 
an adjunct to cytology or as a complete substitute, is not possible before the 
results of current prospective randomized trials become available [273]. These 
are expected to become available in the next coming years. Because a 
conversion to LBC or automated cytologic screening, to HPV testing, or both 
has severe organizational implications, countries that did not yet convert to 
automated or LBC screening systems may probably better await these trial 
results. 
We conclude that current liquid based and automated systems for cervical 
cancer screening show unfavourable cost per life year gained compared with 
conventional Pap test screening, even in situations with a low screening 
intensity, and with realistic assumptions on Pap test accuracy. This conclusion 
is even stronger in countries with more intensive screening policies (e.g. 2- or 3-
yearly screening). Only in situations with low Pap smear quality, low Pap test 
sensitivy and low incremental costs per test, new cytologic screening 
technologies might be a cost-effective alternative. Yet, this should be weighed 
against other measures to improve the efficiency of cervical cancer screening, 
such as alternative measures to improve Pap smear quality, HPV screening, and 
targeting high-risk populations that are not reached in current screening 
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programmes. The present use of liquid based or automated technologies for 
population based screening in several countries is likely to be inefficient and is 
not evidence-based. 
Appendix 
The Papnet™ system (TriPath Inc.) [162] is a neural network based technology 
that selects the 128 most suspicious cells or cell groups from a conventional 
slide to be photographed. The images can be assessed from a computer screen, 
and if necessary through additional conventional microscopy. The Papnet™ 
system has been FDA approved as rescreening instrument for smears initially 
assessed as normal. 
The AutoPap™ system (TriPath Inc.) [215] is an automated device that, after 
scanning of a conventional slide, assigns a score to each slide that indicates the 
likelihood that abnormalities are present. This score is based on an algorithm. 
The purpose is to form an enriched sample of slides that are to be manually 
screened. The AutoPap™ system has been FDA approved both as a rescreening 
device and as a primary screening device. When used as a primary screening 
device, the FDA panel recommended a 75% threshold for selecting slides that 
should be manually screened. 
The ThinPrep™ system (Cytyc Inc.) and SurePath™ (formerly AutoCyte™ 
PREP) system (Tripath Inc.) are liquid-based slide preparation systems. 
Noncellular material (blood, etc.) and inflammatory cells are filtered before the 
cells are deposited in a thin layer on the slide. This facilitates the detection of 
abnormal cells whereas also the area on the slide that should be screened is 
reduced, thereby reducing the amount of review time. The ThinPrep™ system 
and AutoCyte™ PREP system have been FDA approved for primary screening. 
The AutoCyte™ SCREEN system (Tripath Inc.) [19] combines the technologies 
of the AutoPap™ system and the AutoCyteTM PREP system. Monolayer 
AutoCyte™ PREP slides are scanned by the system that gives a score indicating 
the likelihood that abnormalities are present. 
A fuller description of these devices has been given in Rosenthal et al. [236]. 
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Table 7.5 Summary statistics and design characteristics of studies on liquid based (A. ThinPrep, B. SurePath) and automated cytology (C. 
AutoCZ::teSCREEN, D. AutoPaE, E. PaEnet~. 
N Relative sensitivity Relative specificity Verified Population Reference test 
Diagnostic threshold LSIL +I LSIL +I HSIL +I LSIL+ I LSIL+ I HSIL+ I 
screening test I LSIL+ HSIL+ HSIL+ LSIL+ HSIL+ HSIL+ 
reference test 
A. ThinPrep TM 
within subjects design ('split sample) 
Sheets, 1995 [244] 445 1.09 -- -- 0.992 -- -- 100% women referred histology 
for colposcopy 
Ferenczy, 1996 [85] 364 a 1.11 1.06 -- 0.985 0.925 -- 100% women referred histology 
1.03 b 
for colposcopy 
Roberts, 1997 [234] 35,560 -- -- -- -- -- 74% I screening and histology 
75% clinical 
Sherman, 1998 [245] 7,360 1.18 -- -- -- -- -- 100% high-risk cytologic diagnosis 
screening by independent 
pathologist's masked 
review 
Hutchinson, 1999 8,930 1.22 1.12 1.05 1.003 0.998 1.001 100% high-risk cytology or histology 
[114] screening 
Monsonego, 2001 5,428 1.18 -- -- 0.996 -- -- 100% screening most abnormal test 
[184] result after panel 
review 
Park, 2001 [214] 483 0.95 0.97 0.98 1.011 1.016 1.010 33% I women referred biopsy 
33% for colposcopy 
Coste, 2003 [50] 2,586 0.98 h 0.98 h 0.93 h 0.979 h 0.985 h 0.999 h 100% screening and histology 
clinical 
between subjects design 
Bolick, 1998 [25] 39,408 1.12 -- -- 0.985 -- -- 15% I screening biopsy 
(Pap) 2.59 c 14% 
10,694 
(TP) 
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N Relative sensitivity Relative specificity Verified Population Reference test 
Diagnostic threshold LSIL+I LSIL+I HSIL+I LSIL+I LSIL+I HSIL+I 
screening test I LSIL+ HSIL+ HSIL+ LSIL+ HSIL+ HSIL+ 
reference test 
Papilla, 1998 [213] 18,569 -- -- 1.09 0.996 0.994 0.999 70% I screening and biopsy 
(Pap) 1.61 c 1.57 c 1.71 c 66% clinical 
8541 
(TP) 
Carpenter, 1999 [46] 4,660 -- -- 1.00 0.993 0.982 0.996 47% I clinical biopsy 
(Pap) 1.33 c 1.04 c 1.04 c 55% 
2,727 
(TP) 
Diaz-Rosario, 1999 74,573 -- -- 0.83 0.983 0.985 0.996 95% I screening biopsy 
[64] (Pap) 0.81 c 0.72c 0.59c 47% 
56,095 
(TP) 
Guidos, 2000 [1 00] 5,423 -- -- 0.85 0.977 0.971 0.997 76% I screening and biopsy 
(Pap) 4.14 c 5.45c 4.61 c 71% clinical 
9,583 
(TP) 
Weintraub, 2000 [295] 129,619 1.54 1.63 1.98 0.986 0.984 0.999 42% I screening histology 
(Pap) 2.99c 2.99c 3.62c 34% 
39,455 
(TP) 
1.24 ci UK Pilot, 2003 [187] 67,856 -- -- -- -- 1.000 no data screening histology 
(Pap) 
34,128 
(TP) 
B. Sure Path ™ 
within subjects design ('split sample? 
Bishop, 1997 [19] 2032 0.93 1.00 0.38 0.978 0.979 1.003 38% I clinical histology or repeat 
(1.38) (1.11) (0.68) (0.995) (0.981) (0.999) 23% smear (consensus 
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N Relative sensitivity Relative specificity Verified Population Reference test 
Diagnostic threshold LSIL+I LSIL+I HSIL+I LSIL+I LSIL+I HSIL+I 
screening test I LSIL+ HSIL+ HSIL+ LSIL+ HSIL+ HSIL+ 
reference test 
cytologic diagnosis 
by external expert 
panel) 
Bishop, 1998 [21] 8,893 1.14 -- -- 0.996 -- -- 26% I screening and histology or repeat 
24% clinical smear 
Minge, 2000 [181] 2,156 0.93 -- -- 0.984 -- -- no data clinical biopsy 
Hessling, 2001 [1 07] 2,438 0.99 1.00 1.01 -- -- -- 100% enriched most abnormal 
sample of slides cytologic result as 
from clinical determined by 
population majority opinion of 
0.98d 0.93d 0.92d 0.879 d 0.844 d 0.935d 100% 
three pathologists 
Bergeron, 2001 [16] 500 women biopsy 
presenting for 
cone biopsy 
between subjects design 
Vassilakos, 2000 19,923 1.03 1.00 1.21 0.980 0.979 1.000 68% I screening and histology 
[288] (Pap) 1.37c 1.41 c 1.71 c 31% clinical 
81,120 
(SP) 
0.87ci UK Pilot, 2003 [187] 43,280 -- -- -- -- 1.000 no data screening histology 
(Pap) 
21,257 
(SP) 
C. AutoCyte ™ SCREEN 
within subjects design 
('split sample') 
Minge, 200Q_[181] 2,138 1.44 -- -- 0.994 -- -- no data clinical histology 
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N Relative sensitivity Relative specificity Verified Population Reference test 
Diagnostic threshold LSIL +I LSIL +I HSIL +I LSIL +I LSIL +I HSIL +I 
screening test I LSIL+ HSIL+ HSIL+ LSIL+ HSIL+ HSIL+ 
reference test 
D. Auto Pap TM 
Primary screening 
Wilbur, 199811999 25,124 1.08 e 1.05 e -- 1.006 e 1.005 e -- 100% screening judgement of 
[299 300] of discrepant cases by 
discrep panel of three 
ant external pathologists 
cases 
rescreening (quality 
control with 10% cut-
off) 
Colgan, 1995 [49] 3,487 1.06 1.12 -- -- -- -- 100% smears judgement of 
of previously discrepant cases by 
discrep assessed panel of three 
ant normal or external pathologists 
cases ASCUS 
Stevens, 1997 [255] 1,840 1.00 1.00 1.00 -- -- -- 100% smears judgement of 
of previously discrepant cases by 
discrep assessed panel of two internal 
ant normal pathologists 
cases 
Patten, 1997 [216] 12,048 >1.00 >1.00 -- -- -- -- 100% smears judgement of 
of previously discrepant cases by 
discrep assessed panel of three 
ant normal external pathologists 
cases 
E. PAPNET™ 
Primary screening 
Sherman, 1998 [246] 7,323 0.71 0.75 0.73 1.023 1.028 1.007 high-risk cytology and 
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N Relative sensitivity Relative specificity Verified Population Reference test 
Diagnostic threshold LSIL+ I LSIL+ I HSIL+ I LSIL+I LSIL+I HSIL+I 
screening test I LSIL+ HSIL+ HSIL+ LSIL+ HSIL+ HSIL+ 
reference test 
screening histology 
PRISMATIC, 1999 20,008 0.98 1.00 1.01 1.095 1.088 1.010 100% screening judgement of 
[225] of ab- abnormal smears 
normal and random 
s selection of normal 
smears by 
independent panel of 
three pathologists 
rescreening design 
Koss, 1994 [136] 201 only Papnet rescreen 100% abnormal biopsy 
sensitivities were given. smears with 
biopsy-
confirmed SIL + 
Boon, 1994 [29] 63 -- 2.06 I 1.53 I -- -- -- 100% false-negative biopsy 
0.92 f 0.57 1 smears with 
HSIL+ on 
biopsy in next 
screening round 
Rosenthal, 1996 [237] 62 -- 1.75 9 -- -- -- -- 100% false-negative cytology or histology 
smears with 
invasive 
carcinoma at 
follow-up and 
normal controls 
Jenny, 1997 [120] 516 1.16 I 1.17 I -- -- -- -- 100% smears of biopsy 
1.08 1.08 women with 
SIL + on biopsy 
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N Relative sensitivity Relative specificity Verified Population 
Diagnostic threshold 
screening test I 
reference test 
Kaufman, 1998 [127] 
LSIL +I LSIL +I HSIL +I LSIL +I LSIL +I HSIL +I 
LSIL + HSIL + HSIL + LSIL + HSIL + HSIL + 
160 only Papnet rescreen 
sensitivities were given 
100% 
Doornewaard, 1999 
[68] 
6,063 1.01 0.97 f 1.36f 1.001 0.999 f 0.999 f 100% 
LSIL = CIN 1, HSIL = CIN 2/3, TP = ThinPrep, SP = SurePath 
a Based on reported sensitivities and specificities, but underlying data not given. 
b Includes 'inconclusive slides', i.e. high grade abnormalities cannot be excluded. 
c Ratio of detection rates. 
d Unsatisfactory smears have been excluded from the numerator. 
e Test performance for ASCUS+ on cy1ology and LSIL + or HSIL + respectively on histology. 
f Threshold of reference test is CIN Ill+. 
g Threshold of reference test is invasive cancer. 
ASCUS smears 
of which biopsy 
was available 
within 1 year 
screening and 
clinical 
Reference test 
biopsy 
most severe 
diagnosis (biopsy or 
repeat smear) during 
7 years follow-up 
h Results from 'optimised reading'. Relative sensitivity and specificity were higher in the screening population than in the clinical population. 
i Calculated with the positive predictive value multiplied with the number of HSIL + smears. 
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Abstract 
Objective To evaluate the utility of high-risk human papillomavirus (HR-HPV) 
testing for triage of women referred for colposcopy because of abnormal 
smears. 
Methods We considered women with persistent mild or moderate dyskaryosis 
and women with severe dyskaryosis who were referred for colposcopy. For 
both patient groups we evaluated three altemative management policies: 1. 
conventional management based on histological assessment 2. HR-HPV-triage 
with direct treatment without prior histological assessment for HR-HPV-
positive women and conventional management for HR-HPV-negative women, 
and 3. direct treatment without histological assessment for all referred women. 
For each policy the average number of medical procedures, doctor visits and 
the costs per referred woman were calculated. Based on a literature review, the 
results were tested and translated to other patient groups. 
Results Per woman with persistent mild or moderate dyskaryosis and 
compared with conventional policy, HR-HPV-triage will avoid 0.51 
colposcopically directed biopsies, but adds 0.05 local treatments of the cervix 
(i.c.loop excision of the transformation zone) and 0.09 outpatient visits, and 
will cost $134 extra. HPV triage is less efficient in women with borderline or 
mildly dyskaryotic cytology. In women with severe dyskaryosis, direct 
treatment is more efficient as conventional management or HPV triage. 
Conclusion The decision to introduce HPV testing or direct treatment in women 
with persistent mild or moderate dyskaryosis strongly depends on the relative 
burden attributed to a colposcopically directed biopsy and an outpatient visit 
compared to LETZ treatment of the cervix. For women with severe dyskaryosis, 
direct treatment should be seriously considered. 
Meerding WL van Ballegooijen M, Burger MPM, van den Akker-van Marle ME, 
Quint WGV, Habbema JDF. Human papillomavirus testing for triage of women 
referred because of abnormal smears: a decision analysis considering outcomes 
and costs. J Clin Epid 2002;55:1025-32. 
Human papillomavirus testing for 
triage of women referred because 
of abnormal Pap smears 
8.1 Introduction 
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Specific high-risk human papilloma virus (HR-HPV) types are associated with 
the occurrence and/or development of cervical neoplasia [41165]. The value of 
HPV testing as a primary screening tool has been addressed elsewhere [273]. 
The present study asks whether HPV testing can be used as a further diagnostic 
tool in women with abnormal smears. This issue has been raised in several 
studies [52 57 58 87119 126]. 
Conventionally, the histological assessment of colposcopically directed 
biopsy and the adequacy of colposcopy in overseeing the neosquamocolumnar 
junction, determine further management of women with abnormal smears. This 
study investigates the consequences of using HPV testing to triage women 
either to direct treatment (HR-HPV positive) or to conventional practice (HR-
HPV negative). This policy would reduce the number of colposcopically 
directed biopsies, but at the expense of some over-treatment and possibly extra 
costs. We investigated how large these numbers would be and what would be 
the associated costs. 
8.2 Materials and methods 
Study population 
In a prospective study we considered 221 consecutive women aged 30-60 years 
who had persistent (i.e. two consecutive smears) mild or moderate dyskaryosis 
or a single smear reported as severe dyskaryosis, and who consequently were 
referred for further assessment to the university hospital in Groningen, the 
Netherlands [41]. In the Netherlands organized cervical cancer screening takes 
place targeting women between 30-60 years. 
HPV-testing and histology 
HPV-testing and histological assessment by colposcopically directed biopsy 
was performed in all women [41]. HPV was detected using the GP5/6 general 
primer mediated polymerase chain reaction (PCR), which was one of the most 
sensitive tests for the detection of HPV at that time. Besides, this test enabled 
the analysis of alternative groups of HPV types. Positive samples were 
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subsequently analyzed by means of type-specific primers for low-risk HPV-
types 6f 11 and HR-HPV types 16f 18f 3t and 33 separately [173]. 
Management policies 
In both patient groups we compared the numbers of medical procedures and 
their costs for the following alternative management policies: 
1. conventional management: treatment is based on colposcopic and 
histological assessment. This is the current management policy in the 
Netherlands and also in many other countries. 
2. women are triaged by HPV testing: HR-HPV-positive women are treated 
directly with loop excision of the transformation zone (LETZ) without prior 
histological assessmentf while HR-HPV-negative women follow the 
conventional management policy. 
3. direct LETZ treatment without prior virologic or histological assessment. 
This policy is not current practicef but is added for comparative purposesf 
and is the aggressive counterpart of the first two management policies. 
Diagnostic and treatment procedures 
We collected the number of diagnostic and treatment procedures in the study 
population which was conventionally treated [42]f and translated these figures 
to the situations following each of the three management policies. These 
policies concern a setting in which LETZ is the local treatment of choice. In a 
situation without prior biopsy (policy 2 and 3) this is important because LETZ 
provides a histological diagnosis. We assumed that women with histological 
low-grade squamous intraepitheliallesions (LSIL) are in principal not treated. 
As a resultf the number of treatments in these women will be similar to what 
has been observed in women with normal histology. We further assumed that 
women who are not treated in the conventional and HPV triage policyf are 
treated with LETZ in the direct treatment policy. As a resultf the policies differ 
only in the frequency of LETZ and not of conisation and hysterectomy. 
Treatment of women with high-grade SIL (HSIL) is according to what has been 
observed in the study. In our calculations, women with LSIL or HSIL who are 
treated are followed up with annual Pap smears during five years. Women with 
normal histology or with low-grade SIL (LSIL) who are not treated, are 
followed up with two (six-monthly) smears and colposcopies over one year. 
Each smear, biopsy and treatment requires an outpatient visit. In all policies an 
extra visit is assumed at the start to discuss the management process with the 
patient. In the conventional policy (policy 1), the result and consequences of the 
histological examination are discussed during an additional visit. In the HPV 
policy (policy 2) one extra visit for HPV testing is assumed. 
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Unit costs of diagnostic and treatment procedures 
Costs of HPV testing were estimated using the PCR (Polymerase Chain 
Reaction) technique and Southern blotting. Two alternative testing procedures 
were considered. More are available but their costs are intermediate. In the 
baseline estimation, one PCR using a general primer (GP) for all known HPV 
types is performed, while subsequent PCRs are performed on GP-positive 
samples with type-specific primers. In the alternative situation, prior specified 
HPV -types are detected through one PCR using a cocktail probe. This 
procedure is the cheapest one possible because only one PCR is needed, while 
the first one has the advantage that infection with other (although unknown) 
HPV types can be confirmed. 
In the cost calculations unit costs are determined by the number of 
PCRs performed per test. Economies of scale by a more efficient use of 
equipment, housing and standard quality control measures, are accounted for: 
the average costs per PCR decrease when the production scale of the laboratory 
(number of PCRs per year) increases. The application of the PCR-technique 
requires specific investments and standard control procedures in order to avoid 
contamination and confounding of test results. 
Relevant information for the cost assessment was gathered on the use 
of materials, required personnel, equipment, administration and overhead costs 
from laboratories for several production levels. The resource needs for each 
production level reflect a situation in which HPV testing is routinely applied. 
An additional number of 2000 PCRs processed for non-HPV tests was assumed, 
because equipment and housing can be used for the processing of other PCR-
based tests. As a consequence, the costs per HPV test depend on the type of 
PCR testing procedure used and on the laboratory scale. For example, of 
women with two LSIL smears 56% are HPV positive for all types. Then, with 
the baseline technique 1 + 3 x 0.56 = 2.68 PCRs are used per test, compared with 
one PCR per test when using a cocktail probe (PCRs for control samples not 
included). With the baseline technique, unit costs per HPV test are less than 2.68 
times the cocktail probe costs (which requires only 1 PCR), especially at high 
levels of scale. 
Cost of colposcopy was assessed by interviewing colposcopists for time 
investment, by reviewing financial accounts of gynecology departments, and by 
cost analysis of the equipment [269]. The unit costs of hospital days and 
outpatient visits include hotel costs, nursing and medical staff, standard 
medical equipment, medication and overhead costs [210]. For other procedures 
we assumed that current fees were representative for their costs. 
LETZ is predominantly an outpatient procedure, but we assumed that 
10% requires a short hospital stay of a few hours. Because a societal perspective 
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is taken [96], time costs are included for women for outpatient and general 
practitioner visits, based on the average hourly labor wage for women. Costs 
are expressed in 1999 US$ using an exchange rate of 2.07 Dutch guilders for one 
dollar. 
Literature search 
In order to test the external validity of the findings on HPV prevalence in our 
study, and to test our results of the HPV triage to alternative patient groups and 
HPV tests, we performed an extensive literature search. We searched Medline 
(key words: "cervical intraepithelial neoplasia", "vaginal smears", "squamous 
intraepitheliallesion", "ASCUS", "LSIL", "HSIL", "abnormal smear", in 
combination with "human papillomavirus") for studies on HR-HPV prevalence 
in referral populations, with known histology results. We only included studies 
in which results were presented for well-defined patient groups (referral 
cytology containing not more than two subsequent cytomorphologic 
categories), and HPV testing by second generation Hybrid Capture (HC-II) or 
PCR (including at least HR-HPV 16, 31 and 33), because only these tests have a 
relatively high sensitivity for the detection of HPV [54]. Studies with high risk 
populations (e.g. HIV) were excluded. Of all studies we determined population 
characteristics and major test characteristics of referral cytology and HPV 
testing. 
8.3 Results 
HPV positivity 
47% of women with persistent cytologic mild or moderate dyskaryosis and 69% 
of women with severe dyskaryosis were positive for HR-HPV 16, 18, 31 or 33 
(table 8.1). The presence of only HR-HPV 16, 31 and/or 33 increased the 
probability of high-grade SIL (HSIL), because their positive predictive value 
(PPV) was higher than the PPV of cytology [41]. We used HSIL as the endpoint 
parameter, because these women are treated, and women without SIL or with 
LSIL are in principal not treated. Because triage by HPV testing between direct 
treatment and conventional management is only more efficient when the PPV 
can be increased, only these HR-HPV types will be considered in the 
calculations. 
Table 8.1 HPV status by histological diagnosis in women of 30-60 years with two smears of mild or moderate dyskaryosis or 
one smear of severe dyskaryosis [41]. 
Histology* HPV prevalence Sp 
Normal t LSIL HSIL Total 
two smears of mild or moderate dyskaryosis 
HPV 16, 31 or 33 6 4 36 46 59.0% 77.8% 
(46.7-71.4%) (65.6-89.9%) 
HPV 18:j: 1 2 1 4 1.6% 93.3% 
(0.0-4.8%) (86.0-1 00.0%) 
HPV 6/11 :j:, no HPV 15 17 24 56 n.a. n.a. 
All smears 22 23 61 106 n.a. n.a. 
one smear of severe dyskaryosis 
HPV16,31 or33 0 0 70 70 66.7% 100.0% 
(57.6-75.7%) (n.a.) 
HPV 18:j: 0 2 7 9 6.7% 80.0% 
(1.9-11.4%) (55.2-1 00.0%) 
HPV 6/11:j:, no HPV 6 2 28 36 n.a. n.a. 
6 4 105 115 n.a. n.a. 
SIL=squamous intraepitheliallesion, Sp=specificity of HPV test for HSIL, PPV=positive predictive value for HSIL 
* Histology based on colposcopically directed biopsy. CIN 1 = low-grade SIL (LSIL), CIN 2/3 = high-grade SIL (HSIL) 
t Including borderline changes. 
+Single HPV 18 or 6/11 without 16, 31 or 33. 
PPV 
78.3% 
(66.3-90.2%) 
25.0% 
(0.0-67.4%) 
n.a. 
57.5% 
(48.1-67 .0%) 
100.0% 
(n.a.) 
77.8% 
(50.6-1 00.0%) 
n.a. 
91.3% 
(86.2-96.5%) 
127 
128 
Table 8.2 Average number of diagnostic and treatment procedures per referred woman 
in case of conventional management and direct treatment policies, based on observed 
figures in Academic Hospital of Groningen [42]. 
Conventional management policy 
Biopsyt 
LETZ 
Conisation 
Hysterectomy 
Direct treatment policy 
Biopsyt 
LETZ 
Conisation 
Hysterectomy 
* Including borderline changes. 
t Colposcopically directed biopsy. 
Histology 
Normal* LSIL HSIL 
1.36 
0.11 
0.25 
0.00 
0.00 
0.75 
0.25 
0.00 
1.00 
0.11:j: 
0.25:j: 
0.00 
0.00 
0.75'11 
0.25'11 
0.00 
1.16 
0.60 
0.41 
0.02 
0.00 
0.60 
0.41 
0.02 
:j: We assumed that in the conventional management policy women with LSIL are in principal not 
treated. These women are treated similar to what has been observed in women with normal 
histology. 
'11 In our study population, women with LSIL received LETZ in 74% of the cases and conisation in 
26%. 
Women with persistent mild or moderate dyskaryosis 
We observed that 36% of women with normal histology were actually treated 
based on the colposcopic impression. Therefore, we used this same share for 
women with LSIL (table 8.2). Table 8.4 presents the number of treatment 
procedures resulting from each management policy by combining the figures 
presented in tables 8.1 and 8.2 and the unit costs of medical procedures in table 
8.3. Per woman referred because of two consecutive smears reported as mild or 
moderate dyskaryosis and compared with the conventional management policy 
(policy n HPV triage (policy 2) avoids on average 0.51 colposcopically directed 
biopsies, but adds 0.05 LETZ treatments and 0.09 outpatient visits, with an 
additional cost of $134 (table 8.4). In other words, per additional LETZ 
treatment and 1.7 (CI 2.4, -0.6) outpatient visits, 9.6 (CI 5.7, 23.9) colposcopically 
directed biopsies are avoided. If the alternative cheap HPV test were used, 
additional costs would be only $37. 
Compared with the conventional management policy (policy 1), direct 
treatment without prior histological assessment (policy 3) avoids 7.3 outpatient 
visits of which 4.6 include colposcopically directed biopsy per additional LETZ 
treatment. In addition, this policy would save $114 per woman. 
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Table 8.3 Unit costs ($ 1999) of medical procedures, visits and hospital days. 
Item 
Pap smear 
HPV testing * 
Primary colposcopy 
Secundary colposcopy 
Biopsy 
LETZt 
Conisation :t: 
Hysterectomy :t: 
Outpatient visit excluding costs of procedures 
Hospital day 
Time costs for the woman per outpatient visit 
Time costs for the woman per GP visit 
* Including the collection of sample material. 
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Costs 
21 
202 
80 
59 
44 
284 
1,460 
3,747 
47 
266 
7 
4 
t Including hospital days. It was observed in the Groningen hospital that 10% of LETZ (unit cost 
$265) need day care (unit cost $181 ). 
:t: Including hospital days and pre-operative diagnostics. Average number of hospital days for 
conisation (unit cost $422) and hysterectomy (unit cost $1 ,007) are 3.6 and 10.0 respectively [249]. 
Table 8.4 Results for women referred after two consecutive mild or moderate 
dyskaryotic smears: predicted number of medical procedures per woman by 
mana£!ement polic}:: ~differences with res~ect to conventional polic}::~-
Medical Conventional HPVtriage Direct treatment 
erocedures eolicy 
HPV testing 0.00 
Outpatient visits 8.83 
Colposcopy 2.14 
Biopsy* 1.15 
LETZ 0.41 
All treatmentt 0.77 
Years in follow-up 4.32 
Costs($) 
* Colposcopically-directed biopsy. 
t LETZ, conisation or hysterectomy 
1.00 (+1.00) 0.00 (0.00) 
8.92 (+0.09) 7.02 (-1.81) 
(9.03, 8.82) + ( +0.20,-0.01) 
1.42 (-0.73) 0.00 (-2.14) 
( 1.51, 1.33) + (-0.64,-0.82) 
0.63 (-0.51) 0.00 (-1.15) 
(0.67, 0.60) + ( -0.4 7,-0.55) 
0.46 (+0.05) 0.66 (+0.25) 
(0.49, 0.43) + (+0.08,+0.02) 
0.82 (+0.05) 1.02 (+0.25) 
(0.85, 0.79) + ( +0.08, +0.02) 
4.31 (-0.02) 4.51 (+0.19) 
(4.36, 4.26) + ( +0.03,-0.07) 
(+134) (-114) 
+148,+121 
Cl +Confidence intervals (95% Cl) are based on the statistical uncertainty of the HPV prevalence (table 
8.1 ), and range from unfavourable to favourable for HPV triage 
Women with severe dyskaryosis 
In women referred with one smear of severe dyskaryosis, HPV triage (policy 2) 
does not induce additional treatment of the cervix compared with the 
conventional policy (policy n and saves on average 0.72 colposcopically 
directed biopsies and 0.33 outpatient visits per woman, but with additional 
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costs of $133 per woman. Direct treatment (policy 3) will save on average 2.12 
outpatient visits of which 1.16 include colposcopically directed biopsy and $103 
per woman, and adds on average 0.05 LETZ treatment per woman. In other 
words, 45 outpatient visits of which 25 include biopsy can be saved against one 
additional LETZ treatment. The explanation is that the PPV of a severely 
dyskaryotic smear for the presence of HSIL is already very high (91.3% ), and an 
additional biopsy will save only few women from being treated. 
Table 8.6 Comparison (number of procedures) of management policies in alternative 
referral ~o~ulations. Po~ulations are ranked b~ severit~ of referral c~olo~f 
Referral cytology HPV triage versus conventional Direct treatment versus 
(HPV test) management conventional management 
Avoided Avoided visits Avoided Avoided visits 
biopsies per per additional biopsies per per additional 
additional LETZ additional LETZ 
LETZ LETZ 
2x mild or 1x 
moderate/severe 7.8 1.3 4.0 6.9 
dysplasia (PCR) [58] 
2x borderline/mild or 
1 x moderate/severe 9.0 2.7 4.2 7.8 
dysplasia (PCR) [250] 
Present study: 2x 
mild/moderate 9.6 -1.7 4.6 7.3 
dysplasia (PCR)£42] 
2x mild or 1x 
moderate dysplasia 3.7 -1.2 2.6 5.0 
(PCR) [149] 
2x borderline/mild 
dysplasia (PCR) [1 06] 3.7 -1.2 2.6 4.8 
1x mild dysplasia (HC 
II) [17 48 87 145] 2.1 -0.4 2.0 2.6 
1x borderline (HC II) 
[17 48 87145 163 2.5 0.8 2.2 4.3 
248 253 
LETZ - loop excision of the transformation zone. 
Sensitivity analysis 
The study results are to a large extent determined by three key characteristics: 
1) we used PCR-based HPV-testing with HR-HPV types 16, 31 and 33, 2) the 
population is relatively old compared with other studies, and 3) the referral 
criteria for colposcopy were relatively conservative: two smears reported as 
mild or moderate dyskaryosis or one smear reported as severe dyskaryosis. 
From the literature review appeared that the prevalence and positive predictive 
value (PPV) of HR-HPV for HSIL in the present study are comparable to studies 
with similar populations and PCR-testing (table 8.5) [58 250]. In situations with 
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Table 8.5 HPV status in women referred for colposcopy and with known histology, separate for HC-11 testing and PCR-testing. Studies are 
ranked bl: severitl: of referral cytologf 
Study Referral cytology Age range N PPV HR-HPV specificity PPV HR- NPV HR-HPV for HR-HPV-types 
(mean) cytology for prevalence HR-HPV for HPV for high normal/low 
high gradet in high high gradet gradet (%) gradet (%) 
(%) gradet (%) (%) 
HC-11 testin 
Ferris, 1998 [87] borderline 18+ (27) 143 6 89 40 9 99 16,18,31 ,33,35,39,45,51 ,52 
,56,58,59,68 
Clavel, 1999 [48] borderline 15-72 (37) 23 9 100 57 18 100 id. 
Manos, 1999 [163] borderline 14-92 (40) 973 7 89 64 15 99 id. 
Bergeron, 2000 [17] borderline 15-75 (35) 111 11 83 62 21 97 id. 
Shla:t, 2000 [248] borderline 15-76 (34) 195 8 93 74 23 99 id. 
Lin, 2000 [145] borderline 50+ (62) 74 36 100 74 69 100 id. 
Solomon, 2001 borderline 18+ (29) 114 11 96 49 20 99 id. 
253] 9 
Lytwyn, 2000 [152] borderline or 16-50 (30) 87 9 88 51 15 98 id. 
mild d ska osis 
Ferris, 1998 [87] mild di:ska!1osis 18+ (27) 99 12 92 13 13 92 id. 
Clavel, 1999 [48] mild di:skaryosis 15-72 (37) 56 4 100 24 5 100 id. 
Bergeron, 2000 [17] mild di:ska!1osis 15-75 (35) 267 5 93 44 8 99 id. 
Lin, 2000 [145] mild di:ska!1osis 50+ (62) 45 47 100 46 62 100 id. 
PCR-testing 
Cuzick, 1995 [56] borderline 20-45 (31) 58 14 63 86 42 93 16,18,31 ,33 
Adam, 1998 [2] borderline or 14-75 (28) 454 15 65 60 22 91 16,18,31 ,33,35 
mild dyskariosis 
(2x) 
Herrington, 1995 borderline or -- 165 23 82 75 49 93 16,18,31,33 
[106] mild dyskaryosis 
(2x) 
Cuzick, 1995 [56] mild or moderate 20-45 (31) 52 38 35 69 41 63 16,18,31 ,33 
d skar osis 
Nobbenhuis, 1999* mild or moderate 18-55 (32) 297 34 87 52 48 89 16,18,31 ,33,35,39,45,51 ,52 
[£04] dyskaryosis ,56,58,59,66,68 
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Table 8.5 HPV status in women referred for colposcopy and with known histology, separate for HC-11 testing and PCR-testing. Studies are 
ranked by severit~ of referral cytologt 
Study 
Londesborough, 
1996 [149] 
Bollen, 1997 [26] 
Bollen, 1997 [26] 
Burger, 1995 [42] 
Burger, 1995 [42] 
Sigurdsson, 1997 
[250] 
Cuzick, 1994 [58] 
Referral cytology Age range N 
(mean) 
mild (2x) or 16-69 (31 ) 258 
moderate 
d skar osis 
mild or moderate 16-65 (35) 190 
dyskaryosis ( 1 
or2x 
mild or moderate 16-65 (35) 190 
dyskaryosis (1 
or2x 
mild or moderate 
d~ska~osis (2x) 
mild or moderate 
dyskaryosis (2x) 
borderline or 
mild dyskaryosis 
(2x), moderate 
or severe 
d ska osis 
mild (2x), 
moderate or 
severe 
dyskaryosis 
all ages 157 
(35) 
30-60 106 
(±40) 
18-71 (33) 358 
-- (32) 133 
PPV HR-HPV specificity PPV HR- NPV HR-HPV for HR-HPV-types 
cytology for prevalence HR-HPV for HPV for high normal I low 
high gradet in high high gradet gradet (%) gradet (%) 
(%) gradet (%) (%) 
25 75 74 49 90 16,18,31 ,33,35,45,52,58 
29 68 70 49 84 16,18,31 ,33,35 
29 95 40 40 95 16,18,31 ,33,35,39,45,51 ,52 
,56,58 
58 66 67 73 59 16,18,31,33 
58 59 78 78 58 16,31,33 
54 79 72 78 75 16,18,31 ,33,35 
55 79 75 79 75 16,18,31 ,33,35 
Borderline =ASCUS, mild dyskaryosis = LSIL, moderate or severe dyskaryosis = HSIL, HC = hybrid capture; HR-HPV = high-risk HPV, PPV = positive 
predictive value, NPV = negative predictive value. 
* Histology is highest grade found by biopsy, LETZ, or conisation during surveillance when women reached severe dysplasia assessed by colposcopy or at 
the end of the study (5 year follow-up) in a prospective study. 
t We used high-grade SILas endpoint parameter for calculating test characteristics, because these women are treated, and women without CIN or with 
CIN 1 are in principal not treated. 
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more relaxed referral criteria, such as one smear of mild or moderate 
dyskaryosis or two borderline smears, as presently in e.g. the Netherlands and 
the UK, or even one borderline smear, as in the US in some settings, HPV triage 
by PCR testing with selected high-risk types similarly improves the PPV for the 
presence of HSIL but on a lower level (41-49% compared to 78% in the present 
study) [26 56106 149]. Two studies with relatively young populations showed a 
modest improvement of the PPV by HPV triage [2 56]. The HC-II HPV test, 
which contains a broad range of HR-HPV types, has mainly been applied in 
populations with borderline or mildly dyskaryotic smears. In these populations, 
the HC-II shows a high prevalence of HPV and negative predictive value, but 
the PPV for the presence of HSIL is only modestly increased. 
In table 8.6 the calculated performance of the HPV triage (policy 2) and 
direct treatment management (policy 2) policies in alternative referral 
populations is presented compared to conventional management (policy 1). The 
treatment numbers of table 8.2 were combined with the observed HPV 
prevalences in reviewed studies (table 8.5). For this purpose, HPV findings in 
similar populations and similar HPV tests were aggregated. It appears that 
HPV triage avoids similar numbers of biopsies per added LETZ as in the 
present study in comparable patient groups, but appears less favourable in 
populations with less severe referral cytology or when the HC-II HPV test is 
used. A similar pattern is observed for the direct treatment policy. 
8.4 Discussion 
For women referred because of persistent mild or moderate dyskaryosis on 
cytology, the choice between the considered strategies will, among others, 
depend on the quality of life (QoL) effects that are attributed to outpatient 
visits, colposcopically directed biopsy and conservative treatment (LETZ) 
respectively. Such QoL measurements are however not available. Pain and 
discomfort associated with biopsy and LETZ should be considered, as well as 
uncertainty involved in awaiting histological results. Because HPV triage can 
save 9.6 biopsies per additional LETZ compared with conventional policy, this 
policy will be preferred when undergoing LETZ is considered less than 10 times 
the burden of undergoing colposcopically directed biopsy (neglecting the small 
increase in outpatient visits). In addition, if the overall QoL of the HPV triage 
policy would be more favourable compared to conventional management, this 
must be weighed against the extra financial demands of $114 per referred 
woman. 
For women referred because of a smear reported as severe dyskaryosis, 
direct treatment comes out as an attractive policy, also compared with the HPV 
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mediated policy. It saves a lot of diagnostic procedures at the cost of only very 
few added treatments. This confirms findings reported elsewhere [111]. 
The present study concerns a situation where LETZ is the local 
treatment of choice for SIL. LETZ has the advantage that it can be applied 
without prior histological examination. When for instance cryotherapy is 
included as an alternative, which requires prior biopsy, direct treatment is 
impossible and HPV triage will be less favourable. 
We considered an HPV triage by which women with only HR-HPV 16, 
31 or 33 would be treated directly, because in our study HR-HPV 18 did not 
improve the PPV for the presence of HSIL. As table 8.5 shows, HPV tests that 
include a lot of HR-HPV types beyond 16, 31 and 33 (including the 
commercially available HC-II) are not suitable for triage between direct 
treatment or colposcopy because a high HPV prevalence goes at the expense of 
a low PPV for the presence of HSIL. We conclude that more research should be 
done directed at the identification of those HR-HPV types that are predictive 
for the presence of HSIL. 
There are indications that HPV triage performs more favourable in 
relatively old populations, considered the high PPV found in e.g. Lin [145] and 
in the group of women beyond age 30 compared to those below this age in our 
study (data not shown). In younger populations, the PPV of HPV for the 
presence of HSIL is relatively low. More evidence is needed to assess age as a 
possible additional triage criterium especially in populations with mild 
cytology. 
In the present study, 64% and 50% of women with normal histology or 
LSIL are not treated in the conventional and HPV triage policy respectively, but 
have been followed up during one year with two six-monthly papsmears 
including colposcopy. Is this without risk? HSIL has been found in LETZ or 
cone biopsy in 38% [47] and 41% [251], respectively, of women who initially 
showed negative or LSIL at colposcopically directed biopsy. Some of these 
women - those who are not treated and develop cancer - would be missed in 
the conventional and HPV triage policy. In addition, from the Dutch national 
pathology database we found that of women with mildly or moderately 
dyskaryotic smears and negative histology shortly after, 3.5% had developed 
carcinoma in situ or borderline invasive cancer within five years [71]. It is not 
clear whether these cases have been picked up by follow-up smears or by a 
primary (screening) smear. Lifetime progression from LSIL to HSIL or invasive 
cancer has been estimated at 12% [212], while statistical analyses of screening 
data show slightly higher progression rates from LSIL to HSIL [31287]. 
Considering that these cases are mostly picked up during follow-up or next 
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screening rounds, and that carcinoma in situ and borderline invasive cancer are 
still highly treatable, these figures seem tolerable. 
HPV triage as evaluated in the present study is complementary to the 
current debate on the utility of HPV triage in women with less severe cytology 
(one ASCUS or LSIL smear) than in the present study. In these women, HR-
HPV positives are referred for colposcopy and HR-HPV negative women are 
kept under cytologic surveillance, which is a triage protocol different from the 
present study [51 52 87126 248 253 304]. For this triage definition, a high 
negative predictive value combined with a high HPV prevalence is supportive 
for HPV triage. Such test performance has been shown in several studies, but in 
some studies histological HSIL patients show negative on HPV test results 
(table 8.5, first part). Therefore the increased efficiency in patient management 
(avoided colposcopy) should be weighed against the few patients that are 
missed by HPV testing, and against the burden and risks associated with 
cytologic follow-up: prolonged uncertainty, non-compliance and disease 
progression. Of women with LSIL referral smears who have been followed-up 
cytologically for two years, 23-33% are found to be lost to follow-up and of the 
remainder 55% had progressed to HSIL on histology [3 89]. 
The ongoing technological development of HPV tests results in better 
test characteristics, but possibly in lower costs as well. Besides, lower cost levels 
could already be attained if HPV testing is concentrated in a few laboratories, 
taking advantage of economies of scale. We showed that at a unit price of $68 
HPV testing results in similar costs per referred woman as the conventional 
management policy in women with smears reported as LSIL. This break-even 
point might vary among countries depending on the relative costs of HPV 
testing, colposcopically directed biopsies, LETZ and outpatient visits. For the 
US, $110-200 has been reported as unit costs for colposcopy and $84-100 for 
biopsy [126], which will result in even larger cost savings in the HPV triage and 
direct treatment policies than presented here. 
We conclude that the choice between conventional management, direct 
treatment and HPV testing as a triage instrument in women with persistent 
mild or moderate dyskaryosis will depend on the relative burden for the patient 
that is attributed to outpatient visits and colposcopically directed biopsies 
compared to LETZ. A quantitative assessment of this burden, expressed in the 
reduction in quality of life for each of these procedures, will permit a more 
informed decision. Direct treatment with ablative techniques such as LETZ in 
women referred because of severely dyskaryotic smears seems to deserve 
serious consideration, because this will considerably reduce the burden of 
diagnostic procedures (colposcopy and biopsy), and hardly increase 
overtreatment. 
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General discussion 
9.1 Introduction 
We will summarize the main findings, discuss their methodological robustness, 
compare the findings with other research, draw conclusions and make 
recommendations. We will also integrate the described research by discussing 
the contribution of cost of illness estimates, burden of disease estimates and 
economic evaluations to the effectiveness and efficiency of health care. 
9.2 Cost of illness in the Netherlands 
Main findings 
Health care costs (synonymous for medical costs) are dominated by old age and 
disability (chapter 2). Per capita health care costs are strongly age-dependent: 
they are relatively high in the first year of life, low during childhood and 
adulthood, and increase exponentially beyond age 50. Mental disorders and 
musculoskeletal diseases, two disabling but predominantly non-fatal disease 
clusters, outrank major killers as cancer, coronary heart disease and stroke. 
Almost 60% of total health care costsis accounted for by females, reflecting their 
larger life expectancy and the costs of reproduction. 
How valid are the results? 
The study provides broad insights into the cost distributions rather than precise 
cost estimates. Generally, we had to use indicators of health care consumption 
by diagnostic and demographic variables, that have a strong but imperfect 
relationship with real resource use. For instance, we were unable to distinguish 
between high and low intensity hospital days, thereby underestimating costs of 
diagnoses that account for a relatively large share of intensive care, such as 
coronary heart disease and injury. 
For some types of health care, consumption data by diagnostic and 
demographic variables were not available or lacked detail or quality. Examples 
are old people's homes and home care, that together account for 15% of health 
care costs. As a result costs of chronic disabling diseases with high needs for 
professional care, e.g. musculoskeletal diseases, will have been underestimated, 
and it is difficult or even impossible to indicate any confidence bounds. 
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We defined disease clusters to avoid that results would be distorted by 
misclassification of diagnoses in health care registers. An example is mental 
disorders that are often too complex for mapping in a unidimensional 
classification. However, for other health problems more detailed results would 
be useful. In the field of injuries, both the physical injury and the causal 
mechanisms are relevant aspects of the diagnosis. It is also for these reasons 
that multidimensional classifications have been developed for mental disorders 
(DSM-III) [7], and injuries (ICECI) [298], in addition to the international 
classification of diseases and injuries (ICD) that we used [296]. 
Comorbidity 
An important matter in cor studies is how to attribute costs in case of 
comorbidity, the fact that many patients (often elderly) suffer from more than 
one condition. These conditions may be unrelated (e.g. arthrosis and 
Parkinson's disease), whereas some diseases are risk factors for other diseases 
(e.g. diabetes and coronary heart disease). In our analysis, costs were attributed 
to the primary diagnosis, which is the principal diagnosis that gave cause for 
health care consumption. These costs include possible extra resource use 
because of other health problems. For instance, a woman with a hip fracture 
might have a longer hospital stay and more intensive care if she also suffers 
from a neurologic disorder. All costs have then been attributed to the hip 
fracture. Whether costs of specific diseases are thus over- or underestimated, as 
stated elsewhere [219], depends on the aim of the analysis, such as estimating 
savings through prevention. In our example, had the hip fracture not occurred, 
than also the extra resources because of the neurologic disorder would not have 
been used, and it can be justified to allocate all costs to the hip fracture. 
Alternatively, had the neurologic disorder been absent, only the extra costs 
related to this condition would have been saved. Another example is decubitus, 
that can be prevented by direct measures or by interventions that tackle the 
conditions because of which patients are bedridden. Depending on the aim of 
the analysis, decubitus related costs should be attributed to decubitus or these 
underlying conditions. 
The problem of comorbidity can be solved by attributing costs to more 
than one diagnosis or risk factor. This would give insight into how costs of 
diseases and risk factors are related. This approach has been adopted in a recent 
generic COl study for the Netherlands, but it increases the data needs 
considerably [219]. 
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Comparison with other studies 
Differences between our COr results and those of other studies can have many 
causes. Studies may differ in their level of comprehensiveness, the definition 
and classification of diseases, in applying a top-down or bottom-up approach 
(including differences in the analysis of comorbidity), and in the quality of data 
sources [219]. 
The comprehensiveness of our study with regard to the inclusion of 
health care compares favourably with other studies, that exclude parts of 
psychiatric care, nursing home care and other elderly care [146150]. This 
explains our high cost estimates in old age and mental disorders, including 
dementia. Other studies may include indirect costs of lost production due to 
disease and disability, thereby inflating the total cost estimate considerably, 
depending on the method used to value productivity costs [14]. We disregarded 
productivity costs because of the lack of reliable methods to measure them, the 
lack of good quality work absence data in the Netherlands, and because a 
description confined to health care costs contributes to the interpretability of 
results and the utility for health care policy. 
In our COr study costs reflect health care consumption in a given year 
(i.e. 1994) that can be attributed to population groups defined by age, sex and 
diagnostic group. The resulting costs per population group do not show how 
these costs are distributed within each population group. Some persons will 
consume much health care and others less or even no health care at all. For 
diseased persons health care need is much related to the disease stage. For 
instance, in cancer patients costs may be U-shaped, with high costs at the time 
of diagnosis and treatment, relatively low costs during follow-up, and 
increasing costs upto the end of life in case the cancer is incurable [301]. In other 
words, our study does not give information on the lifetime distribution of 
health care consumption at the individual level. The steap increase of per capita 
health care costs by age may be due to higher levels of disability in old age, but 
may also reflect high costs in the last year of life [91160 220 254]. Whether costs 
are related to (the proximity of) death or to disability in the many years 
preceding death is an important matter for societies with ageing populations. If 
costs are related to disability rather than death, a decrease in mortality will lead 
to more years lived with disability and therefore increasing health care 
consumption. If costs are related to dying rather than ageing, health care 
consumption will be postponed over the human lifespan when mortality 
declines. Accounting for health care costs in the last year of life thus has a 
moderating effect on the projected increase in health care costs. Because about 
10% of total costs are in the last year of life, the impact is very small [220]. 
Another study found that not accounting for costs in the last year of life leads to 
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a 20% overestimate of the increase in health care costs, but the analysis was 
limited to hospital and primary care only [160]. It can be concluded that 
population ageing will lead to an increase in health care costs, because the 
majority of costs are related to chronic, degenerative diseases that start many 
years before the end of life (chapter 2). 
Recommendations and future research 
The comparibility of cor data may be increased by the development of 
guidelines for conducting and reporting cor studies. In this regard, a 
facilitative effort is the EUCOMP project of national statistical offices in EU 
member states, that aims to describe the content of health care providers in 
national statistics of health care costs and production. This helps to define 
packages of health services that are internationally comparable [285]. When 
these data could be integrated with cor data, this would greatly enhance the 
investigation of international differences in health care expenditures, and the 
underlying supply and demand factors. 
Another challenge will be to attribute costs to specific health risks [233]. 
This is essential for targeting prevention. Because most diseases have multiple 
risk factors, and single risk factors often regard more than one disease, a 
comprehensive approach that accounts for multicausality would enable to 
quantify the combined (economic) effect of single or multiple risk factors 
beyond specific diseases [81]. 
9.3 Medical costs of injury 
Main findings 
We linked a national injury surveillance system (LIS) with a bottom-up costing 
model by which health care consumption and costs were estimated per 
individual patient (chapter 3). It thus became possible to estimate total health 
care costs of injury on a continuous basis, and for any subgroup of injury 
patients. Health care costs of injury were 1.1 billion euro or €1,019 per patient in 
1998 (more recent years are also available). Peaks in total costs were observed in 
males between age 15 and 44, primarily due to high numbers of injury in this 
age group, and in females beyond age 65, primarily due to high costs per 
patient such as in hip fractures. Minor injuries without need for hospitalization, 
predominantly superficial injury and open wounds, together accounted for 
more than a third of health care costs of injury. Independent determinants of 
individual health care consumption were age, sex, hospitalization, injury 
diagnosis, motor vehicle crash, and number of injuries. 
Medical costs of injuries could be used as an indicator for the relative 
importance of specific injuries. This is particularly useful for injuries, that 
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include high frequency minor injuries and low frequency severe injuries. 
Although in many cases health care consumption is strongly related to a 
patient's health status, in some cases it does not reflect health care needs. 
Medical costs should therefore be interpreted with caution when used as an 
indicator of population health. 
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Because of the linkage with the national injury surveillance system, the 
costing model can be used for continuous monitoring of injuries on aggregate 
and more detailed level. Because the model is incidence-based, and lifetime 
costs can be estimated per patient, it can provide necessary input for the 
economic evaluation of preventive interventions and trauma care. 
How valid are the results? 
Although the cost of injury study was comprehensive, considering a broad 
range of injuries and medical care, costs have been underestimated. Injury 
patients who are treated by primary care providers (e.g. general practitioners) 
were not considered. Their number is estimated at 1.3 million per year, and 
even exceed the number of patients treated in Emergency Departments (ED) 
[62]. Because injuries treated by primary care providers are predominantly 
minor, not resource intensive injuries, they would add about 10% to our total 
cost estimate (chapter 3). In addition, we did not include long-term costs of 
injury after the first year post-injury because of lack of valid data. 
The statistical uncertainty of our cost estimates is primarily determined 
by the uncertainty of the incidence estimates. The incidence of unadmitted 
patients has been derived from the national injury surveillance system (LIS). LIS 
is based in 17 hospitals, which is the number of observations for the calculation 
of statistical uncertainty. The uncertainty of national incidence estimates will be 
higher when the variance of the incidence is large among hospitals, such as in 
ice-skating injuries. However, our cost estimates can still be regarded robust for 
the following reasons. First, the uncertainty of the incidence estimates is limited 
to nonadmitted patients that account for only a third of total medical costs (we 
used the national hospital discharge register (LMR) with national coverage for 
the number of admitted injury patients). Second, we reported results for 
broadly defined patient groups that are unlikely to have large variation in 
incidence among hospitals. 
To calculate total ED costs, we estimated average costs per ED visit. 
These average ED costs should not be confused with marginal ED costs, defined 
as the costs of adding one extra ED visit. The marginal to average cost ratio of 
EDs has been found to be far below one because of the high fixed costs of 
running an ED, that must be staffed for 24 hours to treat real emergencies [263]. 
Williams estimated the marginal to average cost ratio at 0.41 for nursing 
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resources and infrastructure and 0.35 for physician resources [303]. A time and 
motion study in an academic hospital showed that 45% of nursing time was 
directly related to patient treatment [276]. Our average costs per ED visit can 
therefore not be interpreted as cost savings for instance by shifting nonurgent 
visits to primary care. 
Comparison with other studies 
Our estimates of the costs of injuries are more comprehensive and detailed 
compared to those of generic, top-down cor studies [221275]. Costs of 
unintentional injury were slightly higher in our study (1.1 billion euro) than in 
Polder et al. (1.0 billion euro) [221]. Costs of traffic injury, upper extremity 
injuries and superficial injury (including contusions) were higher in our study, 
predominantly because we separately distinguished ED costs. Our costs of hip 
fracture were lower, because we excluded old people's homes and we limited 
the length of stay in nursing homes to the average observed in patients without 
comorbidity. 
In the international literature, not many comparable cost studies exist 
(chapter 4). In Rice et al. [231 ], per capita medical costs of injury were three 
times our estimate, because of higher costs per patient (costs per patient were 
similar, but Rice et al. also included minor injuries treated by primary care 
providers), and because of a 1.5 times higher incidence. Other estimates for the 
United States were similar to those of Rice et al. [180] or slightly lower because 
of the exclusion of long-term costs [178]. For Australia, per capita medical costs 
were estimated at $145 in a bottom-up analysis [293] (about twice our estimate), 
compared to $105 in a generic, top-down cor study (2000 US$PPP) [164]. 
Interestingly, the difference in per patient costs between the US and the 
Netherlands is analogous to the two times higher total health care costs per 
capita in the US (PPP adjusted). Because per capita health care costs are 
comparable between the Netherlands and Australia (PPP adjusted), this does 
not explain the much higher costs of injury in Australia compared with the 
Netherlands. 
Many cost of injury studies include productivity costs and 'human 
costs' of pain and suffering. Productivity losses are estimated at about three 
times the medical costs, whereas human costs are even higher [22 59]. For the 
Netherlands, van Beeck et al. estimated productivity losses due to injury in 1988 
at $3,293 million with the human capital method (HCM) and at $702 million 
with the friction cost method (FCM), compared to $952 million for medical costs 
[275]. Both types of costs need a further discussion. 
The inclusion of productivity losses in cor studies is theoretically 
justified because disease and injury negatively influences the availability of 
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scarce resources (labour) that have opportunity costs. An matter of concern is 
the validity of the cost estimates. The HCM estimates productivity losses from 
the occurrence of the disease until full recovery or, in case of permanent 
disability, the age of retirement. In contrast, the FCM accounts for the 
possibility that sick workers are replaced sooner or later by formerly 
unemployed persons [131]. The duration of the period until replacement, the 
friction period, primarily depends on the unemployment rate and the type of 
job. The HCM premises that societal welfare loss is the summation of (lifetime) 
individual productivity losses due to temporary or permanent disability and 
premature death. This implicit individual perspective is in contrast with the 
societal perspective of the FCM. The validity of both methods should be further 
tested. The HCM is appropriate in situations of full employment and scarcity of 
labour, and in studies that adopt an individual perspective. The FCM will by 
definition provide an underestimate when not accounting for future friction 
periods that may occur in situations of full employment. These future friction 
periods are however difficult to operationalize. Another concern of the FCM is 
that the main parameters, the duration of the friction period and the production 
elasticity of labour, are likely to be job specific, but we are unaware of any 
empirical data. In addition, more empirical data are needed on compensation of 
lost work hours by colleagues and others [118], and on reduced productivity 
during work hours ('sickness presenteeism') [39]. 
Estimates of 'human costs' are based on monetary valuations of lost 
quality adjusted life years (QAL Y), as empirically derived by willingness-to-pay 
methods (WTP). However, the valuations heavily depend on the method used 
to elicit preferences. In a systematic review of studies, the monetary value per 
QAL Y ranged from $25,000 (HCM) to more than $400,000 (revealed preferences 
for job risks), and with estimates from stated preference methods somewhere 
inbetween [108]. In contrast WTP estimates appear scope insensitive: 
valuations have a weak relationship with the size of the benefits that are to be 
valued. This makes WTP particularly inappropriate for burden of disease 
estimates. In a systematic review of WTP studies, these findings made Olsen et 
al. to conclude that the WTP method is "sensitive to theoretically irrelevant 
information, and insensitive to theoretically relevant information" [209]. 
Recommendations and future research 
The use of cost of injury studies in prioritizing health policy, and the necessary 
conditions, need to be further explored [188]. Another recommendation is that 
data on costs of injury should be complemented with cost-effectiveness 
information of injury control measures. Preventive interventions and trauma 
care, either existing or newly developed, need to be evaluated to further 
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develop, implement or discontinue these activities. In the Netherlands few 
examples exist of economic evaluations in injury control [61 211 222]. 
Health care costs of injury are predominantly determined by the 
incidence and severity of injuries. Because information on injury severity is not 
uniformly registered in most hospitals [274], the use of health care costs as an 
alternative indicator for the burden of injury needs to be tested in two ways. 
First, the combined analysis of trends in incidence and health care costs of 
specific injuries will give a first indication of trends in injury severity, and may 
generate hypotheses that can be tested in further analyses. Second, previous 
findings on the relationship between individual patient costs and injury 
severity as classified by validated instruments (Abbreviated Injury Scale, AIS, 
and Injury Severity Scale, ISS) need to be further explored and tested [155 159 
180]. In addition to severity, this research should consider other determinants of 
individual health care consumption, such as comorbidity and socio-economic 
status. 
Finally, as with generic COI studies, the (international) comparability of 
cost of injury studies could be enhanced by the development of a taxonomy and 
of guidelines for conducting and reporting cost of injury studies. 
9.4 Injury related disability 
Main findings 
We found that the average health status of non-hospitalized patients 2 months 
post-injury, measured by the generic EuroQol instrument (EQ-5D+), was 
comparable to the general population (chapter 5). However, patients with 
injuries to the vertebral column and the extremities or with skull-brain injury 
reported lower than normal levels of functioning. An average of 5 work days 
were lost per non-hospitalized injury, and 5% had not yet returned to work 
after 2 months. 
Hospitalized patients reported higher prevalences of disability than 
non-hospitalized patients in all health domains of the EQ-5D+. The mean EQ-
5D summary measure increased from 0.62 after 2 months to 0.74 after 5 months 
and remained below the population norm at 9 months, particularly in patients 
below age 60. Hospitalized patients with injury to the spinal cord or vertebral 
column or a lower extremity fracture reported the worst health status after 2 
months, also when adjusted for age, sex and educational leveL Those with a 
paid job on average lost 72 work days, and 40%, 20% and 10% had not yet 
returned to work after 2, 5 and 9 months, respectively. Age, sex, educational 
level, injury diagnosis, and several indicators of injury severity were 
independent and significant predictors of functional outcome. 
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How valid are the results? 
The main limitation of our study was the low response rate. We adjusted the 
results for systematic non-response with available data on background 
characteristics, but particularly the 9 month results cannot be considered 
representative for specific subgroups, such as young adults and skull-brain 
injuries. 
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We identified three main causes of the low response. First, the 
population was very heterogeneous, included persons of different socio-
demographic and ethnic groups, and encompassed patients with various 
injuries: minor bums as well as hip fractures and severe brain injury. Young 
adults and elderly, and persons with lower education in general respond less to 
postal questionnaires. We could have limited our research to persons below age 
64 and native Dutch speakers, but the aim of our research was to collect 
representative and comprehensive data on functioning after injury in the Dutch 
population. Second, we used postal questionnaires without reminders and 
other stimuli that could have increased response rates. Reminders, monetary 
incentives, personal follow-up, and personal interviews in stead of postal 
questionnaires in general lead to higher response rates [74]. However, these 
measures need considerable amounts of resources. Third, a number of persons 
refused to participate because of insufficient mental or physical fitness. For 
these persons the use of proxies to fill in the questionnaire would have been a 
good alternative. 
Another limitation of our study was that we did not have adequate 
information of post-clinical mortality. By definition the responders all had 
survived their injury. The mean case fatality rate in injury victims that reach the 
hospital is about 2% [274]. 
We did not collect information on comorbidity, which is particularly 
relevant in elderly patients. Comorbidity is predominantly prevalent among 
elderly, and is an important independent determinant of mortality and 
disability [266]. We used norm scores of health in the general population to 
adjust for disability because of pre-existing conditions. 
Comparison with other studies 
Studies conducted so far on post-injury functioning are very heterogeneous. 
Differences are in general related to the patient sample, measurement 
instruments, follow-up intervals, and other design issues. Our study is one of 
the few that did not exclude patient groups a priori. This explains why 
hospitalized patients in our sample were on average less severely injured than 
in other studies. For instance, a larger proportion of hospitalized patients had 
returned to work after 9 months (90%) than in MacKenzie et al. after one year 
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(57%) [159]. Our observed EQ-5D summary scores after 5 and 9 months (0.74) 
compare favourably with the average Quality of Well-Being (QWB)-score of 
0.63 and 0.67 after six and twelve months, respectively, in Holbrook et al., also 
when accounted for population norms for these measures [109 110]. In 
Holbrook et al. 62% were traffic injuries compared to only 29% in Dutch 
hospitals. 
There are few studies on disability in non-hospitalized patients. In one 
study with non-hospitalized ED patients, 68% were at least partially restricted 
in work activities for one day or more (probably related to the treatment itself), 
and 10% reported restricted activities of daily living. After 1 month, 10% were 
at least partly disabled for work and 1% were restricted in their daily activities 
[292]. These rapid recovery rates explain why we found on average normal 
levels of functioning after 2 months. One should also consider that in the 
Netherlands more than 50% of injury patients at an ED are non-urgent, and 
have minor injuries such as contusions, abrasions, open wounds and small 
bums. The vast majority of these injuries leads to temporary disability, 
although a small proportion will result in long-term disability [258]. It has even 
been asserted that a large proportion of prevalent disability can be attributed to 
non-hospitalized injury patients [217]. We found that, among non-hospitalized 
patients, particularly injuries to the vertebral column had less than normal 
levels of functioning after 2 months. 
Recommendations and future research 
The heterogeneity of research conducted so far on functioning and disability in 
injury patients is likely related to the heterogeneity of injuries itself. All the 
more this stresses the need for uniform methodologies to generate comparative 
information among groups, over time, and among countries. This uniformity 
can be increased by defining a number of standards for study design, and by 
reaching agreement on these in the injury research community [72]. In short, 
these standards consider what, when and how should be measured: 
a. a classification of injuries by which diagnoses with similar functional 
sequelae and speed of recovery are clustered, e.g. with use of the recently 
released International Classification of Functioning [297]. 
b. a minimum set of measurement intervals that match the several stages of 
the recovery process: the acute treatment phase, rehabilitation phase, 
adaptation phase and the stable end situation [72]. If necessary, for specific 
injuries additional measurements could be added to this minimum set, to 
match the particular speed of recovery. 
c. the use of a generic instrument for measuring health that covers physical, 
mental and social functioning as the general constituents of health. If 
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necessary, this generic instrument should be supplemented with specific 
instruments by which injury-specific types of functional loss and 
restrictions in activities and social participation can be measured. Any used 
instruments should be reliable and valid, should closely match the 
functional consequences of injuries, and should be easily administrable and 
not too time consuming. The validity of generic instruments in injury 
populations should be further tested [274]. 
d. utility based instruments enable the calculation of a summary measure 
based on the scores on each domain, and facilitate a rapid comparison 
across different injury groups (see also paragraph 9.7). 
e. in addition to health status, a standard set of personal and injury related 
variables should be collected that are associated with disability, including 
proxy measures in case specific information is not available (e.g. injury 
severity). 
The data on injury disability presented in this thesis are an example of 
the systematic collection of data for calculating the burden of injury, as 
stimulated by the Global Burden of Disease project [194]. Future efforts should 
integrate these data with data on functional outcome from other studies, e.g. 
major trauma patients [283 291] and tibial fractures [112]. An important 
application will be to estimate the burden of injury in the Netherlands by 
combining these data with incidence and mortality data, distributed by relevant 
accident categories. We made preliminary estimates showing that the total 
number of years lived with disability due to injury in 1999 is about 122,000, and 
about 10,000 when adjusted for comorbidity. Of these, 38% is due to home and 
leisure injuries and 27% to traffic injuries [171]. Also, our estimates of disability 
need to be validated and enhanced by new follow-up studies using designs that 
guarantee a sufficient reponse, with shorter time intervals for non-hospitalized 
patients as applied by us, and extending the follow-up period beyond one year 
to capture long-term consequences of injury. 
9.5 Cervical cancer screening 
Main findings 
In chapters 6 and 7 (part II) we investigated the test characteristics of newly 
developed cytologic technologies for cervical cancer screening, and their (cost-
)effectiveness compared to screening with the Pap test. In a critical review of 
trials we found that there is weak evidence that one liquid based 'thinlayer' 
cytology (LBC)system (ThinPrep™) and two automated systems (AutoCyte™ 
SCREEN, AutoPap™) are more sensitive than the Pap test, at the loss of some 
specificity. We designed a decision analytic framework based on a cost-
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effectiveness analysis (CEA) to indicate the minimum test performance 
(sensitivity, specificity, smear adequacy) of any new cytologic screening test for 
which it would have an acceptable C/E ratio, given te costs per test. 
Considering the costs of the current technologies, and that in most countries 
screening is more intensive than in the baseline calculations, it is unlikely that 
they are more cost-effective than the Pap test. 
How valid are the results? 
We estimated the effectiveness of screening with the MISCAN microsimulation 
model. The parameters in the MISCAN model that describe the natural history 
of cervical cancer and the Pap test sensitivity have been quantified with 
screening data from British Columbia [287]. These quantifications were found 
to be consistent with international data on interval cancers [116] and resembled 
the incidence estimates of Gustafsson that were based on Swedish data [101]. 
Also, it was possible to reproduce the epidemiology of cervical cancer in the 
Netherlands with the MISCAN model for the period before screening as well as 
for the years after the introduction of screening [267]. 
We used life years gained as primary outcome measure in the economic 
evaluation without accounting for quality of life (QoL), because of the lack of 
estimates of changes in QoL due to cervical cancer screening. An increased test 
sensitivity will reduce the number of invasive cancers and endstage disease, but 
will result in more primary treatment of pre-clinical stages. Although the QoL 
implications of these opposite effects could not be quantified, it is unlikely that 
the inclusion of QoL effects would considerably change our conclusions. 
Comparison with other studies 
Trials of new cytologic tests necessarily use intermediate outcome measures 
such as numbers of abnormal cytology or histology, because measuring 
differences in mortality would require large numbers of participants and a very 
long follow-up. Our modelling approach has the advantage that these 
intermediate outcome measures can be translated into health effects (invasive 
cancers prevented, life years gained). In addition, a priori evaluation of the C/E 
of new screening tests is possible to inform the design of possible trials of new 
screening tests. 
Our conclusions on the accuracy of new cytologic tests are in line with 
other reviews [37197]. We were able to include some more recent trials, but this 
did not change the outcome. 
In Brown et al., incremental cost-effectiveness rapidly deteriorated with 
more intensive screening, as in our analysis [40]. AutoPap came out relatively 
favourable, which was partly due to an overestimate of the test sensitivity (i.e. 
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95%). Moreover, the duration of pre-clinical stages was described with an 
exponential distribution compared to the Weibull distribution in the MISCAN 
model. As a result, the proportion of fast growing cancers is overestimated by 
Brown et al., and therefore also the favourable effects of screening with a more 
sensitive test. 
Myers estimated incremental cost per life year gained below $3,000 
with a hypothetical new test for a 5 year screening interval [196]. However, he 
assumed a low Pap test sensitivity (51%) and a high sensitivity of the new test 
(99%). We reproduced the analysis with our MISCAN model as far as possible, 
and came up with higher incremental costs per life year gained, whereas the 
estimated gain in life years seemed to be fairly comparable. The differential 
outcome is due to the lower costs of screening and higher treatment costs of 
invasive cancer (and therefore larger cost savings) in Myers' model. 
Human papillomavirus testing (HPV) is increasingly being considered 
as an adjunct or even a substitute for cytologic screening [55]. HPV testing has 
been found to be more sensitive but less specific than the Pap test. So far, small 
longitudinal studies indicate that the screening interval can be lengthened for 
women who are HPV and cytology negative, and this may also apply to HPV 
negative I cytology positive women. For the large number of HPV positive 
women, efficient follow-up strategies should be designed to minimize the 
burden to these women. The HART -study recently showed that one repeat 
testing after 12 months may be sufficient for women with HPV and negative or 
borderline cytology to decide whether or not women should be referred for 
colposcopy [55]. In addition, larger longitudinal trials should give more definite 
information for any decision to change the screening policy and follow-up 
regimen. Because a conversion to LBC or automated cytologic screening, to 
HPV testing, or both has severe organizational implications, countries that did 
not yet convert to automated or LBC screening systems may probably better 
await these trial results. 
Recommendations and future research 
Because an acceptable cost-effectiveness of new cytologic tests for cervical 
cancer screening is difficult to achieve, alternative strategies should be 
investigated to make screening more efficient. A major source of cervical cancer 
mortality is non-participation in screening. Although participation is never 
mandatory, efficient interventions that increase participation are urgently 
needed. 
A major source of uncertainty in the economic evaluation of liquid 
based and automated screening technologies is their true test characteristics. 
Many trials have been performed with weak designs. The evaluation of 
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diagnostic tests is complex, which urges the development of practical 
guidelines for conducting trials in this field. Trials should also capture possible 
learning effects. 
The use of LBC for population based screening of cervical cancer is 
already widespread in several countries, particularly those with more intensive 
screening policies than in the Netherlands. These practices are likely to be 
inefficient. Because the application of LBC is also considered in the 
Netherlands, and already practiced in some laboratories, it should be 
investigated whether the current policies for implementing and financing new 
diagnostic tests guarantee an efficient use of health care resources. 
9.6 Follow-up of abnormal cervical screening smears 
Main findings 
We analyzed whether testing for high-risk human papillomavirus (HR- HPV) 
would result in a more efficient follow-up of screened women who are 
currently referred for colposcopy because of persistent mild or moderate 
dyskaryosis or a single severe dyskaryosis smear (chapter 8). Women with a 
positive HPV test would be treated directly with loop excision of the 
transformation zone (LETZ), without prior histological assessment, and women 
with a negative HPV test would get conventional management ( colposcopically 
directed biopsy). 
Compared to conventional management, HR-HPV triage of women 
with persistent mild or moderate dyskaryosis will avoid histological assessment 
at the expense of some overtreatment: per woman on average 0.51 
colposcopically directed biopsies are avoided, but at the expense of 0.05 LETZ 
treatments and 0.09 outpatient visits per woman. Also costs are $134 higher per 
woman. These numbers imply that about 10 colposcopically directed biopsies 
are avoided per additional LETZ. 
In women with severe dyskaryosis, direct treatment was more efficient 
than HPV triage. Compared to conventional management, 45 outpatient visits, 
of which 25 with colposcopically directed biopsies could be avoided per 
additional LETZ. Considered these numbers, direct treatment should seriously 
be considered in these women. 
How valid are the results? 
We considered women between age 30 and 60 because these women are screen-
eligible in the Netherlands. The positive predictive value (PPV) of HPV testing 
seems to be lower in younger females, and so will be the benefits of HPV triage. 
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We did not have information about patient preferences for the 
considered management policies. Therefore, no definitive conclusions could be 
drawn on the relative effectiveness of the alternative management policies. 
Comparison with other studies 
The prevalence of HPV is very much determined by the type of HPV test and 
the age and referral criteria of the patient population [54]. HPV prevalence and 
PPV for the presence of CIN 2-3 (HSIL) in our study was comparable to studies 
with similar referral populations and HPV tests [58 250]. 
The management protocol considered by us is relatively unique. Other 
studies consider the use of HPV testing as a triage instrument for colposcopy in 
women with ASCUS (""Pap 2) or LSIL (mild dyskaryosis) smears [87125 248 
253]. Women with a negative HPV test do not get further follow-up. Recently, 
the ALTS-trial concluded that HPV testing in women with a single LSIL smear 
has limited potential, because 83% of women were HPV positive (HC-II test) 
[259]. Therefore, only a minority of these women would benefit from HPV 
triage. The ALTS-trial also revealed that in women with an ASCUS smear, 96% 
of HSIL would be detected with HPV triage, whereas the negative predictive 
value (for <HSIL) of the HPV test was 99%. This implies that almost half of the 
women who are referred because of one ASCUS smear would avoid further 
diagnosis, at the expense of a very small number of missed cases. HPV testing 
was superior to a single repeat smear, having a lower PPV and lower sensitivity 
than the HPV test. A recent meta-analysis showed that HPV testing in women 
with one ASCUS smear showed higher sensitivity and similar specificity 
compared to repeat cytology [8]. 
Whether HPV triage of women with ASCUS is cost-effective in the 
Netherlands remains unclear until these results are translated to the Dutch 
screen-eligible age group and laboratory setting: in the US the proportion of 
ASCUS smears is 5-15%, in the Netherlands the proportion of Pap 2 smears has 
been reduced to 2%. HPV triage has been estimated at $33,600 I life year saved 
compared with no follow-up [128], but the assumed specificity was more 
favourable (75-85%) than observed in the ALTS-trial (49%). 
Future research 
We were not able to measure quality of life implications of further diagnosis 
and treatment. Future research should therefore consider the preferences of 
females for different follow-up policies. The recently started project on quality 
of life implications of cervical cancer screening and follow-up is important in 
this respect. 
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In the Netherlands the follow-up policy has recently changed towards 
earlier referral after abnormal repeat smears, with the aim to restrict the 
duration of follow-up. Future research should weigh the pros and cons of all 
possible follow-up strategies, including HPV testing, with use of data of past 
and ongoing trials (e.g. the BOB-study). 
9.7 Burden of disease, cost of illness studies and economic evaluation 
What are the relative merits of burden of disease (BOD) and cost of illness (COl) 
studies and cost-effectiveness analyses (CEA) in allocating health care 
resources? 
The recent debate on BOD studies particularly concerned the Global 
Burden of Disease project of WHO [185 191 302]. It seems that experts in health 
economics and public health have chosen one of two camps: those who are 
criticasters of BOD/COI studies and those who are not. The most recent result of 
this debate is the publication of two voluminous books on the value of 
summary measures of population health and on health systems performance 
assessment [193195]. We support BOD/COI studies, and will argue that 
BOD/COl studies and CEAs are complementary. 
BOD/COl studies provide a cross-sectional description of population 
health and health care costs, respectively, subdivided by diseases. In a 
subsequent step the health burden and costs can be further attributed to 
(multiple) risk factors (see also paragraph 9.2). In other words, BOD and COl 
studies provide essential data regarding the equity of health needs and access 
to health care, respectively. CEAs, on their part provide information on the 
efficiency of health care. If such information would be available for all health 
interventions, optimal efficiency in health care can be achieved by giving 
priority to interventions that maximize health at the least costs. Both BOD/COl 
data and data on the efficiency of health care are a prerequisite for societies that 
aim to optimize the level and distribution of health in accordance with societal 
values. 
Critics put forward that BOD/COI estimates would set priorities based 
on the size of the health problem, measured in epidemiological indicators or 
health care consumption. This would at worst simply increase health care costs 
of those diseases that already account for a large share. However, none of the 
proponents of BOD/COI studies has ever advocated this. An additional 
criticism is that they do not provide information on the efficiency of health care, 
and therefore would not be an aid for decision making on alternative 
interventions [45 53 302]. We oppose, however, that BOD/COI studies never 
pretended to indicate the efficiency of health care, and that indeed CEAs are 
essential for this aim. 
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BOD/COl studies can be used to identify those diseases or risk factors 
with a high current or future burden. These health problems might not be 
identified without the data provided by BOD/COI studies. Subsequently it can 
be investigated whether the identified health problems are eligible for 
interventions, and whether there is any evidence on the effectiveness and 
efficiency of these interventions. A first application of BOD/COl studies is 
therefore the prioritization of research and health policy with respect to the 
design and implementation of (cost-)effective interventions. Comprehensive 
BOD/COI studies are more suitable for this purpose than disease-specific 
studies. Disease-specific studies can be (and often are) used for single disease 
advocacy, which might give unjustified priority to diseases for which data are 
available. Also, the sum of single disease estimates may easily exceed the total 
disease burden and health expenditures. In contrast, the coherent framework of 
comprehensive COI and BOD studies will put specific diseases or injuries into 
perspective and may highlight health problems that receive insufficient 
attention. In other words, without BOD/COI data the search for cost-effective 
interventions will be a blind search. In this regard BOD studies, and we add 
COl studies here, have been mentioned as an essential part of the 'public health 
accounts' similar to what the national accounts are for macro-economic policy, 
and nobody would question the utility of the latter [191]. 
Second, descriptive statistics on population health and health care costs 
in a coherent BOD/COI framework are needed for the comparison of health and 
health care between countries, over time, and between population groups. 
Many of the observed differences and changes may require further explanation 
and exploration [279]. For instance, higher age-specific per capita costs in 
females compared to males indicate differences in specific health care needs 
that could be due to underlying socio-demographic and biomedical factors, and 
that may warrant attention of health care planners. Also, differences in 
mortality or health care costs among geographic regions or among socio-
economic and ethnic groups may point at specific access barriers to health care. 
Because these applications require valid and consistent data that may not be 
available on a sufficient detailed levet BOD/COl studies also play a vital role in 
identifying important data gaps. 
Third, COl studies provide insight in the drain on health care resources 
subdivided by diseases, and in the relative importance of preventive, curative 
or caring activities. As shown in chapter 2, large fractions of health care 
resources are spent on caring activities for people with degenerative disease, 
such as dementia and mental retardation. This illustrates that COl studies aid in 
identifying diseases and health care activities where priority setting based on 
cost-effectiveness is not applicable: homes for disabled persons, nursing homes, 
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etcetera. At least, the concept of 'effectiveness' has a different content in 
prevention and cure (e.g. healthy life years) than in care (e.g. independent 
living, dignity), and therefore standard CEA methods do not apply to care 
activities. 
Fourth, BOD/COl data can be used as an input into and reference 
framework for CEAs [191]. Summary measures of population health have not 
only been designed for descriptive purposes, but can also be used as outcome 
measures in CEAs. National estimates of costs of smoking related diseases and 
coronary heart disease have been used to explore the economic consequences of 
smoking and coronary heart disease interventions, respectively [15 27]. 
Reasoning that the costs and (health) benefits of an intervention should be equal 
to the difference in health care spending and population health with and 
without this intervention, regularly conducted BOD/COl studies can be used to 
monitor the actual impact of interventions at national level [191]. Because the 
medical practice is never a controlled experiment, it will not always be possible 
to attribute actual changes in population health and health care spending to 
specific interventions or even a combination of interventions. Nevertheless, 
specific changes in the burden and cost of illness could at least be indicative for 
the succes or failure of interventions in routine practice. 
So far we did not distinguish between COI and BOD studies with 
respect to their contribution to priority setting in health care. Although patterns 
of resource consumption often resemble the distribution of the burden of 
disease (need), and high medical costs are indicative for a high burden in terms 
of need (chapter 2), COI data should be interpreted with caution. Some diseases 
may be untreatable and may for this reason be cheap or expensive, whereas 
considerable resources may be spent in order to make a disease a negligible 
health burden. 
Some final remarks consider the use of CEAs to prioritize health care. 
First, it is a general misconception that knowledge about the incremental costs 
and health benefits of health care technologies is sufficient for making decisions 
on their implementation and financing, apart from legal, ethical and political 
considerations. Because the budget is limited, one needs a C/E threshold to 
judge whether the intervention is acceptable. The problem of finding a C/E 
criterium to judge whether an intervention is acceptable is often faced in 
practice by policy makers and health care planners, and might partly explain 
why the results of CEAs are so difficult to implement in practice [67]. As a 
result, in actual decisions other, more arbitrary, criteria are used, such as the 
C/E of other (similar) interventions or rules of thumb (see also chapter 7). 
In case of an explicit budget constraint and an additional number of 
assumptions, the CEA paradigm prescribes that an intervention is acceptable if 
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its C/E ratio does not exceed the C/E ratio of the marginal programme, i.e. the 
final programme with the highest C/E that was accepted [294]. In this approach 
information is needed on the C/E of all possible health interventions before an 
implementation decision can be made [121]. However, in practice an explicit 
budget constraint is usually absent, interventions may need extra resources 
beyond the health care budget, or may need fixed assets that are already in use 
by other interventions. Some propose cost-benefit and WTP analysis as a 
solution [67121]. An alternative approach would be to collect information on 
the C/E of activities that would be displaced by the intervention being 
evaluated (opportunity costs) [18 242 294]. The programme to be displaced 
should have a lower C/E ratio and free up enough resources to fund the new 
programme. This approach provides a second best solution because it improves 
but not optimizes resource allocation. 
Second, cost-effectiveness rankings of interventions often have wide 
confidence intervals, neglect considerations of fairness and equity, and may 
hide underlying methodological discrepancies [70]. As a result, the ranking of 
interventions has some degree of arbitrariness, which has compromized 
previous experiences in which CEAs were used or advocated for setting 
priorities in health care, among which the well-known Oregon-experiment [23 
24 94]. This underlines the importance of methodological development in HTA 
research in addition to developing guidelines for conducting HTA. This can be 
illustrated by innovating efforts to present uncertainty [36 84 115 284], measure 
productivity losses [39 131], and elicit preferences for health care [240]. 
Third, CEAs do not give information on the total budget impact of 
interventions, or on impact on total population health once the intervention 
would be implemented on national level. This is a typical example where 
BOD/COl estimates, describing the pre-intervention situation, and cost-
effectiveness data can be sensibly integrated. 
Fourth, decisions based on CEAs of new interventions may not 
guarantee an optimal resource allocation when the reference scenario (the 
situation by which the new intervention is compared) is not efficient. Often the 
reference scenario is 'usual care', usually a heterogeneous mixture of 
interventions. If usual care is itself not efficient, the new intervention may 
compare very favourable. Both usual care and the new intervention should then 
be compared with the null scenario, i.e. a situation without any intervention 
[191]. 
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9.8 Conclusions and recommendations 
1. How are medical costs of injury at national level distributed by type of injury and 
health care sector, and what are their major determinants? 
About a third of health care costs of injury is due to high frequency minor 
injuries that do not need hospitalization, whereas hip fracture, with high costs 
per patient, accounts for a fifth of injury-related health care costs. Young males 
and elderly females contribute significantly to total costs of injury. Hospital care 
accounts for more than two-third of total medical costs of injury, of which a 
quarter is made in the Emergency Department. In addition to age and sex, 
several indicators of injury severity were identified as determinants of 
individual health care consumption: injury diagnosis, hospitalization, motor 
vehicle crash, and number of injuries. 
We recommend the following: 
• Our surveillance based model for calculating the medical costs of injury 
should be applied internationally and may be applicable in other realms of 
population health (e.g. cancer, psychiatric disorders). 
• Medical costs of injury should be used by policy makers as an indicator to 
prioritize the development of interventions that prevent injury and improve 
trauma care. 
• The efficiency of alternative preventive interventions should be evaluated. 
• The efficiency of the current treatment of minor injuries (i.e. injuries 
without need for hospitalization) should be investigated. 
• Costs of injury estimates should be used to develop and test indicators of 
injury severity that differentiate among injuries in terms of health care 
need. 
2. How is injury related disability at national level distributed by type of injury, and 
what are its major determinants? 
The majority of non-hospitalized patients has a normal level of functioning 2 
months post-injury, but persons with vertebral column injury, extremity injury, 
and skull-brain injury were still below general population norms. Those with a 
paid job lost on average one week and this was longest for patients with upper 
extremity fractures. The health status of hospitalized injury patients increased 
up to 5 months post-injury, but remained below population norms even after 9 
months. On average they were 14 weeks absent from work; 40%, 20% and 10% 
had not yet returned to work after 2, 5 and 9 months respectively. Hospitalized 
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patients with injury to the spinal cord or vertebral column, and those with a 
lower extremity fracture reported the worst health status. Both non-hospitalized 
and hospitalized injury patients contribute substantially to injury-related 
disability and particularly work absence. We identified proxy indicators of 
injury severity (hospital length of stay, ICU admission, motor vehicle crash, 
medical operation, number of injuries) that appeared to be independent and 
significant predictors of functioning in addition to age, sex and educational 
leveL 
We recommend the following: 
o To identify the risk factors that contribute significantly to the burden of 
injury. 
o To measure short-term disability in minor, non-hospitalized injuries. 
o To measure permanent functional consequences and their predictors in 
major injuries, including non-hospitalized vertebral column injury, 
extremity injury, and skull-brain injury. 
• Studies investigating quality of life in injury patients should apply uniform 
designs (patient selection criteria, measurement instruments, intervals). 
• The relationship between poor post-injury functioning and socio-
demographic and injury-related characteristics should be further 
investigated, and the implications for injury prevention and trauma care 
determined. 
3. What are the test characteristics of newly developed cytologic technologies for 
cervical cancer screening, and how (cost-)effective are these technologies compared 
to screening with Pap smears? 
There is weak evidence that some liquid based and automated screening 
technologies (ThinPrep™, AutoCyte™ SCREEN, AutoPap™) are more sensitive 
than the Pap test, at the loss of some specificity. The exact test characteristics are 
however not known due to flaws in trial designs. Despite this uncertainty, it is 
unlikely that screening with these tests is within acceptable cost-effectiveness 
levels in the Netherlands. In situations with more intensive screening schedules 
than in the Netherlands, as in many western countries, it is even less likely that 
these tests are cost-effective. In contrast, these tests might be cost-effective in 
situations with low Pap test sensitivity and low Pap test adequacy. 
We recommend the following: 
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• The test characteristics of liquid based cytology (LBC) and automated 
screening devices should be determined. Any trials should have a sufficient 
duration to capture any learning effects. 
• Practical guidelines should be developed to facilitate the complex 
evaluation of diagnostic tests. 
• It should be investigated whether the current policies for implementing and 
financing new diagnostic tests guarantee an efficient use of health care 
resources. 
4. Can the follow-up of women with abnormal Pap smears be made more efficient by 
human papillomavirus testing? 
In women with persistent mild or moderate dyskaryotic smears, HPV triage 
(positives are treated, negatives will receive biopsy) will avoid unnecessary 
colposcopy and biopsies at the expense of some overtreatment. About 10 
colposcopically directed biopsies can be avoided per additional local treatment 
of the cervix (LETZ), at the expense of some extra costs. This HPV triage 
protocol is less efficient in women with borderline cytology or a single mildly 
dyskaryotic smear because of its poor positive predictive value in these women. 
Also in women with severe dyskaryosis HPV triage is not efficient, but direct 
treatment (i.e. without histological assessment) can avoid 45 outpatient visits 
and 25 colposcopically directed biopsies per additional LETZ. 
We recommend the following: 
• Measurement of the quality of life implications of cervical cancer screening 
and follow-up. 
• HPV triage should be considered in women with persistent mild or 
moderate dyskaryosis smears, taking women's preferences into account. 
• Direct treatment (i.e. without histological assessment) with LETZ should be 
seriously considered in women with severely dyskaryotic smears. 
5. To what extent do burden of disease studies, cost of illness studies and economic 
evaluation studies provide helpful information for the prioritization of health care? 
Burden of disease (BOD) and cost of illness (COI) studies are complementary to 
economic evaluation studies (CEAs) in prioritizing health care. They a) help 
identify health areas where research and the design and implementation of 
(cost-)effective interventions is most needed, b) provide useful input for the 
economic evaluation of these interventions, c) generate comparative 
information on population health and health care costs that deserve further 
Chapter 9. General discussion 
exploration, d) help identify important epidemiological and health care data 
gaps, e) give insight in the relative importance of prevention, curative and 
caring activities for specific diseases, and f) act as a reference framework to 
trace the actual impact of interventions on population health and health care 
expenditures. 
We recommend the following: 
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• Existing comprehensive BOD and COl studies in the Netherlands should be 
regularly updated, and should be integrated with disease-specific studies. 
• Cost of illness estimates should be attributed to risk factors using a 
comprehensive approach, to quantify the combined (economic) effect of 
single or multiple risk factors beyond specific diseases. 
• Research should be conducted into acceptable cost-effectiveness thresholds 
that are in line with society's preferences for health care. 
• Cost-effectiveness analyses should evaluate the existing situation ('usual 
care') if insufficient knowledge exists on the individual or combined health 
effects of current interventions. 
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Summary 
Population health has improved considerably in the Netherlands, as can be 
illustrated by the increase in life expectancy since the mid 19th century. Part of 
this improvement can be attributed to an increased access to health care and the 
rapid development of medical technology, in particular since 1950. This also led 
to an increase in health care costs. Currently about 10% of gross national 
product is spent on health care. To contain these costs and at the same time to 
further improve the population's health, we need to give priority to health 
problems where interventions are most needed and rewarding. To inform these 
choices, data are needed on how health care costs and population health are 
distributed by diseases, risk factors, and population groups. In other words, we 
need to know where the money goes and where the need for improving health 
is highest. Also, information is needed on the cost-effectiveness (efficiency) of 
health interventions to select interventions that provide the most 'value for 
money'. In this thesis we present descriptive data on health care costs and 
population health, and information on the cost-effectiveness of interventions, 
with applications in injuries (part 1) and cervical cancer (part 2). In addition, the 
relative importance is discussed of descriptive data on population health and 
health care versus economic evaluations. 
Cost of illness and injury in the Netherlands 
The thesis starts with a generic cost of illness (COl) study, showing that the 
largest proportions of health care resources are spent on chronic, disabling 
diseases (chapter 2). Mental diseases such as mental retardation (Down's 
syndrome) and dementia, and musculoskeletal disorders are among the top 5 of 
diagnostic groups with the highest costs. The main causes of death, i.e. stroke, 
all cancers combined, and coronary heart disease, rank among the top 10 with 
shares of 2.5-3% of health care costs, but costs of dental diseases (4%) are 
higher. The average health care costs per capita are relatively high in the first 
year of life, low during childhood and adulthood, and increase exponentially 
after age 50. Women contribute most to health care costs (almost 60%) which is 
explained by their longer life expectancy and the costs of reproductive care. 
The implications are far-reaching. The skewed cost distribution by age 
has important consequences for societies with an ageing population. Health 
care needs can only increase if life expectancy increases and if costly disabling 
diseases (e.g. dementia, osteoarthritis, hip fracture) remain resistant to controL 
In this study we broke down health care costs in 1994 using sector-
specific administrative data on health care use (cross-sectional design). For 
specific diseases more detailed cost estimates would be useful for policy 
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making. For instance, injuries have heterogeneous causes, and differ in terms of 
severity and health care need. In this area, costs can be a useful summary 
measure to quantify the relative importance of specific injuries. We estimated 
medical costs of injury (excluding adverse medical events) at national level by 
type of injury and health care sector, and identified the major determinants 
(chapter 3). We developed an incidence-based costing model linked to the 
continuous national Injury Surveillance System (LIS). In LIS a representative 
sample of Emergency Department (ED) visits is recorded, and the system 
includes extensive information on the cause of injury. We collected health care 
consumption data from administrative systems (e.g. the hospital discharge 
register) and from a follow-up study among 5,755 injury patients. 
Total health care costs of injury in 1998 amounted to 1.1 billion euro, or 
more than 3% of total health care costs. Injuries with the highest costs are hip 
fractures (21% ), superficial injuries (14% ), open wounds, skull-brain injury, and 
knee/lower leg fractures (each 6%). These high costs are due to a high frequency 
(e.g. superficial injury) or due to high costs per patient (e.g. hip fracture, skull-
brain injury). The same accounts for the cost distribution by age and sex: costs 
are relatively high in young adult males (high frequency) and in elderly females 
(high costs per patient). Two-third of costs are due to hospitalized patients, that 
account for 9% of all injuries. 
Whereas it is widely known that hip fractures cause high costs, this 
study also identified minor injuries as a major source of health care costs: 
superficial injury and open wounds together account for one fifth of injury 
costs. A greater efficiency might be achieved when the treatment of these minor 
injuries can be shifted towards primary care. 
A comparison with studies from other highly developed countries 
revealed that differences in the reported health care costs of injury are large 
(chapter 4). Per capita health care costs ranged from $35-275 (year 2000 
international dollars). We first analysed whether observed differences could be 
explained by differences in methodologies. Within-country differences were up 
to 40% and are by definition caused by methodological differences, particularly 
differences in case definition, cost items included, and approach (bottom-up 
versus top-down). However, real differences in injury epidemiology and costs 
per patient seemed to explain a larger part of between-country differences in 
costs of injury. Our estimates from the Netherlands occupy an intermediate 
position. Per capita costs were highest in the US, because of a higher incidence 
and higher costs per patients. Also in Australia costs were higher than in the 
Netherlands, despite a lower incidence, due to three-fold higher costs per 
patient. Per capita costs were lowest in Sweden, Norway and New Zealand. For 
the subcategory traffic injuries, the within-country differences in costs per 
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capita were higher (up to 60%) as were the between-country differences ($2-
$116 per capita). Also a larger proportion of the international differences could 
be attributed to differences in methodology than for all injuries together. 
Studies that included productivity losses due to injury showed that these were 
consistently almost three-fold higher than the medical costs. 
Functional outcome in injury patients 
Apart from health care costs, quantitative data on the functional outcome of 
injury, and of its major determinants, is important to direct the development of 
preventive interventions and trauma care. With the decline in overall injury 
mortality, the importance of injury-related disability has increased. Because of 
the many functional sequelae and recovery patterns of injuries, the 
measurement of disability is a necessary but also challenging task. Generic (not 
disease-specific) instruments thereby enable a uniform comparison of injuries 
among each other and with other health problems. We measured disability in 
the first year post-injury in a comprehensive population of surviving injury 
patients presenting at EDs, both non-hospitalized and hospitalized, with the 
EuroQol generic instrument (chapter 5). This instrument measures mobility, the 
ability to perform self care and usual activities, pain/discomfort, and 
anxiety/depression. We added a question on cognitive disability. The resulting 
score profiles can be converted to a summary measure (utility) between 0 and 1 
representing the overall level of health. 
After two months the average health status of non-hospitalized patients 
was comparable to the general population's health, and 95% of workers had 
returned to work. However, non-hospitalized patients with vertebral column or 
extremity injury had less than normal levels of health, and patients with upper 
extremity fractures reported the highest work absence. The mean health status 
of hospitalized patients was far below general population norms at 2 months, 
improved up to 5 months, but stabilized thereafter at a suboptimallevet 
predominantly in patients with a long hospital stay. Among workers, 40%, 20% 
and 10% had not (yet) returned to work after 2, 5 and 9 months, respectively. 
Hospitalized patients with hip fractures, injuries to the vertebral column and 
spinal cord, and other lower extremity fractures reported the worst health 
status, also adjusted for age and sex. High levels of cognitive limitations were 
measured in patients with skull-brain injury (e.g up to 40% in those with skull 
fracture or intracranial injury at 2 months). These patients could insufficiently 
be discriminated by the EuroQol. Injury diagnosis, hospitalization, hospital 
duration, IC use, motor vehicle involvement and number of injuries all were 
independent predictors of disability. A lower socio-economic status was 
associated with a worse health status and longer work absence. 
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Evaluation of new cytological tests for cervical cancer screening 
Part 1 (chapters 2-5) of this thesis was devoted to describing the medical costs 
and burden of disease (specifically injuries). In part 2 (chapters 6-8) we changed 
the focus to health interventions. We investigated the efficiency of two 
measures to improve population based cervical cancer screening: the 
introduction of new cytological screening tests (chapters 6 and 7) and the role of 
human papilloma virus (HPV) testing in women with abnormal smears (chapter 
8). Cervical cancer screening has occurred for decades in the Netherlands, and 
organized screening is offered since the late 1980s. Screening has always been 
done by the Pap smear. This test is often criticized for being too insensitive. 
Estimates of its sensitivity vary between 60-90%. Recently, automated 
technologies and liquid based ('thin layer') cytology (LBC) have been 
developed to improve test performance. We investigated the test characteristics 
of these new technologies, and their (cost-)effectiveness compared to screening 
with Pap smears. In this evaluation it is essential to distinguish between single 
test sensitivity and programme sensitivity. Because the natural course of 
cervical cancer takes on average many years- the duration of pre-invasive 
stages is estimated at 12 years on average- women who attend screening at 
regular intervals have generally more than one chance to be detected timely. 
The programme sensitivity therefore depends on both single test sensitivity and 
screening intensity. 
In a systematic review of published trials, that were assessed with a 
standard list of quality criteria, we found that there is weak evidence that one 
liquid based system (ThinPrepTM) and one automated system (AutoPapTM) 
are more sensitive than the Pap test, at the loss of some specificity (maximum 
reported increase in sensitivity of 12%). Using the MISCAN microsimulation 
model for the evaluation of cervical cancer screening, we designed a decision 
analytic framework, and quantified for which combinations of test sensitivity, 
test specificity, and incremental unit costs per test a new screening test would 
be as cost-effective as the Pap test. We used the MISCAN model, which has 
been extensively validated and is a flexible tool for the prospective evaluation 
of changes in the screening programme. In the Dutch situation (screening 
between age 30 and 60 at 5-year intervals) a hypothetical test with optimal (100%) 
sensitivity and specificity may cost additionally €9 per test to be as cost-
effective as the Pap test. This unit cost threshold is lower in countries with more 
intensive screening (because incremental health gains of a more sensitive test 
are lower), but is higher in countries where the Pap test sensitivity is lower than 
assumed at baseline. The baseline Pap test sensitivity (80%) has been derived 
from observed screening data. Comparing the findings in our decision analytic 
framework with the observed test characteristics and unit costs of current new 
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technologies, we concluded that it is unlikely that these technologies are as cost-
effective as the Pap test. This is even less likely in countries with more intensive 
screening, such as the US and the UK where LBC is already widely used. 
HPV triage of women with abnormal smears 
The number of women with abnormal Pap smears is a continuous concern in 
screening programmes. Because the majority of women with a positive 
screening test would never develop cervical cancer in the absence of screening, 
due to spontaneous regression, they run the risk of overtreatment. Currently, 
women with (persistent) abnormal smears are referred for colposcopy, treated if 
necessary, and kept under surveillance. We investigated whether hr-HPV (high 
risk human papillomavirus) testing of women with at least persistent mild or 
moderate dyskaryosis increases the efficiency of further management of these 
women (chapter 8). 
We compared three policies: a) conventional management based on 
colposcopy and biopsy, with only histological positive women getting 
treatment (LETZ treatment) b) testing women on hr-HPV, with hr-HPV positive 
women being treated directly without prior histological assessment, and 
conventional management for hr-HPV negative women, and c) a policy by 
which all women receive LETZ treatment directly without prior histological 
assessment. For each policy we calculated the mean number of clinical 
procedures and costs per woman. We used data on HPV-status and medical 
procedures from a follow-up study among 221 women who were referred for 
colposcopy because of persistent mild or moderate dyskaryosis or a single 
smear reported as severe dyskaryosis. 
We demonstrated that hr-HPV triage (b), compared to conventional 
management (a), would avoid histological assessment at the expense of some 
overtreatment in women with persistent mild or moderate dyskaryosis: per 
woman 0.51 colposcopically directed biopsies would be avoided, but this 
should be weighed against 0.05 extra LETZ and $134 additional costs per 
woman. In other words, the benefit of 10 avoided biopsies should be weighed 
against the burden of one LETZ treatment. In women with one severely 
dyskaryotic smear, direct treatment with LETZ (c) would be more efficient than 
triage with HPV testing (b). Compared with conventional management (a), a 
direct treatment policy (c) would avoid 25 colposcopically directed biopsies for 
each additional LETZ treatment. 
Our findings were robust because they did not change much when we 
used data from foreign studies on HPV prevalence in similar patient groups. 
However, our HPV triage policy appeared to be much less efficient in women 
with only mildly abnormal smears (ASCUS or mild dysplasia). Because data on 
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the quality of life implications of the different management policies were 
unavailable, we could not conclude which policy would be preferred by the 
women. 
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The merits of burden of disease and cost of illness estimates versus economic evaluation 
In the General discussion (chapter 9) we integrated the findings in this thesis by 
discussing the relative contribution of burden of disease (BOD) and cost of 
illness (COI) studies (part 1) on the one hand, and economic evaluations (part 2) 
on the other hand. We argue that both types of analyses are necessary and 
complementary for resource allocation in health care. BOD and cor studies 
provide essential information to identify diseases, risk factors and population 
groups with the highest need for intervention. Comprehensive studies have the 
advantage of providing comparative and internal consistent data, whereas 
disease-specific studies may raise unjustified attention for individual health 
problems. In addition, comparative information on population health and costs 
may generate hypotheses about the explanation of observed differences. 
Because BOD and COr studies provide national estimates in disease burden and 
costs, they may be an input into and reference framework for economic 
evaluations of (combinations of) interventions. As BOD and COI studies 
provide essential data regarding equity of health needs and access to health 
care, respectively, information on the efficiency of health care (costs per 
incremental health gains) is provided by economic evaluations. Although we 
recognize the importance of economic evaluations, we have pointed to a 
number of shortcomings and additional conditions for an effective use. We 
mention here the need for acceptable (ranges of) cost-effectiveness thresholds, 
knowledge of the impact of single interventions on health budgets and on the 
size and distribution of health gains on population level. In addition to new 
interventions, also the existing situation ('usual care') should be evaluated, that 
is usually a heterogeneous mixture of interventions with insufficient evidence 
about their individual or combined effectiveness and efficiency. 
Our conclusions are as follows: 
1. Cost of injury estimates are a useful indicator for the importance of specific 
injuries. Together with epidemiological indicators they should be used to 
prioritize the development of interventions that prevent injuries and improve 
trauma care. Among others the efficiency of the current treatment of minor 
injuries should be investigated. 
2. The lack of methodological consistency of cost of injury studies compromises 
their policy relevance. Guidelines should be developed to improve the 
comparability and transparency of these studies. 
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3. It is well possible to validly measure and compare the functional outcomes of 
heterogeneous injuries. Our empirical data should be complemented with data 
on short-term disability in minor injuries, and with data on permanent 
disability. Future research should also identify the major risk factors 
contributing to the burden of injury. 
4. It is unlikely that liquid based cytology and automated screening 
technologies are currently as cost-effective as the Pap test for cervical cancer 
screening. We recommend that the test characteristics of these technologies 
should be estimated more accurately. Also, it should be investigated whether 
the current decision processes for implementing and financing new diagnostic 
tests guarantee an efficient use of health care resources. 
5. Triage of women with persistent mild or moderate dyskaryosis, based on 
high-risk human papillomavirus testing, could lead to a less burdensome 
treatment of these women. For a definitive answer women's preferences for 
alternative follow-up policies should be investigated. 
6. Comprehensive burden of disease and cost of illness estimates, and 
economic evaluations are complementary for the improvement of health 
systems efficiency. We recommend that burden of disease and cost of illness 
studies are regularly updated. Research should be conducted into acceptable 
cost-effectiveness thresholds for health care interventions, and cost-
effectiveness analyses should evaluate the existing situation ('usual care') in 
addition to new interventions. 
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Samenvatting 
Afgaande op de toegenomen levensverwachting sinds het midden van de 19e 
eeuw, is de volksgezondheid in Nederland sterk verbeterd. Deze verbetering is 
deels te danken aan een verbeterde toegang tot gezondheidszorg en aan de 
snelle ontwikkeling van de medische technologie, vooral vanaf het midden van 
de vorige eeuw. Dit heeft ook tot een stijging in de zorguitgaven geleid. Op dit 
moment wordt circa 10% van het bruto nationaal product uitgegeven aan 
gezondheidszorg. Om de kosten in de hand te houden en tegelijk de 
volksgezondheid verder te verbeteren, is het nodig om voorrang te geven aan 
gezondheidsproblemen waar interventies zowel het meest noodzakelijk als het 
meest efficient zijn. Om deze keuzen te kunnen maken zijn gegevens nodig over 
hoe de zorguitgaven en de volksgezondheid zijn verdeeld over ziekten, 
risicofactoren, en bevolkingsgroepen. Met andere woorden, waar wordt het 
geld aan besteed en waar is de behoefte aan een betere gezondheid het grootst. 
Daamaast is informatie nodig over de kosten-effectiviteit (efficientie) van zorg, 
om zodoende de toegang te beperken tot die interventies die de meeste 
gezondheidswinst opleveren tegen de minste kosten. Beide typen gegevens 
komen in dit proefschrift aan bod, toegepast op twee volksgezondheids-
terreinen: ongevallen (deel1) en baarmoederhalskanker (deel2). Ook wordt 
ingegaan op het relatieve belang van beschrijvende gegevens van de 
volksgezondheid en gezondheidszorg enerzijds, en van economische evaluaties 
anderzijds. 
Kosten van ziekten en ongevalsletsels in Nederland 
Het proefschrift begint met een generieke kosten van ziekten (KVZ) stu die, 
waaruit blijkt dat het grootste deel van de gezondheidszorg wordt besteed aan 
chronische, invaliderende ziekten (hoofdstuk 2). Psychische aandoeningen, 
zoals zwakzinnigheid (Down's syndroom) en dementie, en ziekten van het 
bewegingsapparaat behoren tot de vijf aandoeningen met de hoogste kosten. 
De belangrijkste doodsoorzaken- beroerten, kanker, en coronaire hartziekten-
staan weliswaar in de top 10 van ziekten met de hoogste kosten, maar hun 
aandeel van elk 2,5-3% is lager dan het aandeel van gebitsziekten (4% van de 
totale kosten). De gemiddelde kosten per hoofd van de bevolking zijn relatief 
hoog voor nuljarigen, laag bij kinderen en jongvolwassenen, en stijgen 
exponentieel na de leeftijd van 50 jaar. De meeste kosten (bijna 60%) komen 
voor rekening van vrouwen, wat komt door hun hogere levensverwachting en 
door zwangerschapsgerelateerde kosten. 
Dit alles heeft verreikende implicaties. De scheve kostenverdeling met 
hoge kosten op oudere leeftijd heeft voorspelbare gevolgen voor vergrijzende 
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populaties. Als de levensverwachting stijgt en tegelijkertijd dure invaliderende 
ziekten (bijv. dementie, osteoarthritis, heupfracturen) nauwelijks kunnen 
worden tegengegaan, zullen de zorguitgaven slechts stijgen. 
De kostenschattingen in deze stu die zijn het resultaat van een 
opsplitsing van de zorgkosten in 1994 aan de hand van administratieve 
gegevens van zorggebruik per zorgsector ( cross-sectioneel). Bij sommige 
gezondheidsproblemen zijn echter meer gedetailleerde gegevens noodzakelijk 
voor beleidsontwikkeling. Dit geldt bijvoorbeeld voor ongevallen, waarvan de 
oorzaken zeer heterogeen zijn, terwijl ook de gevolgen voor de slachtoffers erg 
kunnen verschillen qua ernst en zorgbehoefte. Gezien deze heterogeniteit 
kunnen de kosten van ongevallen een nuttige samengestelde maat zijn om het 
relatieve belang van specifieke ongevalscategorieen aan te geven. Wij hebben 
daarom onderzocht hoe de totale medische kosten van ongevallen 
(uitgezonderd medische oorzaken) verdeeld zijn over letseltypen en 
zorgsectoren, en wat de belangrijkste determinanten van kosten zijn (hoofdstuk 
3). Hiervoor werd een incidentie-gebaseerd kostenmodel ontwikkeld die 
gekoppeld werd aan het Letsel Informatie Systeem (LIS). In het LIS wordt een 
representatieve steekproef van ongevalspatienten op de Spoedeisende Hulp 
(SEH) geregistreerd, met uitgebreide toedrachtsinformatie. Gegevens over 
zorggebruik werden verzameld uit administratieve systemen (bijv. de 
ziekenhuisopnameregistratie) en middels een enquete onder 5.755 
ongevalspatienten. 
De zorgkosten van ongevallen in 1998 bedroegen 1,1 miljard euro, meer 
dan 3% van de totale zorguitgaven. De meeste kosten waren voor 
heupfracturen (21 %), oppervlakkige letsels (14%), open wonden, schedel-
hersenletsel, en knie- en onderbeenfracturen (elk 6% ). Hoge kosten zijn het 
gevolg van hoge aantallen letsels (zoals bij oppervlakkige letsels) of van dure 
letsels (zoals heupfracturen, schedel-hersenletsel). Ook de verdeling van de 
kosten naar leeftijd en geslacht kan zo worden verklaard: hoge kosten bij 
jongvolwassen mannen (hoge aantallen) en bij oudere vrouwen ( dure letsels ). 
Van de patienten wordt 9% opgenomen, maar deze zijn samen 
verantwoordelijk voor tweederde van de zorgkosten. 
Hoewel het algemeen bekend is dat heupfracturen veel kosten 
veroorzaken, geeft dit onderzoek aan dat ook milde letsels een belangrijke 
oorzaak van zorgkosten zijn: oppervlakkige letsels en open wonden zijn samen 
goed voor eenvijfde van de kosten. Mogelijk kan de efficiency worden 
verbeterd door de behandeling van deze letsels meer te verplaatsen naar de 
eerstelijnszorg. 
We hebben onze resultaten ook vergeleken met onderzoeken uit andere 
hoogontwikkelde Ianden (hoofdstuk 4). Hieruit bleek dat de intemationale 
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verschillen in gerapporteerde zorgkosten van ongevallen erg groot zijn. De 
gemiddelde kosten per hoofd van de bevolking bedroegen $35-$275 
(internationale dollars peiljaar 2000). Deze verschillen kunnen deels verklaard 
worden door methodologische verschillen. Kostenschattingen binnen eenzelfde 
land verschilden ten hoogste 40% van elkaar. Dit is per definitie verklaarbaar 
door verschillen in methodologie, zoals selectie van patientgroepen, 
kostendefinities, en een bottom-up of top-down aanpak. Internationale 
verschillen in kosten werden echter grotendeels veroorzaakt door werkelijke 
verschillen in het voorkomen van ongevallen en in behandelkosten. Nederland 
neemt qua kosten een tussenpositie in. De gemiddelde kosten per hoofd van de. 
bevolking waren het hoogst in de VS, zowel door een hogere incidentie als door 
hogere behandelkosten per patient. Ook in Australia waren de kosten hoger 
dan in Nederland, ondanks een lagere incidentie, door driemaal hogere 
behandelkosten per patient. De kosten waren het laagst in Zweden, 
Noorwegen, en Nieuw Zeeland. Voor verkeersongevallen bleken de 
gemiddelde kosten per hoofd van de bevolking internationaal nog meer uiteen 
te lopen: $2-$116. Methodologische verschillen speelden hier een nog grotere 
roL Verschillende onderzoeken keken behalve naar medische kosten ook naar 
andere maatschappelijke kosten. Zo werden de productiviteitskosten 
(ziekteverzuim e.d.) consistent bijna drie keer hoger geschat dan de medische 
kosten van ongevallen. 
Functionele gevolgen van ongevalsletsels 
Naast zorgkosten zijn ook gegevens over de functionele gevolgen van 
ongevallen, en de determinanten hiervan, van belang voor het doelgericht 
ontwikkelen van preventieve interventies en van traumazorg. Doordat de 
sterfte door ongevallen is gedaald, is het relatieve belang van functionele 
beperkingen bij de overlevers gestegen. V anwege de heterogeniteit in 
functionele gevolgen en herstelpatronen bij ongevalsletsels, is het meten van 
beperkingen niet aileen noodzakelijk maar ook uitdagend. Met generieke (niet-
ziektespecifieke) instrumenten is het mogelijk om ongevalsletsels op een 
eenduidige wijze met elkaar en met andere gezondheidsproblemen te 
vergelijken. Wij hebben functionele gevolgen gemeten in het eerste jaar na het 
ongeval bij een brede populatie ongevalspatienten die zijn behandeld op de 
SEH, zowel niet-opgenomen als opgenomen patienten (hoofdstuk 5). We 
gebruikten de EuroQol, een generiek instrument waarmee beperkingen worden 
gemeten ten aanzien van mobiliteit, zelfverzorging, dagelijkse activiteiten, pijn 
of ongemak, en angst of somberheid. Een vraag over cognitieve beperkingen 
werd toegevoegd. De EuroQol scoreprofielen kunnen worden vertaald in een 
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somscore (utiliteit) tussen 0 en 1 waarmee de algehele kwaliteit van de 
gezondheidstoestand wordt aangegeven. 
Na 2 maanden was de gemiddelde gezondheidstoestand van niet-
opgenomen letselpatienten vergelijkbaar met de algemene bevolking, en van de 
mensen met een betaalde baan was 95% weer aan het werk. Patienten met letsel 
aan de wervelkolom of met extremiteitenletsel hadden echter een minder goede 
gezondheid. Patienten met een armfractuur verzuimden het langst. Bij 
opgenomen patienten was de gezondheid na 2 maanden gemiddeld ver beneden 
het normale niveau. De gezondheidstoestand verbeterde tot 5 maanden, en 
bleef daama stabiel onder het normale niveau, vooral bij patienten met een 
lange opnameduur. Van de mensen met een betaalde baan was 40%, 20% en 
10% nog niet aan het werk na, respectievelijk, 2, 5 en 9 maanden. Patienten met 
een heupfractuur, met letsel aan wervelkolom of ruggenmerg, of met een 
beenfractuur waren het minst gezond, ook na correctie voor leeftijd en geslacht. 
Veel patienten met schedel-hersenletsel hadden cognitieve beperkingen (na 2 
maanden bijvoorbeeld 40% van de patienten met een schedelfractuur of 
hersenletsel). Deze patienten worden onvoldoende onderscheiden door de 
EuroQoL Het letseltype, opnamestatus, opnameduur, IC opname, al of geen 
motorvoertuigongevat en het aantalletsels bleken onafhankelijke voorspellers 
van beperkingen. Een lagere sociaal-economische status hing samen met een 
slechtere gezondheid en een langere verzuimduur. 
Evaluatie van nieuwe cytologische technieken voor screening op baarmoederhalskanker 
Deel 1 van het proefschrift gaat vooral over beschrijving van de medische 
kosten en van de ziektelast. In deel 2 richten we onze blik op 
gezondheidsinterventies. Wij evalueerden twee maatregelen waarmee de 
efficientie van screening op baarmoederhalskanker mogelijk verbeterd kan 
worden: de introductie van nieuwe cytologische screeningstesten 
(hoofdstukken 6 en 7) en het testen op humaan papillomavirus (HPV) bij 
vrouwen met een afwijkende uitstrijk (hoofdstuk 8). Reeds tientallen jaren 
wordt in Nederland gescreend op baarmoederhalskanker. Sinds eind jaren '80 
bestaat er een landelijk bevolkingsonderzoek. De screening wordt uitgevoerd 
middels een uitstrijk (Pap test). De betrouwbaarheid van deze test wordt vaak 
betwijfeld. Schattingen van de sensitiviteit lopen uiteen van 60-90%. Recentelijk 
zijn geautomatiseerde technologieen en dunnelaag-cytologie systemen (liquid 
based cytologie) ontwikkeld, die betere testeigenschappen pretenderen. Wij 
onderzochten de testeigenschappen van deze technologieen en hun (kosten-
)effectiviteit vergeleken met de uitstrijk. Het is van belang om in deze evaluatie 
onderscheid te maken tussen de sensitiviteit van een individuele test en de 
programmasensitiviteit. Omdat het natuurlijk beloop van 
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baarmoederhalskanker gemiddeld vele jaren in beslag neemt- de duur van 
pre-invasieve stadia wordt geschat op gemiddeld 12 jaar- hebben vrouwen die 
regelmatig worden gescreend in het algemeen meer dan een kans om op tijd te 
worden ontdekt. De programmasensitiviteit hangt daarom a£ van de 
sensitiviteit van een individuele test en van de intensiteit van screening. 
In een systematische review van gepubliceerde trials, die uniform 
beoordeeld werden aan de hand van een lijst met kwaliteitscriteria, vonden we 
slechts zwak aangetoond dat een systeem voor dunnelaag-cytologie 
(ThinPrep™) en een geautomatiseerd systeem (AutoPap™) een hogere 
sensitiviteit (maximaall2% hoger) hadden dan de Pap test, ten koste van een 
enigszins lagere specificiteit. Met het MISCAN microsimulatie model voor de 
evaluatie van screening op baarmoederhalskanker, ontwikkelden we een 
besliskundig raamwerk waarin we berekenden voor welke combinaties van 
sensitiviteit, specificiteit, en testkosten een nieuwe screenings test even kosten-
effectief zou zijn als de Pap test. Met het uitgebreid gevalideerde MISCAN 
model kunnen op flexibele wijze potenti(He veranderingen in het 
screeningsprogramma worden geevalueerd. Het bleek dat in Nederland, waar 
vrouwen tussen de 30 en 60 jaar om de vijf jaar onderzocht worden, een 
hypothetische test met een optimale ( dus 100%) sensitiviteit en specificiteit 
maximaal €9 per test meer zou mogen kosten om even kosten-effectief te zijn als 
de Pap test. Dit drempelbedrag is echter lager in landen met intensievere 
screening ( omdat de potentiele gezondheidswinst minder is), maar is hoger als 
de sensitiviteit van de Pap test lager is dan verondersteld (80%). De sensitiviteit 
van de Pap test is afgeleid van empirische screeningsdata. Wanneer deze 
bevindingen worden vergeleken met de geobserveerde testeigenschappen en 
kosten van nieuwe technologieen, is het onwaarschijnlijk dat de huidige 
technologieen net zo kosten-effectief zijn als de Pap test. Dit geldt des te sterker 
in landen waar intensievere screening plaatsvindt, zoals de VS en Engeland, 
waar dunnelaag-cytologie overigens reeds breed geilnplementeerd is. 
HPV triage van vrouwen met een afwijkende uitstrijk 
Het is belangrijk hoeveel gescreende vrouwen test-positief blijken te zijn. 
Omdat deze vrouwen in meerderheid nooit baarmoederhalskanker zouden 
krijgen door spontane regressie, lopen zij risico op overbehandeling. Op dit 
moment worden vrouwen met een sterk afwijkende uitstrijk of met een 
positieve herhalingsuitstrijk verwezen voor colposcopie, en indien nodig 
behandeld en regelmatig gecontroleerd. Wij onderzochten of de behandeling 
van verwezen vrouwen efficienter kan door ze te testen op hr-HPV (hoog risico 
humaan papillomavirus) (hoofdstuk 8). 
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We vergeleken drie soorten beleid: a) conventionele behandeling 
waarbij vrouwen colposcopisch gebiopteerd worden, en bij histologische 
afwijkingen behandeld worden (LETZ behandeling), b) hr-HPV triage, waarbij 
hr-HPV positieve vrouwen direct worden behandeld (zonder eerst colposcopie 
of biopsie), en hr-HPV negatieve vrouwen conventioneel behandeld worden, en 
c) een beleid waarbij alle vrouwen direct behandeld worden met LETZ zonder 
voorafgaand histologisch onderzoek. V oor elk beleid werd het gemiddeld 
aantal medische procedures per vrouw berekend alsook de kosten. We 
gebruikten hiervoor gegevens over de HPV-prevalentie en de behandeling van 
221 vrouwen die verwezen waren voor colposcopie vanwege twee keer een 
uitstrijk met milde of matige dysplasie, of vanwege een uitstrijk met ernstige 
dysplasie. 
Vergeleken met conventionele behandeling (a) kan door HPV -triage (b) 
van vrouwen met herhaalde milde of matige dysplasie histologisch onderzoek 
worden voorkomen ten koste van enige overbehandeling: per vrouw zouden 
gemiddeld 0.51 minder colposcopische biopsieen plaatsvinden, tegen 
gemiddeld 0.05 extra LETZ-behandelingen en $134 extra kosten per vrouw. Met 
andere woorden, het voordeel van 10 voorkomen biopsieen moet worden 
afgewogen tegen de belasting van 1 LETZ behandeling. Bij vrouwen met een 
uitstrijk met ernstige dysplasie zou directe behandeling (c) efficienter zijn dan 
HPV -triage. Vergeleken met conventionele behandeling (a) zou directe 
behandeling 25 colposcopische biopsieen voorkomen per extra LETZ-
behandeling. 
Onze bevindingen zijn redelijk zeker omdat de resulaten nauwelijks 
veranderden wanneer deze werden doorgerekend met gegevens over de hr-
HPV prevalentie uit andere studies. De HPV-triage zoals hier beschreven bleek 
niet efficient voor vrouwen met licht afwijkende ('Pap 2') uitstrijken. Omdat we 
niet de beschikking had den over kwaliteit van leven data, konden we niet 
aangeven aan welk beleid vrouwen de voorkeur zouden geven. 
Ziektelast en kosten van ziekten versus kosten-effectiviteit van zorg 
In de Discussie (hoofdstuk 9) zijn de bevindingen in dit proefschrift 
gemtegreerd met een discussie over het relatieve belang van gegevens over de 
ziektelast en kosten van ziekten (KVZ) enerzijds ( deel1 ), en van economische 
evaluaties anderzijds ( deel2). Wij beargumenteren dat beide noodzakelijk en 
complementair zijn voor beslissingen aangaande de verdeling van 
zorgmiddelen. Ziektelast- en KVZ-studies geven essentiele informatie over de 
( on)gelijkheid in gezondheid respectievelijk de toe gang tot gezondheidszorg, 
terwijl economische evaluaties informatie geven over de efficiency van 
gezondheidszorg (kosten per eenheid gezondheidswinst). Met gegevens over 
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ziektelast en kosten van ziekten kunnen ziekten, risicofactoren, en 
bevolkingsgroepen gei:dentificeerd worden met de grootste behoefte aan 
zorginterventies. De voorkeur gaat hierbij uit naar brede, veelomvattende 
ziektelast- en KVZ-studies die onderling vergelijkbare en intem consistente 
gegevens opleveren. Ziekte-specifieke studies kunnen onterecht de aandacht 
vestigen op individuele gezondheidsproblemen. Oak kunnen gegevens over de 
verdeling van volksgezondheid en van kosten hypothesen genereren over 
mogelijke verklaringen van eventuele verschillen tussen groepen. Schattingen 
van ziektelast en kosten van ziekten op nationaal niveau kunnen oak gebruikt 
worden als input en als referentiekader voor economische evaluaties van 
( combinaties van) interventies. Hoewel gegevens over de efficientie van zorg 
via economische evaluaties esentieel zijn voor het maken van beleidskeuzen, 
hebben we oak gewezen op een aantal tekortkomingen en op additionele 
voorwaarden voor het gebruik ervan. Te noemen zijn onder andere: wat is een 
maatschappelijk acceptabele grens (of bandbreedte) van kosten-effectiviteit en 
wat zijn de consequenties van invoering van een interventie voor het 
zorgbudget en voor de volksgezondheid. Verder kan het bij de evaluatie van 
een nieuwe interventie noodzakelijk zijn om oak het totale pakket aan huidige 
zorg ('usual care') te evalueren op het niveau van ziekten. De huidige 
behandeling van specifieke ziekten betreft veelal een heterogene mix van 
interventies, waarbij onvoldoende bewijs bestaat over de (kosten-)effectiviteit 
van elk van deze interventies individueet laat staan van de gecombineerde 
kosten-effectiviteit. 
Onze conclusies zijn de volgende: 
1. Schattingen van de kosten van ongevalsletsels zijn een nuttige indicator voor 
het belang van specifieke ongevallen. Samen met epidemiologische indicatoren 
zouden kosten gebruikt moeten worden voor het prioriteren van de 
ontwikkeling van interventies ter preventie van ongevallen en voor de 
verbetering van de traumazorg. De efficientie van de huidige zorg voor 
patienten met lichte letsels zou bijvoorbeeld moeten worden onderzocht. 
2. Het gebrek aan methodologische consistentie bij ramingen van de kosten van 
ongevallen ondergraaft de beleidsrelevantie ervan. Richtlijnen zijn nodig om 
deze schattingen meer vergelijkbaar en transparant te maken. 
3. Het is goed mogelijk om de functionele gevolgen van verschillende 
ongevalsletsels op een valide wijze te meten en te vergelijken. Onze empirische 
gegevens zouden moeten worden aangevuld met gegevens over korte termijn 
beperkingen bij lichte letsels, en met gegevens over permanente gevolgen van 
ongevalsletsels. Oak zou moeten worden onderzocht welke risicofactoren in 
belangrijke mate bijdragen aan de ziektelast van ongevallen. 
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4. Het is niet waarschijnlijk dat dunnelaag-cytologie en geautomatiseerde 
screeningstechnieken op dit moment kosten-effectieve alternatieven zijn voor 
de Pap test bij screening op baarmoederhalskanker. De testeigenschappen van 
deze nieuwe technologieen zouden op een betrouwbare wijze moeten worden 
vastgesteld. Ook zou moeten worden bekeken of huidige beleidsprocessen bij 
de toelating en financiering van nieuwe diagnostische tests een efficient gebruik 
van zorgmiddelen garanderen. 
5. De triage van vrouwen met persistente lichte of matige dysplasie, door 
middel van een test op hoog-risico typen van het humaan papillomavirus, zou 
kunnen leiden tot een minder belastende behandeling van deze vrouwen. V oor 
een definitief antwoord moeten echter de voorkeuren van vrouwen voor 
alternatieve vormen van behandelbeleid worden onderzocht. 
6. Vergeleken met economische evaluatiestudies leveren schattingen van de 
ziektelast en van kosten van ziekten op nationaal niveau een complementaire 
bijdrage aan een efficientere gezondheidszorg. Wij bevelen aan dat schattingen 
van de ziektelast en van kosten van ziekten op nationaal niveau regelmatig 
geactualiseerd worden. V erder zou moeten worden onderzocht wat 
maatschappelijk acceptabele grenswaarden zijn voor kosten-effectiviteit in de 
gezondheidszorg. In kosten-effectiviteitsanalyses van nieuwe zorginterventies 
zou ook het huidige pakket aan zorg bij specifieke ziekten moeten worden 
geevalueerd. 
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